

***** STN Columbus *****

FILE 'HOME' ENTERED AT 13:39:25 ON 27 APR 2005

=> file biosis caba caplus embase japio lifesci medline scisearch uspatfull

=> e hochstrasser denis/au

E1 467 HOCHSTRASSER D F/AU
E2 22 HOCHSTRASSER D L/AU
E3 49 --> HOCHSTRASSER DENIS/AU
E4 1 HOCHSTRASSER DENIS E/AU
E5 320 HOCHSTRASSER DENIS F/AU
E6 1 HOCHSTRASSER DENIS FRAN CEDILLA OIS/AU
E7 1 HOCHSTRASSER DENIS FRANCEDILLAOIS/AU
E8 28 HOCHSTRASSER DENIS FRANCOIS/AU
E9 1 HOCHSTRASSER DF/AU
E10 1 HOCHSTRASSER DIETER/AU
E11 1 HOCHSTRASSER DONALD L/AU
E12 1 HOCHSTRASSER E/AU

=> s e1-e8 and spongiform

L1 19 ("HOCHSTRASSER D F"/AU OR "HOCHSTRASSER D L"/AU OR "HOCHSTRASSER
DENIS"/AU OR "HOCHSTRASSER DENIS E"/AU OR "HOCHSTRASSER DENIS
F"/AU OR "HOCHSTRASSER DENIS FRAN CEDILLA OIS"/AU OR "HOCHSTRASSER
ER DENIS FRANCEDILLAOIS"/AU OR "HOCHSTRASSER DENIS FRANCOIS"/AU)
AND SPONGIFORM

=> dup rem l1

PROCESSING COMPLETED FOR L1

L2 8 DUP REM L1 (11 DUPLICATES REMOVED)

=> d bib ab 1-

YOU HAVE REQUESTED DATA FROM 8 ANSWERS - CONTINUE? Y/(N):y

L2 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 1

AN 2004:722816 CAPLUS

DN 141:239284

TI Diagnostic method for transmissible ***spongiform*** encephalopathies
IN ***Hochstrasser, Denis Francois*** ; Sanchez, Jean-Charles; Guillaume,
Elisabeth

PA Switz.

SO U.S. Pat. Appl. Publ., 61 pp., Cont.-in-part of Appl. No. PCT/EP02/10063.
CODEN: USXXCO

DT Patent

LA English

FAN.CNT 3

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|---------------|------|----------|-----------------|----------|
| PI | US 2004171026 | A1 | 20040902 | US 2003-695194 | 20031028 |
| | GB 2379737 | A1 | 20030319 | GB 2001-21459 | 20010905 |
| | WO 2003023406 | A2 | 20030320 | WO 2002-EP10063 | 20020903 |
| | WO 2003023406 | A3 | 20031127 | | |
| | WO 2003023406 | C2 | 20040226 | | |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,

KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF,
CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI GB 2001-21459 A 20010905
WO 2002-EP10063 A2 20020903
GB 2002-25245 A 20021030
GB 2003-6290 A 20030319

AB Transmissible ***spongiform*** encephalopathy (TSE) is diagnosed in a subject by using mass spectrometry to observe a polypeptide in a sample of body fluid taken from the subject. The polypeptide is differentially contained in the body fluid of TSE-infected subjects and non-infected subjects, and has a mol. wt. in the range of from 1000 to 100000.

L2 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2004:392701 CAPLUS

DN 140:371477

TI Diagnostic method for transmissible ***spongiform*** encephalopathies
IN Sanchez, Jean-Charles; ***Hochstrasser, Denis Francois*** ; Guillaume, Elisabeth

PA Proteome Sciences Plc., UK

SO PCT Int. Appl., 48 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 3

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|---------------|------|----------|-----------------|----------|
| PI | WO 2004040316 | A2 | 20040513 | WO 2003-GB4574 | 20031023 |
| | WO 2004040316 | A3 | 20041229 | | |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI GB 2002-25245 A 20021030
GB 2003-6290 A 20030319

AB Transmissible ***spongiform*** encephalopathy (TSE) is diagnosed in a subject by using mass spectrometry to observe a polypeptide in a sample of body fluid taken from the subject. The polypeptide is differentially contained in the body fluid of TSE-infected subjects and non-infected subjects, and has a mol. wt. in the range of from 1000 to 100000, but excluding the range of from 3500 to 30000. TSE can be diagnosed in a subject by detg. a test amt. of a polypeptide in a sample of body fluid, wherein the polypeptide is Cystatin C or a Hb, a Hb chain or a truncated chain or a fragment thereof which exhibits an immunol. reaction to an antibody to bovine Hb.

L2 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2003:222395 CAPLUS

DN 138:262426

TI Diagnostic method for ***spongiform*** encephalopathy disease
IN Guillaume, Elisabeth; ***Hochstrasser, Denis Francois*** ; Sanchez,

Jean-charles
 PA Universite de Geneve, Switz.
 SO Brit. UK Pat. Appl., 24 pp.
 CODEN: BAXXDU
 DT Patent
 LA English
 FAN.CNT 3

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|---------------|------|----------|-----------------|----------|
| PI | GB 2379737 | A1 | 20030319 | GB 2001-21459 | 20010905 |
| | WO 2003023406 | A2 | 20030320 | WO 2002-EP10063 | 20020903 |
| | WO 2003023406 | A3 | 20031127 | | |
| | WO 2003023406 | C2 | 20040226 | | |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

| | | | | |
|------------|--|----------|----------------|----------|
| EP 1423703 | A2 | 20040602 | EP 2002-767478 | 20020903 |
| R: | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK | | | |

| | | | | |
|---------------|----|----------|----------------|----------|
| JP 2005502882 | T2 | 20050127 | JP 2003-527426 | 20020903 |
| US 2004171026 | A1 | 20040902 | US 2003-695194 | 20031028 |

| | | | |
|------|-----------------|---|----------|
| PRAI | GB 2001-21459 | A | 20010905 |
| | WO 2002-EP10063 | W | 20020903 |
| | GB 2002-25245 | A | 20021030 |
| | GB 2003-6290 | A | 20030319 |

AB Diseases such as BSE, CJD or scrapie are diagnosed in a subject by analyzing a sample of body fluid by mass spectrometry to det. the presence of a polypeptide marker of mol. wt. 3500 to 30000 where the polypeptide is present in different amts. in the body fluid of infected and non-infected subjects. The test sample may be adsorbed on a probe carrying an adsorbent material capable of binding the polypeptide. The material is e.g. a metal chelating group complexed with a metal ion. Kits for carrying out the diagnosis are also disclosed. The body fluid sample may be from humans or cattle.

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 4 OF 8 USPATFULL on STN

AN 2003:225768 USPATFULL

TI Diagnostic assay for transmissible ***spongiform*** encephalopathies

IN ***Hochstrasser, Denis Francois***, Geneva, SWITZERLAND

Sanchez, Jean-Charles, Geneva, SWITZERLAND

Zimmermann, Catherine Gabrielle, Geneva, SWITZERLAND

Guillaume, Elisabeth, Annemasse, FRANCE

| | | | |
|----|---------------|----|----------|
| PI | US 2003157580 | A1 | 20030821 |
|----|---------------|----|----------|

| | | | |
|----|----------------|----|---------------|
| AI | US 2002-238557 | A1 | 20020910 (10) |
|----|----------------|----|---------------|

RLI Continuation of Ser. No. WO 2001-EP2894, filed on 12 Mar 2001, UNKNOWN

| | | |
|------|--------------|----------|
| PRAI | GB 2000-5683 | 20000310 |
|------|--------------|----------|

| | | |
|--|--------------|----------|
| | GB 2000-6064 | 20000314 |
|--|--------------|----------|

DT Utility

FS APPLICATION
LREP BAKER & BOTTS, 30 ROCKEFELLER PLAZA, NEW YORK, NY, 10112
CLMN Number of Claims: 8
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 482

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Heart and brain fatty acid binding proteins (H-FABP, B-FABP) are markers for TSEs, especially CJD. The invention provides a diagnostic assay for either of these markers, preferably by enzyme immunoassay using anti-H-FABP or B-FABP antibody. Since H-FABP is also a marker for acute myocardial infarction (AMI), to distinguish CJD from AMI requires an assay specific to AMI, e.g. using troponin-I or creatine kinase-MB as a marker, also to be carried out.

L2 ANSWER 5 OF 8 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
DUPLICATE 2

AN 2004:60806 BIOSIS

DN PREV200400061254

TI A potential cerebrospinal fluid and plasmatic marker for the diagnosis of Creutzfeldt-Jakob disease.

AU Guillaume, Elisabeth [Reprint Author]; Zimmermann, Catherine; Burkhard, Pierre R.; ***Hochstrasser, Denis F.*** ; Sanchez, Jean-Charles

CS Biomedical Proteomics Research Group, Central Clinical Chemistry Laboratory, Geneva University Hospital, 24, Rue Micheli-du-Crest, 1211, Geneva 14, Switzerland
guillaum@dim.hcuge.ch

SO Proteomics, (August 2003) Vol. 3, No. 8, pp. 1495-1499. print.
ISSN: 1615-9853 (ISSN print).

DT Article

LA English

ED Entered STN: 28 Jan 2004

Last Updated on STN: 28 Jan 2004

AB The recent occurrence of the new variant of Creutzfeldt-Jakob disease (CJD), probably transmitted to humans by cattle affected by the bovine form of ***spongiform*** encephalopathy, has generated renewed interest in the clinical issues related to human ***spongiform*** encephalopathies. Using the current set of diagnostic tools, these rare but devastating conditions may be difficult to diagnose with accuracy before death. The objective of the present communication is to describe the discovery of a potential cerebrospinal fluid (CSF) and plasmatic marker of human transmissible ***spongiform*** encephalopathies. A preliminary two-dimensional electrophoresis approach highlighted a potential neurodegenerative disorder marker called the fatty acid binding protein, FABP. Its heart form, H-FABP, was investigated in a small group of CJD affected patients (n=8) by an immunoassay approach. The amount of FABP appeared to be significantly (p<0.05) increased in all tested samples. H-FABP detection could therefore be helpful as a blood screening test for a pre-mortem diagnosis of the disease and also to prevent the risk of iatrogenic transmission of CJD through blood transfusion.

L2 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2001:677072 CAPLUS

DN 135:207875

TI Diagnostic assay for transmissible ***spongiform*** encephalopathies
IN ***Hochstrasser, Denis Francois*** ; Sanchez, Jean-Charles; Zimmermann, Catherine Gabrielle; Guillaume, Elisabeth

PA Universite de Geneve, Switz.
 SO PCT Int. Appl., 21 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 2001067108 | A2 | 20010913 | WO 2001-EP2894 | 20010312 |
| | WO 2001067108 | A3 | 20020321 | | |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| | RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| | GB 2360089 | A1 | 20010912 | GB 2000-5683 | 20000310 |
| | CA 2402314 | AA | 20010913 | CA 2001-2402314 | 20010312 |
| | EP 1261875 | A2 | 20021204 | EP 2001-931527 | 20010312 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | |
| | JP 2003526788 | T2 | 20030909 | JP 2001-566030 | 20010312 |
| | US 2003157580 | A1 | 20030821 | US 2002-238557 | 20020910 |
| PRAI | GB 2000-5683 | A | 20000310 | | |
| | GB 2000-6064 | A | 20000314 | | |
| | WO 2001-EP2894 | W | 20010312 | | |

AB Heart and brain fatty acid binding proteins (H-FABP, B-FABP) are markers for TSEs, esp. CJD. The invention provides a diagnostic assay for either of these markers, preferably by enzyme immunoassay using a specific antibody thereto. Since H-FABP is also a marker for acute myocardial infarction (AMI), to distinguish CJD from AMI requires an assay specific to AMI, e.g. using troponin-1 or CK-MB as a marker, also to be carried out.

L2 ANSWER 7 OF 8 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation on STN
 AN 2001:488816 SCISEARCH
 GA The Genuine Article (R) Number: 440RB
 TI CSF detection of the 14-3-3 protein in unselected patients with dementia
 AU Burkhard P R (Reprint); Sanchez J C; Landis T; ***Hochstrasser D F***
 CS Univ Hosp Geneva, Dept Neurol, CH-1211 Geneva 14, Switzerland (Reprint); Univ Hosp Geneva, Cent Lab Clin Chem, CH-1211 Geneva, Switzerland
 CYA Switzerland
 SO NEUROLOGY, (12 JUN 2001) Vol. 56, No. 11, pp. 1528-1533.
 Publisher: LIPPINCOTT WILLIAMS & WILKINS, 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA.
 ISSN: 0028-3878.
 DT Article; Journal
 LA English
 REC Reference Count: 26
 ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

AB Objective: To determine the usefulness of the 14-3-3 test in patients with dementia of various causes. Background: Recent reports have suggested that the detection of the 14-3-3 protein in the CSF of patients with

Creutzfeldt-Jakob disease is a highly sensitive and specific marker of the disease that might be used as a diagnostic criterion. We examined the validity of this test when applied to a cohort of unselected patients prospectively examined for an ongoing dementing process. Methods: One hundred patients underwent an extensive neurologic examination for dementia, including a CSF 14-3-3 protein immunoblotting assay. Final clinical diagnoses were compared with the qualitative results of the test, and statistical measures of test validity were carried out. Results: We found a positive test in 14 of 100 patients, only two of whom had definite Creutzfeldt-Jakob disease. Positive results were found in patients with various degenerative dementias, including AD (4), frontotemporal dementia (2), and dementia with Lewy body (1), and in patients with vascular dementia (1), carcinomatous meningitis (1), and anoxic encephalopathy (1). In two other positive patients, the dementia could not be confidently classified. Sensitivity, specificity, and negative predictive value were fairly good, but positive predictive value was poor. Similar results were found independently of the disease duration. There was no correlation between intensity nor pattern of the 14-3-3 protein expression and diagnosis. Conclusions: The 14-3-3 test is not valid for discriminating between Creutzfeldt-Jakob disease and non-Creutzfeldt-Jakob disease in unselected patients with dementia. Positive results are found in various degenerative and secondary, prion-unrelated dementias.

L2 ANSWER 8 OF 8 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
 DUPLICATE 3
 AN 1997:509954 BIOSIS
 DN PREV199799809157
 TI Elevation of apolipoprotein E in the CSF of cattle affected by BSE.
 AU ***Hochstrasser, Denis F.*** ; Frutiger, Severine; Wilkins, Marc R.;
 Hughes, Graham; Sanchez, Jean-Charles [Reprint author]
 CS Clinical Chem. Lab., Geneva Univ. Hosp., 24 Micheli-du-Crest, CH-1211
 Geneva 14, Switzerland
 SO FEBS Letters, (1997) Vol. 416, No. 2, pp. 161-163.
 CODEN: FEBLAL. ISSN: 0014-5793.
 DT Article
 LA English
 ED Entered STN: 10 Dec 1997
 Last Updated on STN: 10 Dec 1997
 AB The cerebrospinal fluid (CSF) of patients suffering from Creutzfeldt-Jakob
 disease (CJD) display two unique polypeptide chains by two-dimensional
 polyacrylamide gel electrophoresis (2-D PAGE). In the absence of a
 well-defined ante-mortem diagnostic test for bovine ***spongiform***
 encephalopathy (BSE), spinal fluid samples of eight normal cows and eight
 cows known to carry BSE by postmortem histological analysis were
 investigated to verify if equivalent polypeptides were present. Proteins
 with similar migration to human CJD polypeptides were not detected. But
 surprisingly, a cluster of polypeptide spots that was faint or not
 detected in normal bovine CSF samples was found to be elevated or
 massively increased in BSE CSF samples (more than 10-fold increase).
 These elevated polypeptide chains were identified as apolipoprotein E.

=> e sanchez jean/au
 E1 4 SANCHEZ JAVIER R/AU
 E2 2 SANCHEZ JAVIER R M/AU
 E3 2 --> SANCHEZ JEAN/AU
 E4 1 SANCHEZ JEAN A/AU

E5 304 SANCHEZ JEAN CHARLES/AU
 E6 23 SANCHEZ JEAN FREDERIC/AU
 E7 16 SANCHEZ JEAN LOUIS/AU
 E8 4 SANCHEZ JEAN PIERRE/AU
 E9 64 SANCHEZ JEAN YVES/AU
 E10 2 SANCHEZ JENNIFER/AU
 E11 6 SANCHEZ JENNIFER F/AU
 E12 1 SANCHEZ JENNIFER FREDERICK/AU

=> s e5 and spongiform

L3 11 "SANCHEZ JEAN CHARLES"/AU AND SPONGIFORM

=> dup rem l3

PROCESSING COMPLETED FOR L3

L4 7 DUP REM L3 (4 DUPLICATES REMOVED)

=> d bib ab 1-

YOU HAVE REQUESTED DATA FROM 7 ANSWERS - CONTINUE? Y/(N):y

L4 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 1

AN 2004:722816 CAPLUS

DN 141:239284

TI Diagnostic method for transmissible ***spongiform*** encephalopathies

IN Hochstrasser, Denis Francois; ***Sanchez, Jean-Charles*** ; Guillaume, Elisabeth

PA Switz.

SO U.S. Pat. Appl. Publ., 61 pp., Cont.-in-part of Appl. No. PCT/EP02/10063.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 3

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|---------------|------|----------|-----------------|----------|
| PI | US 2004171026 | A1 | 20040902 | US 2003-695194 | 20031028 |
| | GB 2379737 | A1 | 20030319 | GB 2001-21459 | 20010905 |
| | WO 2003023406 | A2 | 20030320 | WO 2002-EP10063 | 20020903 |
| | WO 2003023406 | A3 | 20031127 | | |
| | WO 2003023406 | C2 | 20040226 | | |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI GB 2001-21459 A 20010905
 WO 2002-EP10063 A2 20020903
 GB 2002-25245 A 20021030
 GB 2003-6290 A 20030319

AB Transmissible ***spongiform*** encephalopathy (TSE) is diagnosed in a subject by using mass spectrometry to observe a polypeptide in a sample of body fluid taken from the subject. The polypeptide is differentially contained in the body fluid of TSE-infected subjects and non-infected subjects, and has a mol. wt. in the range of from 1000 to 100000.

L4 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 2004:392701 CAPLUS
 DN 140:371477
 TI Diagnostic method for transmissible ***spongiform*** encephalopathies
 IN ***Sanchez, Jean-Charles*** ; Hochstrasser, Denis Francois; Guillaume, Elisabeth
 PA Proteome Sciences Plc., UK
 SO PCT Int. Appl., 48 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 3

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---------------|--|----------|-----------------|----------|
| PI | WO 2004040316 | A2 | 20040513 | WO 2003-GB4574 | 20031023 |
| | WO 2004040316 | A3 | 20041229 | | |
| | W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | |
| | RW: | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | |
| PRAI | GB 2002-25245 | A | 20021030 | | |
| | GB 2003-6290 | A | 20030319 | | |

AB Transmissible ***spongiform*** encephalopathy (TSE) is diagnosed in a subject by using mass spectrometry to observe a polypeptide in a sample of body fluid taken from the subject. The polypeptide is differentially contained in the body fluid of TSE-infected subjects and non-infected subjects, and has a mol. wt. in the range of from 1000 to 100000, but excluding the range of from 3500 to 30000. TSE can be diagnosed in a subject by detg. a test amt. of a polypeptide in a sample of body fluid, wherein the polypeptide is Cystatin C or a Hb, a Hb chain or a truncated chain or a fragment thereof which exhibits an immunol. reaction to an antibody to bovine Hb.

L4 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 2003:222395 CAPLUS
 DN 138:262426
 TI Diagnostic method for ***spongiform*** encephalopathy disease
 IN Guillaume, Elisabeth; Hochstrasser, Denis Francois; ***Sanchez,***
 *** Jean-charles***
 PA Universite de Geneve, Switz.
 SO Brit. UK Pat. Appl., 24 pp.
 CODEN: BAXXDU
 DT Patent
 LA English
 FAN.CNT 3

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|---------------|------|----------|-----------------|----------|
| PI | GB 2379737 | A1 | 20030319 | GB 2001-21459 | 20010905 |
| | WO 2003023406 | A2 | 20030320 | WO 2002-EP10063 | 20020903 |
| | WO 2003023406 | A3 | 20031127 | | |

WO 2003023406 C2 20040226

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1423703 A2 20040602 EP 2002-767478 20020903

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK

JP 2005502882 T2 20050127 JP 2003-527426 20020903

US 2004171026 A1 20040902 US 2003-695194 20031028

PRAI GB 2001-21459 A 20010905

WO 2002-EP10063 W 20020903

GB 2002-25245 A 20021030

GB 2003-6290 A 20030319

AB Diseases such as BSE, CJD or scrapie are diagnosed in a subject by analyzing a sample of body fluid by mass spectrometry to det. the presence of a polypeptide marker of mol. wt. 3500 to 30000 where the polypeptide is present in different amts. in the body fluid of infected and non-infected subjects. The test sample may be adsorbed on a probe carrying an adsorbent material capable of binding the polypeptide. The material is e.g. a metal chelating group complexed with a metal ion. Kits for carrying out the diagnosis are also disclosed. The body fluid sample may be from humans or cattle.

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 7 USPATFULL on STN

AN 2003:225768 USPATFULL

TI Diagnostic assay for transmissible ***spongiform*** encephalopathies

IN Hochstrasser, Denis Francois, Geneva, SWITZERLAND
Sanchez, Jean-Charles, Geneva, SWITZERLAND
Zimmermann, Catherine Gabrielle, Geneva, SWITZERLAND
Guillaume, Elisabeth, Annemasse, FRANCE

PI US 2003157580 A1 20030821

AI US 2002-238557 A1 20020910 (10)

RLI Continuation of Ser. No. WO 2001-EP2894, filed on 12 Mar 2001, UNKNOWN

PRAI GB 2000-5683 20000310

GB 2000-6064 20000314

DT Utility

FS APPLICATION

LREP BAKER & BOTTS, 30 ROCKEFELLER PLAZA, NEW YORK, NY, 10112

CLMN Number of Claims: 8

ECL Exemplary Claim: 1

DRWN 1 Drawing Page(s)

LN.CNT 482

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Heart and brain fatty acid binding proteins (H-FABP, B-FABP) are markers for TSEs, especially CJD. The invention provides a diagnostic assay for either of these markers, preferably by enzyme immunoassay using anti-H-FABP or B-FABP antibody. Since H-FABP is also a marker for acute myocardial infarction (AMI), to distinguish CJD from AMI requires an

assay specific to AMI, e.g. using troponin-I or creatine kinase-MB as a marker, also to be carried out.

L4 ANSWER 5 OF 7 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
DUPLICATE 2
AN 2004:60806 BIOSIS
DN PREV200400061254
TI A potential cerebrospinal fluid and plasmatic marker for the diagnosis of
Creutzfeldt-Jakob disease.
AU Guillaume, Elisabeth [Reprint Author]; Zimmermann, Catherine; Burkhard,
Pierre R.; Hochstrasser, Denis F.; ***Sanchez, Jean-Charles***
CS Biomedical Proteomics Research Group, Central Clinical Chemistry
Laboratory, Geneva University Hospital, 24, Rue Micheli-du-Crest, 1211,
Geneva 14, Switzerland
guillaum@dim.hcuge.ch
SO Proteomics, (August 2003) Vol. 3, No. 8, pp. 1495-1499. print.
ISSN: 1615-9853 (ISSN print).
DT Article
LA English
ED Entered STN: 28 Jan 2004
Last Updated on STN: 28 Jan 2004
AB The recent occurrence of the new variant of Creutzfeldt-Jakob disease
(CJD), probably transmitted to humans by cattle affected by the bovine
form of ***spongiform*** encephalopathy, has generated renewed
interest in the clinical issues related to human ***spongiform***
encephalopathies. Using the current set of diagnostic tools, these rare
but devastating conditions may be difficult to diagnose with accuracy
before death. The objective of the present communication is to describe
the discovery of a potential cerebrospinal fluid (CSF) and plasmatic
marker of human transmissible ***spongiform*** encephalopathies. A
preliminary two-dimensional electrophoresis approach highlighted a
potential neurodegenerative disorder marker called the fatty acid binding
protein, FABP. Its heart form, H-FABP, was investigated in a small group
of CJD affected patients (n=8) by an immunoassay approach. The amount of
FABP appeared to be significantly (p<0.05) increased in all tested
samples. H-FABP detection could therefore be helpful as a blood screening
test for a pre-mortem diagnosis of the disease and also to prevent the
risk of iatrogenic transmission of CJD through blood transfusion.

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2001:677072 CAPLUS
DN 135:207875
TI Diagnostic assay for transmissible ***spongiform*** encephalopathies
IN Hochstrasser, Denis Francois; ***Sanchez, Jean-Charles*** ; Zimmermann,
Catherine Gabrielle; Guillaume, Elisabeth
PA Universite de Geneve, Switz.
SO PCT Int. Appl., 21 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|---------------|------|----------|-----------------|----------|
| PI | WO 2001067108 | A2 | 20010913 | WO 2001-EP2894 | 20010312 |
| | WO 2001067108 | A3 | 20020321 | | |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM,

HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS,
 LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO,
 RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ,
 VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
 BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

| | | | | |
|------------|----|----------|-----------------|----------|
| GB 2360089 | A1 | 20010912 | GB 2000-5683 | 20000310 |
| CA 2402314 | AA | 20010913 | CA 2001-2402314 | 20010312 |
| EP 1261875 | A2 | 20021204 | EP 2001-931527 | 20010312 |

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

| | | | | |
|---------------|----|----------|----------------|----------|
| JP 2003526788 | T2 | 20030909 | JP 2001-566030 | 20010312 |
| US 2003157580 | A1 | 20030821 | US 2002-238557 | 20020910 |

PRAI GB 2000-5683 A 20000310
 GB 2000-6064 A 20000314
 WO 2001-EP2894 W 20010312

AB Heart and brain fatty acid binding proteins (H-FABP, B-FABP) are markers
 for TSEs, esp. CJD. The invention provides a diagnostic assay for either
 of these markers, preferably by enzyme immunoassay using a specific
 antibody thereto. Since H-FABP is also a marker for acute myocardial
 infarction (AMI), to distinguish CJD from AMI requires an assay specific
 to AMI, e.g. using troponin-1 or CK-MB as a marker, also to be carried
 out.

L4 ANSWER 7 OF 7 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
 DUPLICATE 3
 AN 1997:509954 BIOSIS
 DN PREV199799809157
 TI Elevation of apolipoprotein E in the CSF of cattle affected by BSE.
 AU Hochstrasser, Denis F.; Frutiger, Severine; Wilkins, Marc R.; Hughes,
 Graham; ***Sanchez, Jean-Charles*** [Reprint author]
 CS Clinical Chem. Lab., Geneva Univ. Hosp., 24 Micheli-du-Crest, CH-1211
 Geneva 14, Switzerland
 SO FEBS Letters, (1997) Vol. 416, No. 2, pp. 161-163.
 CODEN: FEELAL. ISSN: 0014-5793.
 DT Article
 LA English
 ED Entered STN: 10 Dec 1997
 Last Updated on STN: 10 Dec 1997

AB The cerebrospinal fluid (CSF) of patients suffering from Creutzfeldt-Jakob
 disease (CJD) display two unique polypeptide chains by two-dimensional
 polyacrylamide gel electrophoresis (2-D PAGE). In the absence of a
 well-defined ante-mortem diagnostic test for bovine ***spongiform***
 encephalopathy (BSE), spinal fluid samples of eight normal cows and eight
 cows known to carry BSE by postmortem histological analysis were
 investigated to verify if equivalent polypeptides were present. Proteins
 with similar migration to human CJD polypeptides were not detected. But
 surprisingly, a cluster of polypeptide spots that was faint or not
 detected in normal bovine CSF samples was found to be elevated or
 massively increased in BSE CSF samples (more than 10-fold increase).
 These elevated polypeptide chains were identified as apolipoprotein E.

=> e guillaume elisabeth/au
 E1 2 GUILLAUME E W/AU
 E2 1 GUILLAUME EDOUARD/AU

E3 26 --> GUILLAUME ELISABETH/AU
 E4 6 GUILLAUME EMILE/AU
 E5 7 GUILLAUME EMILE A H/AU
 E6 1 GUILLAUME EMILE ARMAND HENRI/AU
 E7 1 GUILLAUME EMMANELLE/AU
 E8 2 GUILLAUME EMMANUEL/AU
 E9 2 GUILLAUME EMMANUELLE C/AU
 E10 1 GUILLAUME EON JEAN/AU
 E11 1 GUILLAUME ERRICK/AU
 E12 200 GUILLAUME F/AU

=> s e3

L5 26 "GUILLAUME ELISABETH"/AU

=> dup rem l5

PROCESSING COMPLETED FOR L5

L6 14 DUP REM L5 (12 DUPLICATES REMOVED)

=> d bib ab 1-

YOU HAVE REQUESTED DATA FROM 14 ANSWERS - CONTINUE? Y/(N):y

L6 ANSWER 1 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2005:134137 CAPLUS

DN 142:216620

TI Use of antithrombin III, Apo C-I, Apo C-III, or serum amyloid A as diagnostic markers for stroke and immunological and SELDI-MS assays for the markers

IN ***Guillaume, Elisabeth*** ; Sanchez, Jean-Charles; Hochstrasser, Denis Francois; Allard, Laure; Lescuyer, Pierre

PA Universite De Geneve, Switz.

SO Brit. UK Pat. Appl., 51 pp.

CODEN: BAXXDU

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|-----|--|------|----------|-----------------|----------|
| PI | GB 2404981 | A1 | 20050216 | GB 2003-19167 | 20030815 |
| | WO 2005017523 | A2 | 20050224 | WO 2004-GB3512 | 20040816 |
| W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: | BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |

PRAI GB 2003-19167 A 20030815

AB A method is described for diagnosing stroke which comprises detg. concns. of either antithrombin III, apolipoprotein C-I (Apo C-I), Apo C-III, or serum amyloid A protein (SAA) in a patient's body fluid, preferably plasma. The specific proteins are preferably detected using Surface Enhanced Laser Desorption Ionization (SELDI) Mass Spectroscopy (MS).

Proteins from body fluid are chromatog. absorbed to protein chip arrays for anal. by SELDI-MS. Alternatively the proteins may be detected using specific antibodies in immunochem. assays particularly using solid-phase antibody chips. Data indicate that Apo C-III, and serum amyloid A protein are differentially expressed in stroke patients compared to controls.

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 1
AN 2004:722816 CAPLUS
DN 141:239284
TI Diagnostic method for transmissible spongiform encephalopathies
IN Hochstrasser, Denis Francois; Sanchez, Jean-Charles; ***Guillaume,***
*** Elisabeth***
PA Switz.
SO U.S. Pat. Appl. Publ., 61 pp., Cont.-in-part of Appl. No. PCT/EP02/10063.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 3

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|---------------|------|----------|-----------------|----------|
| PI | US 2004171026 | A1 | 20040902 | US 2003-695194 | 20031028 |
| | GB 2379737 | A1 | 20030319 | GB 2001-21459 | 20010905 |
| | WO 2003023406 | A2 | 20030320 | WO 2002-EP10063 | 20020903 |
| | WO 2003023406 | A3 | 20031127 | | |
| | WO 2003023406 | C2 | 20040226 | | |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI GB 2001-21459 A 20010905
WO 2002-EP10063 A2 20020903
GB 2002-25245 A 20021030
GB 2003-6290 A 20030319

AB Transmissible spongiform encephalopathy (TSE) is diagnosed in a subject by using mass spectrometry to observe a polypeptide in a sample of body fluid taken from the subject. The polypeptide is differentially contained in the body fluid of TSE-infected subjects and non-infected subjects, and has a mol. wt. in the range of from 1000 to 100000.

L6 ANSWER 3 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:392701 CAPLUS
DN 140:371477
TI Diagnostic method for transmissible spongiform encephalopathies
IN Sanchez, Jean-Charles; Hochstrasser, Denis Francois; ***Guillaume,***
*** Elisabeth***
PA Proteome Sciences Plc., UK
SO PCT Int. Appl., 48 pp.
CODEN: PIXXD2
DT Patent

LA English

FAN.CNT 3

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|---|------|----------|-----------------|----------|
| PI | WO 2004040316 | A2 | 20040513 | WO 2003-GB4574 | 20031023 |
| | WO 2004040316 | A3 | 20041229 | | |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| | RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |

PRAI GB 2002-25245 A 20021030

GB 2003-6290 A 20030319

AB Transmissible spongiform encephalopathy (TSE) is diagnosed in a subject by using mass spectrometry to observe a polypeptide in a sample of body fluid taken from the subject. The polypeptide is differentially contained in the body fluid of TSE-infected subjects and non-infected subjects, and has a mol. wt. in the range of from 1000 to 100000, but excluding the range of from 3500 to 30000. TSE can be diagnosed in a subject by detg. a test amt. of a polypeptide in a sample of body fluid, wherein the polypeptide is Cystatin C or a Hb, a Hb chain or a truncated chain or a fragment thereof which exhibits an immunol. reaction to an antibody to bovine Hb.

L6 ANSWER 4 OF 14 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN DUPLICATE 2

AN 2004:432942 BIOSIS

DN PREV200400431029

TI Cystatin C as a potential cerebrospinal fluid marker for the diagnosis of Creutzfeldt-Jakob disease.

AU Sanchez, Jean-Charles [Reprint Author]; ***Guillaume, Elisabeth*** ; Lescuyer, Pierre; Allard, Laure; Carrette, Odile; Scherl, Alex; Burgess, Jennifer; Corthals, Garry L.; Burkhard, Pierre R.; Hochstrasser, Denis F.
CS Biomed Proteom Res GrpCent Clin Chem Lab, Geneva Univ Hosp, 24 Rue Micheli Du Crest, CH-1211, Geneva, 14, Switzerland
sanchez@sim.hcuge.ch

SO Proteomics, (August 2004) Vol. 4, No. 8, pp. 2229-2233. print.
ISSN: 1615-9853 (ISSN print).

DT Article

LA English

ED Entered STN: 10 Nov 2004

Last Updated on STN: 10 Nov 2004

AB The definite diagnosis of Creutzfeldt-Jakob disease (CJD), the most common form of human prion diseases, relies upon neuropathological data usually obtained at autopsy. In living patients, the diagnosis, based on suggestive clinical features and EEG abnormalities, can be aided by the detection of altered levels of isoforms of the 14-3-3 protein in the cerebrospinal fluid (CSF). However, the validity of this test has been recently challenged and the search for other, more reliable biomarkers for CJD remains highly desirable. The present study describes the identification of a new potential surrogate marker in the CSF of CJD-affected patients. A preliminary study employing surface-enhanced laser desorption/ionization-time of flight (SELDI-TOF) technology

highlighted a protein at 13.4 kDa in a small group (n = 8) of CJD-affected patients. Further analysis aimed at identifying this protein using cationic exchange chromatography, sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), and liquid chromatography-tandem mass spectrometry (LC-MS/MS) revealed it to be cystatin C. Additional immunoblot assays confirmed that the level of cystatin C was significantly increased (p ltoreq 0.05) in all tested samples (n = 8). We conclude that the analysis of cystatin C levels in CSF could be useful as a pre-mortern indicator of the disease.

L6 ANSWER 5 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 2003:657025 CAPLUS
 DN 139:176362
 TI Diagnostic method for stroke
 IN Hochstrasser, Denis Francois; Sanchez, Jean-Charles; ***Guillaume,***
 *** Elisabeth*** ; Allard, Laure
 PA Universite De Geneve, Switz.
 SO PCT Int. Appl., 37 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|----------------|--|----------|-----------------|----------|
| PI | WO 2003069346 | A2 | 20030821 | WO 2003-EP1462 | 20030213 |
| | WO 2003069346 | A3 | 20040311 | | |
| | W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | |
| | RW: | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | |
| | EP 1476759 | A2 | 20041117 | EP 2003-739491 | 20030213 |
| | R: | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | |
| PRAI | GB 2002-3768 | A | 20020218 | | |
| | WO 2003-EP1462 | W | 20030213 | | |

AB Stroke is diagnosed in a subject by using mass spectrometry to observe a polypeptide in a sample of body fluid taken from the subject. The polypeptide is differentially contained in the body fluid of stroke-affected subjects and non-stroke-affected subjects, and has a mol. wt. in the range of from 3000 to 30000.

L6 ANSWER 6 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 2003:222395 CAPLUS
 DN 138:262426
 TI Diagnostic method for spongiform encephalopathy disease
 IN ***Guillaume, Elisabeth*** ; Hochstrasser, Denis Francois; Sanchez, Jean-charles
 PA Universite de Geneve, Switz.
 SO Brit. UK Pat. Appl., 24 pp.
 CODEN: BAXXDU
 DT Patent

LA English

FAN.CNT 3

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---------------|---|----------|----------------|-----------------|----------|
| PI | GB 2379737 | A1 | 20030319 | GB 2001-21459 | 20010905 |
| | WO 2003023406 | A2 | 20030320 | WO 2002-EP10063 | 20020903 |
| | WO 2003023406 | A3 | 20031127 | | |
| | WO 2003023406 | C2 | 20040226 | | |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| | RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| EP 1423703 | A2 | 20040602 | EP 2002-767478 | | 20020903 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK | | | | |
| JP 2005502882 | T2 | 20050127 | JP 2003-527426 | | 20020903 |
| US 2004171026 | A1 | 20040902 | US 2003-695194 | | 20031028 |
| PRAI | GB 2001-21459 | A | 20010905 | | |
| | WO 2002-EP10063 | W | 20020903 | | |
| | GB 2002-25245 | A | 20021030 | | |
| | GB 2003-6290 | A | 20030319 | | |

AB Diseases such as BSE, CJD or scrapie are diagnosed in a subject by analyzing a sample of body fluid by mass spectrometry to det. the presence of a polypeptide marker of mol. wt. 3500 to 30000 where the polypeptide is present in different amts. in the body fluid of infected and non-infected subjects. The test sample may be adsorbed on a probe carrying an adsorbent material capable of binding the polypeptide. The material is e.g. a metal chelating group complexed with a metal ion. Kits for carrying out the diagnosis are also disclosed. The body fluid sample may be from humans or cattle.

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 7 OF 14 USPATFULL on STN

AN 2003:225768 USPATFULL

TI Diagnostic assay for transmissible spongiform encephalopathies

IN Hochstrasser, Denis Francois, Geneva, SWITZERLAND

Sanchez, Jean-Charles, Geneva, SWITZERLAND

Zimmermann, Catherine Gabrielle, Geneva, SWITZERLAND

Guillaume, Elisabeth, Annemasse, FRANCE

PI US 2003157580 A1 20030821

AI US 2002-238557 A1 20020910 (10)

RLI Continuation of Ser. No. WO 2001-EP2894, filed on 12 Mar 2001, UNKNOWN

PRAI GB 2000-5683 20000310

GB 2000-6064 20000314

DT Utility

FS APPLICATION

LREP BAKER & BOTTS, 30 ROCKEFELLER PLAZA, NEW YORK, NY, 10112

CLMN Number of Claims: 8

ECL Exemplary Claim: 1

DRWN 1 Drawing Page(s)

LN.CNT 482

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Heart and brain fatty acid binding proteins (H-FABP, B-FABP) are markers for TSEs, especially CJD. The invention provides a diagnostic assay for either of these markers, preferably by enzyme immunoassay using anti-H-FABP or B-FABP antibody. Since H-FABP is also a marker for acute myocardial infarction (AMI), to distinguish CJD from AMI requires an assay specific to AMI, e.g. using troponin-I or creatine kinase-MB as a marker, also to be carried out.

L6 ANSWER 8 OF 14 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
DUPLICATE 3

AN 2004:60813 BIOSIS

DN PREV200400061261

TI Proteomics application exercise of the Swiss Proteomics Society: Report of the SPS'02 session.

AU Binz, Pierre-Alain [Reprint Author]; Abdi, Fadi; Affolter, Michael; Allard, Laure; Barblan, Jachen; Bhardwaj, Sanjeev; Bienvenut, Willy V.; Bulet, Philippe; Burgess, Jennifer; Carrette, Odile; Corthals, Garry; Delalande, Francois; Diemer, Helene; Favreau, Philippe; Giuliano, Elia; Gueguen, Yannick; ***Guillaume, Elisabeth***; Hahner, Stephanie; Man, Petr; Michalet, Sophie; Neri, Dario; Noukakis, Dimitrios; Palagi, Patricia; Paroutaud, Pierre; Pimenta, Daniel Carvalho; Quadroni, Manfredo; Resemann, Anja; Richert, Sophie; Rybak, Jascha; Sanchez, Jean-Charles; Scherl, Alexander; Scheurer, Simone; Hufnagel, Ulrike Schweiger; Siethoff, Christoph; Suckau, Detlev; Van Dorsselaer, Alain; Redeker, Winfried Wagner; Walter, Nadia; Stocklin, Reto

CS Proteome Informatics Group, Swiss Institute of Bioinformatics, 1, .
Michel-Servet, CH-1211, Geneva, Switzerland
pierre-alain.binz@isb-sib.ch

SO Proteomics, (August 2003) Vol. 3, No. 8, pp. 1562-1566. print.
ISSN: 1615-9853 (ISSN print).

DT Article

LA English

ED Entered STN: 28 Jan 2004

Last Updated on STN: 28 Jan 2004

AB After the success of the mass spectrometry (MS) round table that was held at the first Swiss Proteomics Society congress (SPS'01) in Geneva, the SPS has organized a proteomics application exercise and allocated a full session at the SPS'02 congress. The main objective was to encourage the exchange of expertise in protein identification, with a focus on the use of mass spectrometry, and to create a bridge between the users' questions and the instrument providers' solutions. Two samples were sent to fifteen interested labs, including academic groups and MS hardware providers. Participants were asked to identify and partially characterize the samples. They consisted of a complex mixture of peptide/proteins (sample A) and an almost pure recombinant peptide carrying post-translational modifications (sample B). Sample A was an extract of snake venom from the species Bothrops jararaca. Sample B was a recombinant and modified peptide derived from the shrimp Penaeus vannamei penaeidin 3a. The eight labs that returned results reported the use of a wide range of MS instrumentation and techniques. They mentioned a variety of time and manpower allocations. The origin of sample A was generally identified together with a number of database protein entries. The difficulty of the sample identification lay in the incomplete knowledge of the Bothrops species genome sequence and is discussed. Sample B was generally and correctly identified as penaeidin. However, only one group reported the

full primary structure. Interestingly, the approaches were again varied and are discussed in the text.

L6 ANSWER 9 OF 14 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
DUPLICATE 4
AN 2004:60806 BIOSIS
DN PREV200400061254
TI A potential cerebrospinal fluid and plasmatic marker for the diagnosis of
Creutzfeldt-Jakob disease.
AU ***Guillaume, Elisabeth*** [Reprint Author]; Zimmermann, Catherine;
Burkhard, Pierre R.; Hochstrasser, Denis F.; Sanchez, Jean-Charles
CS Biomedical Proteomics Research Group, Central Clinical Chemistry
Laboratory, Geneva University Hospital, 24, Rue Micheli-du-Crest, 1211,
Geneva 14, Switzerland
guillaum@dim.hcuge.ch
SO Proteomics, (August 2003) Vol. 3, No. 8, pp. 1495-1499. print.
ISSN: 1615-9853 (ISSN print).
DT Article
LA English
ED Entered STN: 28 Jan 2004
Last Updated on STN: 28 Jan 2004
AB The recent occurrence of the new variant of Creutzfeldt-Jakob disease
(CJD), probably transmitted to humans by cattle affected by the bovine
form of spongiform encephalopathy, has generated renewed interest in the
clinical issues related to human spongiform encephalopathies. Using the
current set of diagnostic tools, these rare but devastating conditions may
be difficult to diagnose with accuracy before death. The objective of the
present communication is to describe the discovery of a potential
cerebrospinal fluid (CSF) and plasmatic marker of human transmissible
spongiform encephalopathies. A preliminary two-dimensional
electrophoresis approach highlighted a potential neurodegenerative
disorder marker called the fatty acid binding protein, FABP. Its heart
form, H-FABP, was investigated in a small group of CJD affected patients
(n=8) by an immunoassay approach. The amount of FABP appeared to be
significantly (p<0.05) increased in all tested samples. H-FABP
detection could therefore be helpful as a blood screening test for a
pre-mortem diagnosis of the disease and also to prevent the risk of
iatrogenic transmission of CJD through blood transfusion.

L6 ANSWER 10 OF 14 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on
STN DUPLICATE 5
AN 2003:512147 BIOSIS
DN PREV200300515495
TI Production of the antiviral proteins 2'5'oligoadenylate synthetase, PKR
and Mx in interstitial cells and spermatogonia.
AU Melaine, Nathalie; Lienard, Marie-Odile; ***Guillaume, Elisabeth*** ;
Ruffault, Annick; Dejucq-Rainsford, Nathalie; Jegou, Bernard [Reprint
Author]
CS GERM-INSERM U.435, Universite de Rennes I, Campus de Beaulieu, 35 042,
Rennes Cedex, Bretagne, France
bernard.jegou@rennes.inserm.fr
SO Journal of Reproductive Immunology, (June 2003) Vol. 59, No. 1, pp. 53-60.
print.
CODEN: JRIMDR. ISSN: 0165-0378.
DT Article
LA English
ED Entered STN: 5 Nov 2003

Last Updated on STN: 5 Nov 2003

AB We report an in vitro analysis of the spatial pattern of production of three antiviral proteins (2'5'oligoadenylate synthetase, 2'5'AS; double-stranded RNA-activated protein kinase, PKR; and Mx protein, Mx) in the rat testis, in basal conditions and following stimulation with interferon (IFN) or Sendai virus. The two major constituents of interstitial tissue-Leydig cells and macrophages-constitutively produce 2'5' oligoadenylate synthetase (2'5'AS), PKR and Mx. Production of an isoform of 2'5'AS was induced following Leydig cells stimulation by the Sendai virus. The most immature germ cells, spermatogonia, were devoid of 2'5'AS whatever the type of stimulation, whereas IFN treatment induced Mx production and increased PKR production in this cell type. IFN stimulation strongly increased PKR production in all three cell types. This new set of data extends our previous investigations and demonstrates that the testis possesses an anti-viral defense system involving IFNs and IFN-induced anti-viral proteins.

L6 ANSWER 11 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2001:677072 CAPLUS

DN 135:207875

TI Diagnostic assay for transmissible spongiform encephalopathies

IN Hochstrasser, Denis Francois; Sanchez, Jean-Charles; Zimmermann, Catherine Gabrielle; ***Guillaume, Elisabeth***

PA Universite de Geneve, Switz.

SO PCT Int. Appl., 21 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|----------------|--|----------|-----------------|----------|
| PI | WO 2001067108 | A2 | 20010913 | WO 2001-EP2894 | 20010312 |
| | WO 2001067108 | A3 | 20020321 | | |
| | W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | |
| | RW: | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | |
| | GB 2360089 | A1 | 20010912 | GB 2000-5683 | 20000310 |
| | CA 2402314 | AA | 20010913 | CA 2001-2402314 | 20010312 |
| | EP 1261875 | A2 | 20021204 | EP 2001-931527 | 20010312 |
| | R: | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | |
| | JP 2003526788 | T2 | 20030909 | JP 2001-566030 | 20010312 |
| | US 2003157580 | A1 | 20030821 | US 2002-238557 | 20020910 |
| PRAI | GB 2000-5683 | A | 20000310 | | |
| | GB 2000-6064 | A | 20000314 | | |
| | WO 2001-EP2894 | W | 20010312 | | |

AB Heart and brain fatty acid binding proteins (H-FABP, B-FABP) are markers for TSEs, esp. CJD. The invention provides a diagnostic assay for either of these markers, preferably by enzyme immunoassay using a specific antibody thereto. Since H-FABP is also a marker for acute myocardial infarction (AMI), to distinguish CJD from AMI requires an assay specific

to AMI, e.g. using troponin-1 or CK-MB as a marker, also to be carried out.

L6 ANSWER 12 OF 14 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on
STN DUPLICATE 6

AN 2001:452668 BIOSIS

DN PREV200100452668

TI Cellular distribution of translationally controlled tumor protein in rat and human testes.

AU ***Guillaume, Elisabeth*** ; Pineau, Charles [Reprint author]; Evrard, Bertrand; Dupaix, Alain; Moertz, Ejvind; Sanchez, Jean-Charles; Hochstrasser, Denis F.; Jegou, Bernard

CS GERM - INSERM U.435, Universite de Rennes I, Campus de Beaulieu, 35042, Rennes Cedex, Bretagne, France
charles.pineau@rennes.inserm.fr

SO Proteomics, (July, 2001) Vol. 1, No. 7, pp. 880-889. print.
ISSN: 1615-9853.

DT Article

LA English

ED Entered.STN: 26 Sep 2001

Last Updated on STN: 22 Feb 2002

AB In a recent proteomic study we identified 53 spermatogonial proteins among which was the translationally controlled tumor protein (TCTP). This is a protein previously reported as being implicated in proliferation events in normal and tumoral tissues that had never previously been seen in the testis. The present study was aimed at establishing the complete cellular distribution of TCTP and its transcript and the ontogenetic expression of this gene within the testis. Using an immunohistochemistry technique, an intense TCTP signal was detected in gonocytes (the prespermatogonia) in the fetal rat testis and in spermatogonia within adult human and neonatal and adult rat testes. Meiotic spermatocytes and postmeiotic haploid spermatids were also strongly immunostained in a stage-dependent manner in human and rat testes. In addition, different levels of TCTP expression were also observed in the testicular somatic cells, with strong expression in Leydig cells and peritubular cells, and weak expression in Sertoli cells. Western and Northern blot analyses confirmed the presence of TCTP at all ages studied, with higher levels of RNA expression at 9 and 20 d postpartum, when spermatogonia and primary spermatocytes represent the highest proportion of germ cells: it was also confirmed that TCTP is present in all populations of isolated testicular cells. A transcript of 0.85 kb corresponding to TCTP, was expressed at all ages studied. This transcript was found to be expressed strongly in spermatogonia, somewhat less in isolated Leydig, resident macrophage, peritubular and Sertoli cells, weakly in the primary spermatocytes but not at all in spermatids. Interestingly, in the latter, a different transcript of 1.1 kb was present. The same 1.1 kb transcript appeared in testis extracts from 35 days postpartum onwards, corresponding to an age when spermatids accumulate within the tubules. Of note is that resident macrophages were found to express both the 0.85 and the 1.1 kb transcripts. We conclude that the strong expression of TCTP in spermatogonia makes it highly likely that the protein plays a significant role in spermatogenesis.

L6 ANSWER 13 OF 14 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on
STN DUPLICATE 7

AN 2002:25145 BIOSIS

DN PREV200200025145

TI Proteome analysis of rat spermatogonia: Reinvestigation of stathmin

spatio-temporal expression within the testis.

AU ***Guillaume, Elisabeth*** ; Evrard, Bertrand; Com, Emmanuelle; Moertz, Ejvind; Jegou, Bernard; Pineau, Charles [Reprint author]

CS GERM-INSERM U.435, Universite de Rennes I, Campus de Beaulieu, 35042, Rennes Cedex, Bretagne, France
charles.pineau@rennes.inserm.fr

SO Molecular Reproduction and Development, (December, 2001) Vol. 60, No. 4, pp. 439-445. print.
CODEN: MREDEE. ISSN: 1040-452X.

DT Article

LA English

ED Entered STN: 26 Dec 2001
Last Updated on STN: 25 Feb 2002

AB Stathmin is a protein known to be involved in various cell processes including cell proliferation and differentiation. It has already been described in the testis but its recent identification using a proteomic approach in mitotic spermatogenic stem cells named spermatogonia (Guillaume et al., 2000) has lead us to reinvestigate its expression within the testis. Stathmin and its mRNAs were studied in isolated cells by Western and Northern blots and in situ using immunohistochemistry. We demonstrated that stathmin is indeed expressed in spermatogonia, and that it is also intensively expressed in the meiotic spermatocytes and in the first generations of spermatids. Furthermore, we showed aggregations of the protein in the cytoplasm of the later generations of spermatids preceding its elimination at the time of spermiation. Our Northern blots reveal the presence of two stathmin transcripts of 1.1 and 3.2 kb within the testis from the fetal stage onwards, in spermatogonia, spermatocytes, and spermatids. However, the 3.2 kb RNA transcript was barely detectable in the spermatids. Stathmin expression is known to be associated with microtubule dynamics. Therefore, its expression in the germ line is most probably related to the extremely complex structural cellular rearrangements occurring in germ cells during spermatogenesis. However, the exact role of stathmin and the reason of the existence of two transcripts in the male germ lineage awaits further investigation.

L6 ANSWER 14 OF 14 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN DUPLICATE 8

AN 1998:353791 BIOSIS

DN PREV199800353791

TI Expression of interferons-alpha and -gamma in testicular interstitial tissue and spermatogonia of the rat.

AU Dejucq, Nathalie; Lienard, Marie-Odile; ***Guillaume, Elisabeth*** ; Dorval, Isabelle; Jegou, Bernard [Reprint author]

CS GERM-INSERM U-435, Univ. Rennes I, Campus Beaulieu, 35042 Rennes Cedex, Bretagne, France

SO Endocrinology, (July, 1998) Vol. 139, No. 7, pp. 3081-3087. print.
CODEN: ENDOAO. ISSN: 0013-7227.

DT Article

LA English

ED Entered STN: 13 Aug 1998
Last Updated on STN: 13 Aug 1998

AB The testis is divided into two compartments: the seminiferous tubules and the interstitial tissue. The latter essentially consists of the blood and lymphatic vessels, testosterone-producing Leydig cells, and testicular macrophages. In the exploration of the testicular antiviral defense system, we initially searched for interferon (IFN) production by the seminiferous tubule cells. The site of virus entry into the testis is

probably the interstitial compartment; thus, it is important to know whether and how the cells in this compartment are protected against viral infection. In addition, as germ cell precursors (spermatogonia) are only partially protected by the blood-testis barrier, it was important to explore the antiviral capability of these cells. In this study we searched for IFN production by Leydig cells, testicular macrophages, and spermatogonia after exposure to Sendai virus. We also investigated the effect of viral exposure on testosterone production by Leydig cells. Our results show that spermatogonia do not constitutively express IFNs and give a very poor response to the virus. In contrast, testicular macrophages constitutively produced type I IFNs, and this production was markedly stimulated by Sendai virus. Leydig cells produced twice as much type I IFNs as testicular macrophages after viral exposure, and they were the only cells producing both IFNalpha and -gamma, with these IFNs being dramatically induced/increased in response to exposure to the virus. Furthermore, incubation of Leydig cells with the Sendai virus stimulated testosterone production. In conclusion, this study further establishes the topography of IFN expression within the testis. This allows us to hypothesize that the potential antiviral system represented by Leydig cells and, to a lesser extent, by macrophages plays a key role in protecting both androgen production and spermatogenesis.

```
=> s diagnos? and (transmissible spongiform encephalo?)
L7      1688 DIAGNOS? AND (TRANSMISSIBLE SPONGIFORM ENCEPHALO?)
```

```
=> s l7 and spectrometry
L8      261 L7 AND SPECTROMETRY
```

```
=> dup rem l8
PROCESSING COMPLETED FOR L8
L9      258 DUP REM L8 (3 DUPLICATES REMOVED)
```

```
=> s l9 and polypeptide?
L10     242 L9 AND POLYPEPTIDE?
```

```
=> s l10 and (molecular weight)
L11     227 L10 AND (MOLECULAR WEIGHT)
```

<-----User Break----->

```
SEARCH ENDED BY USER
SEARCH ENDED BY USER
```

```
=> s l11 and ((cerebrospinal fluid)or CSF or (body fluid?) or plasma or serum or
blood or tears or urine or saliva)
L12     226 L11 AND ((CEREBROSPINAL FLUID) OR CSF OR (BODY FLUID?) OR PLASMA
OR SERUM OR BLOOD OR TEARS OR URINE OR SALIVA)
```

```
=> s l12 and (diagnos?/ab or diagnos?/ti)
'AB' IS NOT A VALID FIELD CODE
'AB' IS NOT A VALID FIELD CODE
'AB' IS NOT A VALID FIELD CODE
L13     212 L12 AND (DIAGNOS?/AB OR DIAGNOS?/TI)
```

```
=> s l13 and (spectrometr?/ab or spectrometr?/ti)
'AB' IS NOT A VALID FIELD CODE
```

'AB' IS NOT A VALID FIELD CODE
'AB' IS NOT A VALID FIELD CODE
L14 1 L13 AND (SPECTROMETR?/AB OR SPECTROMETR?/TI)

=> d

L14 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:722816 CAPLUS
DN 141:239284
TI ***Diagnostic*** method for ***transmissible*** ***spongiform***
encephalopathies
IN Hochstrasser, Denis Francois; Sanchez, Jean-Charles; Guillaume, Elisabeth
PA Switz.
SO U.S. Pat. Appl. Publ., 61 pp., Cont.-in-part of Appl. No. PCT/EP02/10063.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 3

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | US 2004171026 | A1 | 20040902 | US 2003-695194 | 20031028 |
| | GB 2379737 | A1 | 20030319 | GB 2001-21459 | 20010905 |
| | WO 2003023406 | A2 | 20030320 | WO 2002-EP10063 | 20020903 |
| | WO 2003023406 | A3 | 20031127 | | |
| | WO 2003023406 | C2 | 20040226 | | |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| | RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| PRAI | GB 2001-21459 | A | 20010905 | | |
| | WO 2002-EP10063 | A2 | 20020903 | | |
| | GB 2002-25245 | A | 20021030 | | |
| | GB 2003-6290 | A | 20030319 | | |

=> s 113 and (mass spectrometry)
L15 212 L13 AND (MASS SPECTROMETRY)

=> s 115 and (chip array?)
L16 154 L15 AND (CHIP ARRAY?)

=> d bib ab 1-
YOU HAVE REQUESTED DATA FROM 154 ANSWERS - CONTINUE? Y/(N):y

L16 ANSWER 1 OF 154 USPATFULL on STN
AN 2005:75247 USPATFULL
TI 69583 and 85924 Novel human protein kinase family members and uses therefor
IN Kapeller-Libermann, Rosana, Chestnut Hill, MA, UNITED STATES
Spurling, Heidi Lynn, Malden, MA, UNITED STATES
PI US 2005064544 A1 20050324

AI US 2004-490592 A1 20040323 (10)
 WO 2002-US34037 20021024
 PRAI US 2001-338690P 20011024 (60)
 DT Utility
 FS APPLICATION
 LREP Jean M Silveri, Millennium Pharmaceuticals Inc, 40 Landsdowne Street,
 Cambridge, MA, 02139
 CLMN Number of Claims: 29
 ECL Exemplary Claim: 1
 DRWN 2 Drawing Page(s)
 LN.CNT 6620
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB The invention provides isolated nucleic acids molecules, designated
 69583 and 85924 nucleic acid molecules, which encode novel protein
 kinase family members. The invention also provides antisense nucleic
 acid molecules, recombinant expression vectors containing 69583 or 85924
 nucleic acid molecules, host cells into which the expression vectors
 have been introduced, and nonhuman transgenic animals in which a 69583
 or 85924 gene has been introduced or disrupted. The invention still
 further provides isolated 69583 or 85924 proteins, fusion proteins,
 antigenic peptides and anti-69583 or -85924 antibodies.
 Diagnostic and therapeutic methods utilizing compositions of
 the
 invention are also provided.

 L16 ANSWER 2 OF 154 USPATFULL on STN
 AN 2005:23294 USPATFULL
 TI Novel human membrane-associated protein and cell surface protein family
 members
 IN Meyers, Rachel E., Newton, MA, UNITED STATES
 Glucksmann, Maria Alexandra, Lexington, MA, UNITED STATES
 Curtis, Rory A.J., Ashland, MA, UNITED STATES
 Kapeller-Libermann, Rosana, Chestnut Hill, MA, UNITED STATES
 Bandaru, Rajasekhar, Watertown, MA, UNITED STATES
 Leiby, Kevin R., Natick, MA, UNITED STATES
 PA Millennium Pharmaceuticals, Inc., Cambridge, MA (U.S. corporation)
 PI US 2005019838 A1 20050127
 AI US 2004-860779 A1 20040603 (10)
 RLI Continuation of Ser. No. US 2002-162435, filed on 4 Jun 2002, PENDING
 Continuation-in-part of Ser. No. US 2001-836499, filed on 17 Apr 2001,
 ABANDONED Continuation-in-part of Ser. No. WO 2001-US12420, filed on 17
 Apr 2001, PENDING Continuation-in-part of Ser. No. US 2001-891008, filed
 on 25 Jun 2001, ABANDONED Continuation-in-part of Ser. No. WO
 2001-US19963, filed on 25 Jun 2001, PENDING Continuation-in-part of Ser.
 No. US 2001-860868, filed on 18 May 2001, ABANDONED Continuation-in-part
 of Ser. No. WO 2001-US16013, filed on 18 May 2001, PENDING
 Continuation-in-part of Ser. No. US 2001-886429, filed on 21 Jun 2001,
 ABANDONED Continuation-in-part of Ser. No. WO 2001-US20055, filed on 21
 Jun 2001, PENDING Continuation-in-part of Ser. No. US 2002-41406, filed
 on 8 Jan 2002, ABANDONED Continuation-in-part of Ser. No. WO 2002-US275,
 filed on 8 Jan 2002, PENDING Continuation-in-part of Ser. No. US
 2001-934268, filed on 21 Aug 2001, ABANDONED Continuation-in-part of
 Ser. No. WO 2001-US41811, filed on 21 Aug 2001, PENDING
 PRAI US 2000-197507P 20000418 (60)
 US 2000-214220P 20000623 (60)
 US 2000-205674P 20000519 (60)
 US 2000-213963P 20000623 (60)

US 2001-260286P 20010108 (60)
US 2000-226612P 20000821 (60)
DT Utility
FS APPLICATION
LREP MILLENNIUM PHARMACEUTICALS, INC., 40 Landsdowne Street, CAMBRIDGE, MA,
02139
CLMN Number of Claims: 19
ECL Exemplary Claim: 1
DRWN 22 Drawing Page(s)
LN.CNT 30445
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated
16051a, 16051b, 58199, 57805, 56739, 39362, and 23228 nucleic acid
molecules, which encode novel human membrane-associated protein family
members, and human cell surface protein family members. The invention
also provides antisense nucleic acid molecules, recombinant expression
vectors containing 16051a, 16051b, 58199, 57805, 56739, 39362, or 23228
nucleic acid molecules, host cells into which the expression vectors
have been introduced, and nonhuman transgenic animals in which a 16051a,
16051b, 58199, 57805, 56739, 39362, or 23228 gene has been introduced or
disrupted. The invention still further provides isolated 16051a, 16051b,
58199, 57805, 56739, 39362, or 23228 proteins, fusion proteins,
antigenic peptides and anti-16051a, 16051b, 58199, 57805, 56739, 39362,
or 23228 antibodies. ***Diagnostic*** methods utilizing compositions
of the invention are also provided.

L16 ANSWER 3 OF 154 USPATFULL on STN
AN 2004:327379 USPATFULL
TI 32544, Novel human phospholipase C and uses thereof
IN Meyers, Rachel, Newton, MA, UNITED STATES
Silos-Santiago, Inmaculada, Cambridge, MA, UNITED STATES
PA Millennium Pharmaceuticals, Inc. (U.S. corporation)
PI US 2004259199 A1 20041223
AI US 2004-784089 A1 20040220 (10)
RLI Division of Ser. No. US 2001-927112, filed on 10 Aug 2001, PENDING
PRAI US 2000-246808P 20001108 (60)
DT Utility
FS APPLICATION
LREP MILLENNIUM PHARMACEUTICALS, INC., 40 Landsdowne Street, CAMBRIDGE, MA,
02139
CLMN Number of Claims: 23
ECL Exemplary Claim: 1
DRWN 8 Drawing Page(s)
LN.CNT 5297
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated
32544 nucleic acid molecules, which encode novel phospholipase family
members. The invention also provides antisense nucleic acid molecules,
recombinant expression vectors containing 32544 nucleic acid molecules,
host cells into which the expression vectors have been introduced, and
nonhuman transgenic animals in which a 32544 gene has been introduced or
disrupted. The invention still further provides isolated 32544 proteins,
fusion proteins, antigenic peptides and anti-32544 antibodies.
Diagnostic methods utilizing compositions of the invention are
also provided.

L16 ANSWER 4 OF 154 USPATFULL on STN

AN 2004:314570 USPATFULL
 TI 47153, A HUMAN GLYCOSYLTRANSFERASE FAMILY MEMBER AND USES THEREFOR
 IN Meyers, Rachel, Newton, MA, UNITED STATES
 Rosenfeld, Julie Beth, Sharon, MA, UNITED STATES
 PI US 2004248242 A1 20041209
 US 6849437 B2 20050201
 AI US 2002-113709 A1 20020328 (10)
 PRAI US 2001-279647P 20010328 (60)
 DT Utility
 FS APPLICATION
 LREP Intellectual Property Group, MILLENIUM PHARMACEUTICALS, INC., 75 Sidney
 Street, Cambridge, MA, 02139
 CLMN Number of Claims: 18
 ECL Exemplary Claim: 1
 DRWN 8 Drawing Page(s)
 LN.CNT 4650

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated
 47153 nucleic acid molecules, which encode novel glycosyltransferase
 family members. The invention also provides antisense nucleic acid
 molecules, recombinant expression vectors containing 47153 nucleic acid
 molecules, host cells into which the expression vectors have been
 introduced, and nonhuman transgenic animals in which a 47153 gene has
 been introduced or disrupted. The invention still further provides
 isolated 47153 proteins, fusion proteins, antigenic peptides and
 anti-47153 antibodies. ***Diagnostic*** and therapeutic methods
 utilizing compositions of the invention are also provided.

L16 ANSWER 5 OF 154 USPATFULL on STN

AN 2004:314488 USPATFULL
 TI Novel 14275, 54420, 8797, 27439, 68730, 69112 and 52908 molecules and
 uses therefor
 IN Glucksmann, Maria A., Lexington, MA, UNITED STATES
 Curtis, Rory A.J., Ashland, MA, UNITED STATES
 Tsai, Fong-Ying, Newton, MA, UNITED STATES
 Hodge, Martin R., Lexington, MA, UNITED STATES
 Meyers, Rachel E., Newton, MA, UNITED STATES
 MacBeth, Kyle J., Boston, MA, UNITED STATES
 Bandaru, Rajasekhar, Watertown, MA, UNITED STATES
 PA Millennium Pharmaceuticals, Inc. (U.S. corporation)
 PI US 2004248160 A1 20041209
 AI US 2004-782695 A1 20040219 (10)
 RLI Continuation-in-part of Ser. No. US 2001-7399, filed on 5 Nov 2001,
 ABANDONED Continuation of Ser. No. US 1999-390039, filed on 3 Sep 1999,
 ABANDONED Continuation-in-part of Ser. No. US 1998-146416, filed on 3
 Sep 1998, ABANDONED Continuation-in-part of Ser. No. US 2002-103458,
 filed on 22 Mar 2002, ABANDONED Continuation of Ser. No. US 2000-544797,
 filed on 7 Apr 2000, ABANDONED Continuation-in-part of Ser. No. US
 2001-945254, filed on 31 Aug 2001, ABANDONED Continuation-in-part of
 Ser. No. US 2001-945301, filed on 31 Aug 2001, ABANDONED
 Continuation-in-part of Ser. No. US 2001-24036, filed on 17 Dec 2001,
 ABANDONED Continuation-in-part of Ser. No. US 2002-192440, filed on 10
 Jul 2002, ABANDONED
 PRAI US 2000-229829P 20000831 (60)
 US 2000-229301P 20000901 (60)
 US 2000-258222P 20001222 (60)
 US 2001-341953P 20011219 (60)

US 2001-304243P 20010710 (60)
DT Utility
FS APPLICATION
LREP Jean M. Silveri, Millennium Pharmaceuticals, Inc., 40 Landsdowne Street,
Cambridge, MA, 02139
CLMN Number of Claims: 18
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 27443

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 14275, 54420, 8797, 27439, 68730, 69112 or 52908 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 14275, 54420, 8797, 27439, 68730, 69112 or 52908 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 14275, 54420, 8797, 27439, 68730, 69112 or 52908 gene has been introduced or disrupted. The invention still further provides isolated 14275, 54420, 8797, 27439, 68730, 69112 or 52908 proteins, fusion proteins, antigenic peptides and anti-14275, 54420, 8797, 27439, 68730, 69112 or 52908 antibodies. ***Diagnostic*** and therapeutic methods utilizing compositions of the invention are also provided.

L16 ANSWER 6 OF 154 USPATFULL on STN

AN 2004:274256 USPATFULL

TI Novel human hydrolase family members and uses thereof

IN Meyers, Rachel E., Newton, MA, UNITED STATES

Glucksmann, Maria Alexandra, Lexington, MA, UNITED STATES

Curtis, Rory A. J., Framingham, MA, UNITED STATES

Rudolph-Owen, Laura A., Jamaica Plain, MA, UNITED STATES

PI US 2004214758 A1 20041028

AI US 2002-193452 A1 20020711 (10)

RLI Continuation-in-part of Ser. No. US 2001-816664, filed on 23 Mar 2001,
ABANDONED

PRAI US 2000-191973P 20000324 (60)
US 2000-199559P 20000425 (60)
US 2000-206036P 20000522 (60)
US 2000-205442P 20000519 (60)
US 2000-209949P 20000606 (60)
US 2000-214948P 20000629 (60)
US 2000-220008P 20000721 (60)
US 2000-220040P 20000721 (60)
US 2000-226774P 20000821 (60)
US 2000-235033P 20000925 (60)
US 2000-238170P 20001005 (60)
US 2001-267054P 20010207 (60)
US 2000-213688P 20000623 (60)

DT Utility

FS APPLICATION

LREP Intellectual Property Group, MILLENNIUM PHARMACEUTICALS, INC., 75 Sidney
Street, Cambridge, MA, 02139

CLMN Number of Claims: 19

ECL Exemplary Claim: 1

DRWN 62 Drawing Page(s)

LN.CNT 68657

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated

26443, 46873, 61833, 26493, 58224, 46980, 32225, 47508, 56939, 33410, 33521, 23479, 48120, 46689, 80091, and 46508 nucleic acid molecules, which encode novel human hydrolase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 26443, 46873, 61833, 26493, 58224, 46980, 32225, 47508, 56939, 33410, 33521, 23479, 48120, 46689, 80091, or 46508 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 26443, 46873, 61833, 26493, 58224, 46980, 32225, 47508, 56939, 33410, 33521, 23479, 48120, 46689, 80091, or 46508 gene has been introduced or disrupted. The invention still further provides isolated 26443, 46873, 61833, 26493, 58224, 46980, 32225, 47508, 56939, 33410, 33521, 23479, 48120, 46689, 80091, or 46508 proteins, fusion proteins, antigenic peptides and anti-26443, 46873, 61833, 26493, 58224, 46980, 32225, 47508, 56939, 33410, 33521, 23479, 48120, 46689, 80091, or 46508 antibodies.

Diagnostic methods utilizing compositions of the invention are also provided.

L16 ANSWER 7 OF 154 USPATFULL on STN

AN 2004:171926 USPATFULL

TI Novel human enzyme family members and uses thereof

IN Meyers, Rachel E., Newton, MA, UNITED STATES

Glucksmann, Maria Alexandria, Lexington, MA, UNITED STATES

Rudolph-Owen, Laura A., Medford, MA, UNITED STATES

PA Millennium Pharmaceuticals, Inc., Cambridge, MA, 02139 (U.S. corporation)

PI US 2004132087 A1 20040708

AI US 2004-776871 A1 20040211 (10)

RLI Continuation of Ser. No. US 2002-175696, filed on 20 Jun 2002, PENDING
Continuation-in-part of Ser. No. US 2002-67668, filed on 4 Feb 2002, ABANDONED
Continuation-in-part of Ser. No. US 2001-823901, filed on 30 Mar 2001, ABANDONED
Continuation-in-part of Ser. No. WO 2001-US10720, filed on 2 Apr 2001, PENDING
Continuation-in-part of Ser. No. US 2001-862658, filed on 21 May 2001, ABANDONED
Continuation-in-part of Ser. No. WO 2001-US16380, filed on 21 May 2001, PENDING
Continuation-in-part of Ser. No. US 2001-882837, filed on 15 Jun 2001, ABANDONED
Continuation-in-part of Ser. No. WO 2001-US19319, filed on 15 Jun 2001, PENDING

PRAI US 2001-266140P 20010202 (60)

US 2000-193920P 20000331 (60)

US 2000-205675P 20000519 (60)

US 2000-211727P 20000615 (60)

DT Utility

FS APPLICATION

LREP MILLENNIUM PHARMACEUTICALS, INC., 40 Landsdowne Street, CAMBRIDGE, MA, 02139

CLMN Number of Claims: 19

ECL Exemplary Claim: 1

DRWN 27 Drawing Page(s)

LN.CNT 21375

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 33312, 33303, 32579, 21509, 33770, 46638, and 50090 nucleic acid molecules, which encode novel G protein-coupled receptor family members, human thioredoxin family members, human leucine-rich repeat family members, and human ringfinger family member. The invention also provides antisense nucleic acid molecules, recombinant expression vectors

containing 33312, 33303, 32579, 21509, 33770, 46638, or 50090 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 33312, 33303, 32579, 21509, 33770, 46638, or 50090 gene has been introduced or disrupted. The invention still further provides isolated 33312, 33303, 32579, 21509, 33770, 46638, or 50090 proteins, fusion proteins, antigenic peptides and anti-33312, 33303, 32579, 21509, 33770, 46638, or 50090 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided.

L16 ANSWER 8 OF 154 USPATFULL on STN

AN 2004:158550 USPATFULL

TI Novel 27877, 18080, 14081, 32140, 50352, 16658, 14223, 16002, 50566, 65552 and 65577 molecules and uses therefor

IN Meyers, Rachel E., Newton, MA, UNITED STATES

Carroll, Joseph M., Cambridge, MA, UNITED STATES

Cook, William James, Hanover, NH, UNITED STATES

Kapeller-Libermann, Rosana, Chestnut Hill, MA, UNITED STATES

Weich, Nadine S., Brookline, MA, UNITED STATES

Bandaru, Rajasekhar, Watertown, MA, UNITED STATES

PA Millennium Pharmaceuticals, Inc. (U.S. corporation)

PI US 2004121349 A1 20040624

AI US 2003-391364 A1 20030318 (10)

RLI Continuation-in-part of Ser. No. US 2001-950370, filed on 10 Sep 2001, ABANDONED Continuation-in-part of Ser. No. US 2002-294039, filed on 13 Nov 2002, PENDING Continuation-in-part of Ser. No. US 2002-266035, filed on 7 Oct 2002, PENDING Continuation-in-part of Ser. No. US 2000-717926, filed on 21 Nov 2000, GRANTED, Pat. No. US 6569657 Continuation-in-part of Ser. No. US 2002-268036, filed on 9 Oct 2002, PENDING Continuation-in-part of Ser. No. US 2001-922138, filed on 3 Aug 2001, PENDING Continuation-in-part of Ser. No. US 2001-945327, filed on 31 Aug 2001, PENDING Continuation-in-part of Ser. No. US 2002-163316, filed on 5 Jun 2002, PENDING Continuation-in-part of Ser. No. US 2002-103377, filed on 21 Mar 2002, PENDING

PRAI US 2000-231084P 20000908 (60)

US 2001-338587P 20011113 (60)

US 2001-328198P 20011009 (60)

US 2000-214707P 20000627 (60)

US 2001-327820P 20011009 (60)

US 2000-229299P 20000901 (60)

US 2000-229425P 20000831 (60)

US 2001-297863P 20010613 (60)

US 2001-278347P 20010323 (60)

DT Utility

FS APPLICATION

LREP Jean M. Silveri, Millennium Pharmaceuticals, Inc., 75 Sidney Street, Cambridge, MA, 02139

CLMN Number of Claims: 19

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 15849

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 27877, 18080, 14081, 32140, 50352, 16658, 14223, 16002, 50566, 65552 and 65577 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 27877, 18080, 14081, 32140, 50352, 16658, 14223, 16002, 50566, 65552 and 65577

nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 27877, 18080, 14081, 32140, 50352, 16658, 14223, 16002, 50566, 65552 or 65577 gene has been introduced or disrupted. The invention still further provides isolated 27877, 18080, 14081, 32140, 50352, 16658, 14223, 16002, 50566, 65552 or 65577 proteins, fusion proteins, antigenic peptides and anti-27877, 18080, 14081, 32140, 50352, 16658, 14223, 16002, 50566, 65552 or 65577 antibodies. ***Diagnostic*** and therapeutic methods utilizing compositions of the invention are also provided.

L16 ANSWER 9 OF 154 USPATFULL on STN
 AN 2004:114083 USPATFULL
 TI 53010, a novel human carboxylesterase family member and uses thereof
 IN Curtis, Rory A. J., Southborough, MA, UNITED STATES
 Silos-Santiago, Immaculada, Jamaica Plain, MA, UNITED STATES
 PA Millennium Pharmaceuticals, Inc. (U.S. corporation)
 PI US 2004086922 A1 20040506
 AI US 2003-674636 A1 20030929 (10)
 RLI Division of Ser. No. US 2001-23515, filed on 18 Dec 2001, GRANTED, Pat.
 No. US 6664091
 PRAI US 2000-256369P 20001218 (60)
 US 2001-279508P 20010328 (60)
 DT Utility
 FS APPLICATION
 LREP MILLENNIUM PHARMACEUTICALS, INC., 40 Landsdowne Street, CAMBRIDGE, MA,
 02139
 CLMN Number of Claims: 20
 ECL Exemplary Claim: 1
 DRWN 3 Drawing Page(s)
 LN.CNT 5079

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 53010 nucleic acid molecules, which encode novel carboxylesterase members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 53010 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 53010 gene has been introduced or disrupted. The invention still further provides isolated 53010 proteins, fusion proteins, antigenic peptides and anti-53010 antibodies.
 Diagnostic methods utilizing compositions of the invention are also provided.

L16 ANSWER 10 OF 154 USPATFULL on STN
 AN 2004:114082 USPATFULL
 TI 57242, a novel human G protein-coupled receptor family member and uses therefor
 IN Glucksmann, Maria Alexandra, Lexington, MA, UNITED STATES
 Gimeno, Ruth, Wellesley, MA, UNITED STATES
 White, David, Braintree, MA, UNITED STATES
 PA Millennium Pharmaceuticals, Inc. (U.S. corporation)
 PI US 2004086921 A1 20040506
 AI US 2003-665956 A1 20030918 (10)
 RLI Continuation of Ser. No. US 2001-942374, filed on 29 Aug 2001, ABANDONED
 PRAI US 2000-228409P 20000829 (60)
 DT Utility
 FS APPLICATION

LREP MILLENNIUM PHARMACEUTICALS, INC., Intellectual Property Department, 75
Sidney Street, Cambridge, MA, 02139
CLMN Number of Claims: 104
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 4729

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to methods and compositions for the
diagnosis and treatment of metabolic disorders, including, but
not limited to, obesity, diabetes, hyperlipidemia, overweight anorexia,
or cachexia. The invention provides isolated nucleic acids molecules,
designated 57242 nucleic acid molecules, which encode novel G
protein-coupled receptor family members. The invention also provides
antisense nucleic acid molecules, recombinant expression vectors
containing 57242 nucleic acid molecules, host cells into which the
expression vectors have been introduced, and nonhuman transgenic animals
in which a 57242 gene has been introduced or disrupted. The invention
still further provides isolated 57242 proteins, fusion proteins,
antigenic peptides and anti-57242 antibodies. Methods of use of the
provided 57242 compositions for screening, ***diagnostic*** and
therapeutic methods in connection with metabolic disorders are also
disclosed.

L16 ANSWER 11 OF 154 USPATFULL on STN

AN 2004:109094 USPATFULL

TI 18431 and 32374, novel human protein kinase family members and uses
therefor

IN Meyers, Rachel, Newton, MA, UNITED STATES

Kapeller-Libermann, Rosana, Chestnut Hill, MA, UNITED STATES

Silos-Santiago, Immaculada, Cambridge, MA, UNITED STATES

PA Millennium Pharmaceuticals, Inc. (U.S. corporation)

PI US 2004083496 A1 20040429

AI US 2003-678786 A1 20031003 (10)

RLI Continuation of Ser. No. US 2001-916790, filed on 27 Jul 2001, ABANDONED

PRAI US 2000-221543P 20000728 (60)

DT Utility

FS APPLICATION

LREP MILLENNIUM PHARMACEUTICALS, INC., 75 Sidney Street, Cambridge, MA, 02139

CLMN Number of Claims: 24

ECL Exemplary Claim: 1

DRWN 21 Drawing Page(s)

LN.CNT 6026

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated
32374 or 18431 nucleic acid molecules, which encode novel protein kinase
family members. The invention also provides antisense nucleic acid
molecules, recombinant expression vectors containing 32374 or 18431
nucleic acid molecules, host cells into which the expression vectors
have been introduced, and nonhuman transgenic animals in which a 32374
or 18431 gene has been introduced or disrupted. The invention still
further provides isolated 32374 or 18431 proteins, fusion proteins,
antigenic peptides and anti-32374 or -18431 antibodies.
Diagnostic methods utilizing compositions of the invention are
also provided.

L16 ANSWER 12 OF 154 USPATFULL on STN

AN 2004:107607 USPATFULL

TI 47174, a novel human glycosyltransferase and uses thereof
IN Kapeller-Libermann, Rosana, Chestnut Hill, MA, UNITED STATES
PA Millennium Pharmaceuticals, Inc. (U.S. corporation)
PI US 2004082007 A1 20040429
AI US 2003-713345 A1 20031114 (10)
RLI Division of Ser. No. US 2001-973457, filed on 9 Oct 2001, GRANTED, Pat.
No. US 6703230
PRAI US 2000-238849P 20001006 (60)
DT Utility
FS APPLICATION
LREP MILLENNIUM PHARMACEUTICALS, INC., 75 Sidney Street, Cambridge, MA, 02139
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 4 Drawing Page(s)
LN.CNT 4889

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 47174 nucleic acid molecules, which encode novel glycosyltransferase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 47174 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 47174 gene has been introduced or disrupted. The invention still further provides isolated 47174 proteins, fusion proteins, antigenic peptides and anti-47174 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided. The invention also provides methods of modulating pain or pain related disorders utilizing the compositions of the invention. Accordingly, methods of treating, preventing and/or ***diagnosing*** neurological disorders are disclosed.

L16 ANSWER 13 OF 154 USPATFULL on STN

AN 2004:76577 USPATFULL

TI Novel 21910, 56634, 55053, 2504, 15977, 14760, 25501, 17903, 3700, 21529, 26176, 26343, 56638, 18610, 33217, 21967, H1983, M1983, 38555 or 593 molecules and uses therefor

IN Kapeller-Libermann, Rosana, Chestnut Hill, MA, UNITED STATES

Hunter, John Joseph, Somerville, MA, UNITED STATES

Meyers, Rachel E., Newton, MA, UNITED STATES

Rudolph-Owen, Laura A., Medford, MA, UNITED STATES

Curtis, Rory A. J., Framingham, MA, UNITED STATES

Olandt, Peter J., Newton, MA, UNITED STATES

Tsai, Fong-Ying, Newton, MA, UNITED STATES

Galvin, Katherine M., Jamaica Plain, MA, UNITED STATES

Chun, Miyoung, Belmont, MA, UNITED STATES

Williamson, Mark J., Saugus, MA, UNITED STATES

Silos-Santiago, Inmaculada, Del Mar, CA, UNITED STATES

Bandaru, Rajasekhar, Watertown, MA, UNITED STATES

PA Millennium Pharmaceuticals, Inc. (U.S. corporation)

PI US 2004058355 A1 20040325

AI US 2003-423543 A1 20030425 (10)

RLI Continuation-in-part of Ser. No. US 2002-278036, filed on 22 Oct 2002, PENDING Continuation of Ser. No. US 2000-711216, filed on 9 Nov 2000, ABANDONED Continuation-in-part of Ser. No. US 2001-12055, filed on 13 Nov 2001, PENDING Continuation-in-part of Ser. No. US 2001-3690, filed on 15 Nov 2001, PENDING Continuation-in-part of Ser. No. US 2001-797039, filed on 28 Feb 2001, PENDING Continuation-in-part of Ser. No. US

2002-217168, filed on 12 Aug 2002, PENDING Continuation-in-part of Ser. No. US 2001-929218, filed on 14 Aug 2001, ABANDONED Continuation-in-part of Ser. No. US 2001-963159, filed on 25 Sep 2001, ABANDONED Continuation-in-part of Ser. No. US 2002-121911, filed on 12 Apr 2002, GRANTED, Pat. No. US 6607892 Division of Ser. No. US 1999-412210, filed on 5 Oct 1999, GRANTED, Pat. No. US 6403358 Continuation-in-part of Ser. No. US 2002-105989, filed on 25 Mar 2002, PENDING Continuation of Ser. No. US 1999-392189, filed on 9 Sep 1999, ABANDONED Continuation-in-part of Ser. No. US 2003-336153, filed on 3 Jan 2003, PENDING Continuation of Ser. No. US 2001-845044, filed on 27 Apr 2001, ABANDONED Continuation-in-part of Ser. No. US 2001-928531, filed on 13 Aug 2001, ABANDONED Continuation-in-part of Ser. No. US 2001-920346, filed on 31 Jul 2001, PENDING Continuation-in-part of Ser. No. US 2001-8016, filed on 8 Nov 2001, PENDING Continuation-in-part of Ser. No. US 2001-909743, filed on 20 Jul 2001, PENDING Division of Ser. No. US 1999-448076, filed on 23 Nov 1999, GRANTED, Pat. No. US 6300092 Continuation-in-part of Ser. No. US 1999-276400, filed on 25 Mar 1999, GRANTED, Pat. No. US 6140056 Continuation-in-part of Ser. No. US 2003-336489, filed on 2 Jan 2003, PENDING Continuation of Ser. No. US 2000-608921, filed on 30 Jun 2000, ABANDONED Continuation-in-part of Ser. No. US 1998-163821, filed on 30 Sep 1998, ABANDONED Continuation-in-part of Ser. No. US 2002-60763, filed on 30 Jan 2002, ABANDONED Continuation of Ser. No. US 1999-365162, filed on 30 Jul 1999, ABANDONED

PRAI US 2000-205447P 20000519 (60)
 US 2000-248325P 20001114 (60)
 US 2000-248893P 20001115 (60)
 US 2000-186061P 20000229 (60)
 US 2001-312539P 20010815 (60)
 US 2000-257511P 20001222 (60)
 US 2000-234922P 20000925 (60)
 US 2000-200688P 20000428 (60)
 US 2000-235035P 20000925 (60)
 US 2000-221925P 20000731 (60)
 US 2001-260166P 20010105 (60)
 US 2000-246669P 20001108 (60)
 US 1999-117580P 19990127 (60)

DT Utility

FS APPLICATION

LREP Millennium Pharmaceuticals, Inc., 75 Sidney Street, Cambridge, MA, 02139

CLMN Number of Claims: 19

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 14751

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 21910, 56634, 55053, 2504, 15977, 14760, 25501, 17903, 3700, 21529, 26176, 26343, 56638, 18610, 33217, 21967, h1983, m1983, 38555 and 593 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 21910, 56634, 55053, 2504, 15977, 14760, 25501, 17903, 3700, 21529, 26176, 26343, 56638, 18610, 33217, 21967, h1983, m1983, 38555 and 593 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 21910, 56634, 55053, 2504, 15977, 14760, 25501, 17903, 3700, 21529, 26176, 26343, 56638, 18610, 33217, 21967, h1983, m1983, 38555 or 593 gene has been introduced or disrupted. The invention still further provides isolated 21910, 56634, 55053, 2504, 15977, 14760, 25501, 17903, 3700, 21529,

26176, 26343, 56638, 18610, 33217, 21967, h1983, m1983, 38555 or 593 proteins, fusion proteins, antigenic peptides and anti-21910, 56634, 55053, 2504, 15977, 14760, 25501, 17903, 3700, 21529, 26176, 26343, 56638, 18610, 33217, 21967, h1983, m1983, 38555 or 593 antibodies.
Diagnostic and therapeutic methods utilizing compositions of

the

invention are also provided.

L16 ANSWER 14 OF 154 USPATFULL on STN

AN 2004:69999 USPATFULL

TI 23430, a novel human ubiquitin hydrolase family member and uses therefor

IN Kapeller-Libermann, Rosana, Chestnut Hill, MA, UNITED STATES

PI US 2004053226 A1 20040318

AI US 2001-905301 A1 20010713 (9)

PRAI US 2000-218245P 20000714 (60)

DT Utility

FS APPLICATION

LREP MORRISON & FOERSTER LLP, 3811 VALLEY CENTRE DRIVE, SUITE 500, SAN DIEGO, CA, 92130-2332

CLMN Number of Claims: 23

ECL Exemplary Claim: 1

DRWN 8 Drawing Page(s)

LN CNT 4612

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 23430 nucleic acid molecules, which encode novel ubiquitin hydrolase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 23430 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 23430 gene has been introduced or disrupted. The invention still further provides isolated 23430 proteins, fusion proteins, antigenic peptides and anti-23430 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided.

L16 ANSWER 15 OF 154 USPATFULL on STN

AN 2004:44517 USPATFULL

TI Novel 13237, 18480, 2245, 16228, 7677, 26320, 46619, 33166, 16836, 46867, 21617, 55562, 39228, 62088, 46745, 23155, 21657, 42755, 32229, 22325, 46863 and 32252 molecules and uses therefor

IN Meyers, Rachel E., Newton, MA, UNITED STATES

Williamson, Mark J., Saugus, MA, UNITED STATES

Kapeller-Libermann, Rosana, Chestnut Hill, MA, UNITED STATES

MacBeth, Kyle J., Boston, MA, UNITED STATES

Hunter, John Joseph, Somerville, MA, UNITED STATES

Rudolph-Owen, Laura A., Medford, MA, UNITED STATES

Bandaru, Rajasekhar, Watertown, MA, UNITED STATES

Tsai, Fong-Ying, Newton, MA, UNITED STATES

PA Millennium Pharmaceuticals, Inc. (U.S. corporation)

PI US 2004033509 A1 20040219

AI US 2003-377097 A1 20030228 (10)

RLI Continuation-in-part of Ser. No. US 2001-910150, filed on 18 Jul 2001, ABANDONED Continuation-in-part of Ser. No. US 2002-251507, filed on 20 Sep 2002, PENDING

PRAI US 2000-219028P 20000718 (60)

DT Utility

FS APPLICATION

LREP MILLENNIUM PHARMACEUTICALS, INC., 75 Sidney Street, Cambridge, MA, 02139
CLMN Number of Claims: 18
ECL Exemplary Claim: 1
DRWN No Drawings
LN: CNT 15960

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 13237, 18480, 2245, 16228, 7677, 26320, 46619, 33166, 16836, 46867, 21617, 55562, 39228, 62088, 46745, 23155, 21657, 42755, 32229, 22325, 46863 and 32252 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 13237, 18480, 2245, 16228, 7677, 26320, 46619, 33166, 16836, 46867, 21617, 55562, 39228, 62088, 46745, 23155, 21657, 42755, 32229, 22325, 46863 and 32252 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 13237, 18480, 2245, 16228, 7677, 26320, 46619, 33166, 16836, 46867, 21617, 55562, 39228, 62088, 46745, 23155, 21657, 42755, 32229, 22325, 46863 or 32252 gene has been introduced or disrupted. The invention still further provides isolated 13237, 18480, 2245, 16228, 7677, 26320, 46619, 33166, 16836, 46867, 21617, 55562, 39228, 62088, 46745, 23155, 21657, 42755, 32229, 22325, 46863 or 32252 proteins, fusion proteins, antigenic peptides and anti-13237, 18480, 2245, 16228, 7677, 26320, 46619, 33166, 16836, 46867, 21617, 55562, 39228, 62088, 46745, 23155, 21657, 42755, 32229, 22325, 46863 or 32252 antibodies.
Diagnostic and therapeutic methods utilizing compositions of

the

invention are also provided.

L16 ANSWER 16 OF 154 USPATFULL on STN

AN 2004:27065 USPATFULL

TI 25934, a novel fatty acid desaturase and uses therefor

IN Logan, Thomas Joseph, Needham, MA, United States

Glucksmann, Maria Alexandra, Lexington, MA, United States

PA Millennium Pharmaceuticals, Inc., Cambridge, MA, United States (U.S. corporation)

PI US 6686185 B1 20040203

AI US 2000-723806 20001128 (9)

PRAI US 2000-187455P 20000307 (60)

DT Utility

FS GRANTED

EXNAM Primary Examiner: Slobodyansky, Elizabeth

LREP Millennium Pharmaceuticals Inc.

CLMN Number of Claims: 24

ECL Exemplary Claim: 1

DRWN 9 Drawing Figure(s); 9 Drawing Page(s)

LN: CNT 4706

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 25934 nucleic acid molecules, which encode a novel desaturase family member. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 25934 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 25934 gene has been introduced or disrupted. The invention still further provides isolated 25934 proteins, fusion proteins, antigenic peptides and anti-25934 antibodies.
Diagnostic methods utilizing compositions of the invention are also provided. The invention also provides methods for modulating fatty

acid metabolism utilizing the compositions of the invention. Accordingly, methods of treating, preventing and/or ***diagnosing*** cardiovascular disorders, such as atherosclerosis, hypertriglyceridemia, hypercholesterolemia, and hyperlipidemia, are disclosed.

L16 ANSWER 17 OF 154 USPATFULL on STN
AN 2004:12981 USPATFULL
TI Novel 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 and 49933 molecules and uses therefor
IN Curtis, Rory A. J., Ashland, MA, UNITED STATES
Logan, Thomas Joseph, Springfield, PA, UNITED STATES
Glucksmann, Maria Alexandra, Lexington, MA, UNITED STATES
Meyers, Rachel E., Newton, MA, UNITED STATES
Williamson, Mark J., Saugus, MA, UNITED STATES
Rudolph-Owen, Laura A., Medford, MA, UNITED STATES
Chun, Miyoung, Belmont, MA, UNITED STATES
Tsai, Fong-Ying, Newton, MA, UNITED STATES
PA Millennium Pharmaceuticals, Inc. (U.S. corporation)
PI US 2004009501 A1 20040115
US 2004157221 A9 20040812
AI US 2003-377072 A1 20030227 (10)
RLI Continuation-in-part of Ser. No. US 2001-895860, filed on 29 Jun 2001, PENDING Continuation-in-part of Ser. No. US 2000-723806, filed on 28 Nov 2000, PENDING Continuation-in-part of Ser. No. US 2001-843297, filed on 25 Apr 2001, GRANTED, Pat. No. US 6569667 Continuation-in-part of Ser. No. US 2001-861801, filed on 21 May 2001, ABANDONED Continuation-in-part of Ser. No. US 2001-816494, filed on 23 Mar 2001, PENDING Continuation-in-part of Ser. No. US 2001-888911, filed on 25 Jun 2001, ABANDONED Continuation-in-part of Ser. No. US 2001-908664, filed on 17 Jul 2001, ABANDONED Continuation-in-part of Ser. No. US 2001-935291, filed on 21 Aug 2001, ABANDONED
PRAI US 2000-215370P 20000629 (60)
US 2000-187455P 20000307 (60)
US 2000-199801P 20000426 (60)
US 2000-205508P 20000519 (60)
US 2000-213688P 20000623 (60)
US 2000-218675P 20000717 (60)
US 2000-250932P 20001130 (60)
US 2000-226504P 20000821 (60)
DT Utility
FS APPLICATION
LREP Jean M. Silveri, 75 Sidney Street, Cambridge, MA, 02139
CLMN Number of Claims: 19
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 16123
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 and 49933 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 gene has been introduced or disrupted. The invention still further provides isolated 25869, 25934,

26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 proteins, fusion proteins, antigenic peptides and anti-25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 antibodies. ***Diagnostic*** and therapeutic methods utilizing compositions of the invention are also provided.

L16 ANSWER 18 OF 154 USPATFULL on STN

AN 2004:7430 USPATFULL

TI Novel 26199, 33530, 33949, 47148, 50226, 58764, 62113, 32144, 32235, 23565, 13305, 14911, 86216, 25206 and 8843 molecules and uses therefor

IN Meyers, Rachel E., Newton, MA, UNITED STATES

MacBeth, Kyle J., Boston, MA, UNITED STATES

Curtis, Rory A. J., Ashland, MA, UNITED STATES

Rudolph-Owen, Laura A., Medford, MA, UNITED STATES

Weich, Nadine S., Brookline, MA, UNITED STATES

Olandt, Peter J., Buffalo, NY, UNITED STATES

Tsai, Fong-Ying, Newton, MA, UNITED STATES

Kapeller-Libermann, Rosana, Chestnut Hill, MA, UNITED STATES

Carroll, Joseph M., Cambridge, MA, UNITED STATES

PA Millennium Pharmaceuticals, Inc. (U.S. corporation)

PI US 2004005664 A1 20040108

AI US 2003-410764 A1 20030410 (10)

RLI Continuation-in-part of Ser. No. US 2001-924358, filed on 6 Aug 2001, PENDING Continuation-in-part of Ser. No. US 2003-350553, filed on 24 Jan 2003, PENDING Continuation-in-part of Ser. No. US 2001-966614, filed on 27 Sep 2001, PENDING Continuation-in-part of Ser. No. US 2002-281094, filed on 25 Oct 2002, PENDING Continuation-in-part of Ser. No. US 2002-76535, filed on 15 Feb 2002, PENDING Continuation-in-part of Ser. No. US 2001-860352, filed on 17 May 2001, ABANDONED Continuation-in-part of Ser. No. US 2000-593927, filed on 15 Jun 2000, ABANDONED Continuation-in-part of Ser. No. US 2002-226410, filed on 23 Aug 2002, PENDING Continuation-in-part of Ser. No. US 2001-997816, filed on 29 Nov 2001, ABANDONED Continuation-in-part of Ser. No. US 2000-686673, filed on 11 Oct 2000, PENDING

PRAI US 2000-229300P 20000901 (60)

US 2002-351572P 20020124 (60)

US 2000-238054P 20001005 (60)

US 2001-347815P 20011029 (60)

US 2001-269440P 20010216 (60)

US 2000-205301P 20000519 (60)

US 2000-199391P 20000425 (60)

US 2001-314884P 20010824 (60)

US 2000-250186P 20001130 (60)

DT Utility

FS APPLICATION

LREP Jean M. Silveri, Millennium Pharmaceuticals, Inc., 75 Sidney Street, Cambridge, MA, 02139

CLMN Number of Claims: 19

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 17049

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 26199, 33530, 33949, 47148, 50226, 58764, 62113, 32144, 32235, 23565, 13305, 14911, 86216, 25206 and 8843 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 26199, 33530, 33949, 47148, 50226, 58764,

62113, 32144, 32235, 23565, 13305, 14911, 86216, 25206 and 8843 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 26199, 33530, 33949, 47148, 50226, 58764, 62113, 32144, 32235, 23565, 13305, 14911, 86216, 25206 or 8843 gene has been introduced or disrupted. The invention still further provides isolated 26199, 33530, 33949, 47148, 50226, 58764, 62113, 32144, 32235, 23565, 13305, 14911, 86216, 25206 or 8843 proteins, fusion proteins, antigenic peptides and anti-26199, 33530, 33949, 47148, 50226, 58764, 62113, 32144, 32235, 23565, 13305, 14911, 86216, 25206 or 8843 antibodies. ***Diagnostic*** and therapeutic methods utilizing compositions of the invention are also provided.

L16 ANSWER 19 OF 154 USPATFULL on STN

AN 2004:7390 USPATFULL

TI 84573, a human protein kinase family member and uses therefor

IN Tayber, Olga, Newton, MA, UNITED STATES

PA Millennium Pharmaceuticals, Inc. (U.S. corporation)

PI US 2004005624 A1 20040108

AI US 2003-460545 A1 20030612 (10)

PRAI US 2002-388031P 20020612 (60)

DT Utility

FS APPLICATION

LRÉP MILLENNIUM PHARMACEUTICALS, INC., 75 SIDNEY STREET, CAMBRIDGE, MA, 02139

CLMN Number of Claims: 32

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 5146

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 84573 nucleic acid molecules, which encode novel protein kinase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 84573 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 84573 gene has been introduced or disrupted. The invention still further provides isolated 84573 proteins, fusion proteins, antigenic peptides and anti-84573 antibodies. ***Diagnostic*** and therapeutic methods utilizing compositions of

the

invention are also provided.

L16 ANSWER 20 OF 154 USPATFULL on STN

AN 2003:330125 USPATFULL

TI Novel human ion channel and transporter family members

IN Curtis, Rory A. J., Framingham, MA, UNITED STATES

Silos-Santiago, Inmaculada, Jamaica Plain, MA, UNITED STATES

Gu, Wei, Brookline, MA, UNITED STATES

PI US 2003232336 A1 20031218

AI US 2002-162102 A1 20020604 (10)

RLI Continuation-in-part of Ser. No. US 2001-875321, filed on 6 Jun 2001, PENDING Continuation-in-part of Ser. No. WO 2001-US18340, filed on 6 Jun 2001, PENDING

PRAI WO 2001-US18340 20010606

WO 2001-US18398 20010605

WO 2001-US18247 20010605

WO 2001-US25474 20010815

WO 2001-US26096 20010821

WO 2002-US9728 20020328
US 2001-290288P 20010511 (60)
US 2001-279281P 20010328 (60)
US 2000-226770P 20000821 (60)
US 2000-227068P 20000822 (60)
US 2000-209845P 20000606 (60)
DT Utility
FS APPLICATION
LREP Intellectual Property Group, MILLENNIUM PHARMACEUTICALS, INC., 75 Sidney
Street, Cambridge, MA, 02139
CLMN Number of Claims: 19
ECL Exemplary Claim: 1
DRWN 40 Drawing Page(s)
LN.CNT 38135

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 52906, 33408, 12189, 21784, 56201, 32620, 44589, 84226, and 8105 nucleic acid molecules, which encode novel human calcium channel family members, human sodium ion channel family members, human potassium channel family members, human sodium-sugar symporter family members, human ABC transporter family members, human cation family members, and human sugar transporter family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 52906, 33408, 12189, 21784, 56201, 32620, 44589, 84226, or 8105 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 52906, 33408, 12189, 21784, 56201, 32620, 44589, 84226, or 8105 gene has been introduced or disrupted. The invention still further provides isolated 52906, 33408, 12189, 21784, 56201, 32620, 44589, 84226, or 8105 proteins, fusion proteins, antigenic peptides and anti-52906, 33408, 12189, 21784, 56201, 32620, 44589, 84226, or 8105 antibodies.
Diagnostic methods utilizing compositions of the invention are also provided.

L16 ANSWER 21 OF 154 USPATFULL on STN

AN 2003:318632 USPATFULL

TI Novel human transferase family members and uses thereof
IN Meyers, Rachel E., Newton, MA, UNITED STATES

Williamson, Mark, Saugus, MA, UNITED STATES

Leiby, Kevin R., Natick, MA, UNITED STATES

Kapeller-Libermann, Rosana, Chestnut Hill, MA, UNITED STATES

Olandt, Peter J., Newton, MA, UNITED STATES

MacBeth, Kyle J., Boston, MA, UNITED STATES

Rudolph-Owen, Laura A., Jamaica Plain, MA, UNITED STATES

Tsai, Fong-Ying, Newton, MA, UNITED STATES

Hunter, John J., Somerville, MA, UNITED STATES

PI US 2003224376 A1 20031204

AI US 2002-184648 A1 20020627 (10)

RLI Continuation-in-part of Ser. No. US 2001-815028, filed on 22 Mar 2001,
PENDING Continuation-in-part of Ser. No. US 2001-801220, filed on 7 Mar
2001, PENDING Continuation-in-part of Ser. No. US 2001-816714, filed on
23 Mar 2001, ABANDONED Continuation-in-part of Ser. No. US 2001-844948,
filed on 27 Apr 2001, PENDING Continuation-in-part of Ser. No. US
2001-861164, filed on 18 May 2001, ABANDONED Continuation-in-part of
Ser. No. US 2001-883060, filed on 15 Jun 2001, PENDING
Continuation-in-part of Ser. No. US 2001-962678, filed on 25 Sep 2001,
PENDING Continuation-in-part of Ser. No. US 2001-973457, filed on 9 Oct

2001, PENDING Continuation-in-part of Ser. No. US 2002-72285, filed on 8 Feb 2002, PENDING Continuation-in-part of Ser. No. US 2001-817910, filed on 26 Mar 2001, PENDING Continuation-in-part of Ser. No. US 2001-842528, filed on 25 Apr 2001, ABANDONED Continuation-in-part of Ser. No. US 2001-882836, filed on 15 Jun 2001, PENDING Continuation-in-part of Ser. No. US 2001-882872, filed on 15 Jun 2001, ABANDONED

PRAI WO 2001-US9358 20010322
WO 2001-US7269 20010307
WO 2001-US9468 20010323
WO 2001-US13805 20010427
WO 2001-US16292 20010518
WO 2001-US19138 20010615
WO 2001-US29963 20010925
WO 2002-US3736 20020208
WO 2001-US9633 20010326
WO 2001-US40607 20010425
WO 2001-US19543 20010615
WO 2001-US19153 20010615
US 2000-191964P 20000324 (60)
US 2000-187456P 20000307 (60)
US 2000-191865P 20000324 (60)
US 2000-200604P 20000428 (60)
US 2000-205408P 20000519 (60)
US 2000-212079P 20000615 (60)
US 2000-235044P 20000925 (60)
US 2000-238849P 20001006 (60)
US 2001-267494P 20010208 (60)
US 2000-192092P 20000324 (60)
US 2000-199500P 20000425 (60)
US 2000-211730P 20000615 (60)
US 2000-212077P 20000615 (60)

DT Utility

FS APPLICATION

LREP Theodore R. Allen, Millennium Pharmaceuticals, Inc., 75 Sidney Street, Cambridge, MA, 02139

CLMN Number of Claims: 19

ECL Exemplary Claim: 1

DRWN 125 Drawing Page(s)

LN.CNT 66695

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 33877, 47179, 26886, 25552, 32132, 32244, 23680, 32624, 47174, 60491, 46743, 27417, 27960, 32252, and 53320 nucleic acid molecules, which encode novel human transferase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 33877, 47179, 26886, 25552, 32132, 32244, 23680, 32624, 47174, 60491, 46743, 27417, 27960, 32252, or 53320 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 33877, 47179, 26886, 25552, 32132, 32244, 23680, 32624, 47174, 60491, 46743, 27417, 27960, 32252, or 53320 gene has been introduced or disrupted. The invention still further provides isolated 33877, 47179, 26886, 25552, 32132, 32244, 23680, 32624, 47174, 60491, 46743, 27417, 27960, 32252, or 53320 proteins, fusion proteins, antigenic peptides and anti-33877, 47179, 26886, 25552, 32132, 32244, 23680, 32624, 47174, 60491, 46743, 27417, 27960, 32252, or 53320 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided.

L16 ANSWER 22 OF 154 USPATFULL on STN
 AN 2003:312209 USPATFULL
 TI Novel 18607, 15603, 69318, 12303, 48000, 52920, 5433, 38554, 57301, 58324, 55063, 52991, 59914, 59921 and 33751 molecules and uses therefor
 IN Glucksmann, Maria A., Lexington, MA, UNITED STATES
 Curtis, Rory A.J., Ashland, MA, UNITED STATES
 Lora, Jose M., Arlington, MA, UNITED STATES
 Galvin, Katherine M., Jamaica Plain, MA, UNITED STATES
 Silos-Santiago, Inmaculada, Del Mar, CA, UNITED STATES
 PA Millennium Pharmaceuticals, Inc. (U.S. corporation)
 PI US 2003219806 A1 20031127
 AI US 2003-391399 A1 20030318 (10)
 RLI Continuation-in-part of Ser. No. US 2001-789481, filed on 20 Feb 2001, PENDING Continuation-in-part of Ser. No. US 2000-634669, filed on 8 Aug 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-583373, filed on 31 May 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-510706, filed on 22 Feb 2000, ABANDONED Continuation-in-part of Ser. No. US 2002-309804, filed on 4 Dec 2002, PENDING Continuation-in-part of Ser. No. US 2002-94214, filed on 8 Mar 2002, PENDING Continuation-in-part of Ser. No. US 2001-828035, filed on 6 Apr 2001, ABANDONED Continuation-in-part of Ser. No. US 2001-891762, filed on 26 Jun 2001, PENDING Continuation-in-part of Ser. No. US 2002-245121, filed on 17 Sep 2002, PENDING Continuation-in-part of Ser. No. US 2002-95139, filed on 11 Mar 2002, PENDING Continuation-in-part of Ser. No. US 2001-957683, filed on 19 Sep 2001, ABANDONED Continuation-in-part of Ser. No. US 2001-942447, filed on 29 Aug 2001, ABANDONED Continuation-in-part of Ser. No. US 2002-62937, filed on 31 Jan 2002, PENDING Continuation-in-part of Ser. No. US 2002-255532, filed on 26 Sep 2002, PENDING
 PRAI US 2001-336936P 20011204 (60)
 US 2001-275078P 20010312 (60)
 US 2000-195734P 20000407 (60)
 US 2000-214176P 20000626 (60)
 US 2001-322983P 20010917 (60)
 US 2001-275172P 20010312 (60)
 US 2000-233537P 20000919 (60)
 US 2000-229036P 20000831 (60)
 US 2001-267076P 20010201 (60)
 US 2001-325854P 20010927 (60)
 DT Utility
 FS APPLICATION
 LREP Jean M. Silveri, Millennium Pharmaceuticals, Inc., 75 Sidney Street, Cambridge, MA, 02139
 CLMN Number of Claims: 19
 ECL Exemplary Claim: 1
 DRWN No Drawings
 LN.CNT 19893
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB The invention provides isolated nucleic acids molecules, designated 18607, 15603, 69318, 12303, 48000, 52920, 5433, 38554, 57301, 58324, 55063, 52991, 59914, 59921 and 33751 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 18607, 15603, 69318, 12303, 48000, 52920, 5433, 38554, 57301, 58324, 55063, 52991, 59914, 59921 and 33751 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 18607, 15603,

69318, 12303, 48000, 52920, 5433, 38554, 57301, 58324, 55063, 52991, 59914, 59921 or 33751 gene has been introduced or disrupted. The invention still further provides isolated 18607, 15603, 69318, 12303, 48000, 52920, 5433, 38554, 57301, 58324, 55063, 52991, 59914, 59921 or 33751 proteins, fusion proteins, antigenic peptides and anti-18607, 15603, 69318, 12303, 48000, 52920, 5433, 38554, 57301, 58324, 55063, 52991, 59914, 59921 or 33751 antibodies. ***Diagnostic*** and therapeutic methods utilizing compositions of the invention are also provided.

L16 ANSWER 23 OF 154 USPATFULL on STN

AN 2003:306426 USPATFULL

TI Novel 18636, 2466, 43238, 1983, 52881, 2398, 45449, 50289, 52872 and 26908 molecules and uses therefor

IN Glucksmann, Maria A., Lexington, MA, UNITED STATES
 Silos-Santiago, Inmaculada, Del Mar, CA, UNITED STATES
 Carroll, Joseph M., Cambridge, MA, UNITED STATES
 Galvin, Katherine M., Jamaica Plain, MA, UNITED STATES

PA Millennium Pharmaceuticals, Inc. (U.S. corporation)

PI US 2003215860 A1 20031120

AI US 2003-407079 A1 20030403 (10)

RLI Continuation-in-part of Ser. No. US 2002-226102, filed on 22 Aug 2002, PENDING Continuation-in-part of Ser. No. US 2002-225094, filed on 21 Aug 2002, PENDING Continuation-in-part of Ser. No. US 2002-272417, filed on 15 Oct 2002, PENDING Continuation of Ser. No. US 2000-715790, filed on 17 Nov 2000, ABANDONED Continuation-in-part of Ser. No. US 2002-282837, filed on 29 Oct 2002, PENDING Continuation of Ser. No. US 2001-796338, filed on 28 Feb 2001, ABANDONED Continuation-in-part of Ser. No. US 2001-863200, filed on 22 May 2001, ABANDONED

PRAI US 2001-314041P 20010822 (60)

US 2001-314185P 20010822 (60)

US 2000-191845P 20000324 (60)

US 2000-186059P 20000229 (60)

US 2000-206019P 20000522 (60)

DT Utility

FS APPLICATION

LREP Jean M. Silveri, Millennium Pharmaceuticals, Inc., 75 Sidney Street, Cambridge, MA, 02139

CLMN Number of Claims: 19

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 12157

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 18636, 2466, 43238, 1983, 52881, 2398, 45449, 50289, 52872 and 26908 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 18636, 2466, 43238, 1983, 52881, 2398, 45449, 50289, 52872 and 26908 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 18636, 2466, 43238, 1983, 52881, 2398, 45449, 50289, 52872 or 26908 gene has been introduced or disrupted. The invention still further provides isolated 18636, 2466, 43238, 1983, 52881, 2398, 45449, 50289, 52872 or 26908 proteins, fusion proteins, antigenic peptides and anti-18636, 2466, 43238, 1983, 52881, 2398, 45449, 50289, 52872 or 26908 antibodies. ***Diagnostic*** and therapeutic methods utilizing compositions of

the

invention are also provided.

L16 ANSWER 24 OF 154 USPATFULL on STN

AN 2003:265842 USPATFULL

TI 58224, a novel helicase family member and uses therefor

IN Glucksmann, Maria Alexandra, Lexington, MA, UNITED STATES

PI US 2003186859 A1 20031002

AI US 2001-861165 A1 20010518 (9)

PRAI US 2000-205442P 20000519 (60)

DT Utility

FS APPLICATION

LREP FISH & RICHARDSON PC, 225 FRANKLIN ST, BOSTON, MA, 02110

CLMN Number of Claims: 31

ECL Exemplary Claim: 1

DRWN 3 Drawing Page(s)

LN.CNT 5147

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 58224 nucleic acid molecules, which encode novel helicase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 58224 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 58224 gene has been introduced or disrupted. The invention still further provides isolated 58224 proteins, fusion proteins, antigenic peptides and anti-58224 antibodies.

Diagnostic methods utilizing compositions of the invention are also provided.

L16 ANSWER 25 OF 154 USPATFULL on STN

AN 2003:257879 USPATFULL

TI Novel human protein kinase, phosphatase, and protease family members and uses thereof

IN Meyers, Rachel E., Newton, MA, UNITED STATES

Olandt, Peter J., Newton, MA, UNITED STATES

Kapeller-Libermann, Rosana, Chestnut Hill, MA, UNITED STATES

Curtis, Rory A. J., Framingham, MA, UNITED STATES

Williamson, Mark, Saugus, MA, UNITED STATES

Weich, Nadine, Brookline, MA, UNITED STATES

PI US 2003180930 A1 20030925

AI US 2002-170789 A1 20020613 (10)

RLI Continuation-in-part of Ser. No. US 2001-797039, filed on 28 Feb 2001, PENDING Continuation-in-part of Ser. No. US 2001-882166, filed on 15 Jun 2001, PENDING Continuation-in-part of Ser. No. US 2001-934406, filed on 21 Aug 2001, PENDING Continuation-in-part of Ser. No. US 2001-861801, filed on 21 May 2001, PENDING Continuation-in-part of Ser. No. US 2001-801267, filed on 6 Mar 2001, PENDING Continuation-in-part of Ser. No. US 2001-829671, filed on 10 Apr 2001, PENDING Continuation-in-part of Ser. No. US 2001-961721, filed on 24 Sep 2001, PENDING Continuation-in-part of Ser. No. US 2001-45367, filed on 7 Nov 2001, PENDING Continuation-in-part of Ser. No. US 2001-801275, filed on 6 Mar 2001, PENDING

PRAI WO 2001-US6525 20010228

WO 2001-US19269 20010615

WO 2001-US26052 20010821

WO 2001-US16549 20010521

WO 2001-US7138 20010305

WO 2001-US40483 20010411

WO 2001-US29904 20010924
WO 2001-US7074 20010305
US 2000-186061P 20000229 (60)
US 2000-212078P 20000615 (60)
US 2000-226740P 20000821 (60)
US 2000-205508P 20000519 (60)
US 2000-187454P 20000307 (60)
US 2000-197508P 20000418 (60)
US 2000-235023P 20000925 (60)
US 2000-246561P 20001107 (60)
US 2000-187420P 20000307 (60)

DT Utility

FS APPLICATION

LREP LOUIS MYERS, Fish & Richardson P.C., 225 Franklin Street, Boston, MA,
02110-2804

CLMN Number of Claims: 19

ECL Exemplary Claim: 1

DRWN 62 Drawing Page(s)

LN.CNT 45159

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 2504, 15977, 14760, 53070, 15985, 50365, 26583, 21953, m32404, 14089, and 23436 nucleic acid molecules, which encode novel human protein kinase family members, serine/threonine protein kinase family members, hexokinase family members, serine/threonine phosphatase family members, prolyl oligopeptidase family members, trypsin family members, trypsin serine protease family members, and ubiquitin protease family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 2504, 15977, 14760, 53070, 15985, 50365, 26583, 21953, m32404, 14089, or 23436 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 2504, 15977, 14760, 53070, 15985, 50365, 26583, 21953, m32404, 14089, or 23436 gene has been introduced or disrupted. The invention still further provides isolated 2504, 15977, 14760, 53070, 15985, 50365, 26583, 21953, m32404, 14089, or 23436 proteins, fusion proteins, antigenic peptides and anti-2504, 15977, 14760, 53070, 15985, 50365, 26583, 21953, m32404, 14089, or 23436 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided.

L16 ANSWER 26 OF 154 USPATFULL on STN

AN 2003:251541 USPATFULL

TI 55562 and 21617, novel human proteins and methods of use thereof

IN Bandaru, Rajasekhar, Watertown, MA, UNITED STATES
Meyers, Rachel E., Newton, MA, UNITED STATES

PI US 2003176330 A1 20030918

AI US 2001-23617 A1 20011218 (10)

PRAI US 2000-256249P 20001218 (60)

US 2000-256405P 20001218 (60)

DT Utility

FS APPLICATION

LREP FISH & RICHARDSON PC, 225 FRANKLIN ST, BOSTON, MA, 02110

CLMN Number of Claims: 22

ECL Exemplary Claim: 1

DRWN 6 Drawing Page(s)

LN.CNT 6105

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 21617 and 55562 nucleic acid molecules, which encode novel dehydrogenase or tetratricopeptide repeat members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 21617 or 55562 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 21617 or 55562 gene has been introduced or disrupted. The invention still further provides isolated 21617 or 55562 proteins, fusion proteins, antigenic peptides and anti-21617 or 55562 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided.

L16 ANSWER 27 OF 154 USPATFULL on STN

AN 2003:238736 USPATFULL

TI 14715, a human fringe family member and uses therefor

IN Kapeller-Libermann, Rosana, Chestnut Hill, MA, UNITED STATES

Anderson, Karen L., Watertown, MA, UNITED STATES

PA Millennium Pharmaceuticals, Inc. (U.S. corporation)

PI US 2003166894 A1 20030904

AI US 2002-141604 A1 20020508 (10)

PRAI US 2001-289894P 20010509 (60)

DT Utility

FS APPLICATION

LREP Jean M. Silveri, Millennium Pharmaceuticals, Inc., 75 Sidney Street, Cambridge, MA, 02139

CLMN Number of Claims: 22

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 4683

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 14715 nucleic acid molecules, which encode novel fringe family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 14715 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 14715 gene has been introduced or disrupted. The invention still further provides isolated 14715 proteins, fusion proteins, antigenic peptides and anti-14715 antibodies. ***Diagnostic*** and therapeutic methods utilizing compositions of

the

invention are also provided.

L16 ANSWER 28 OF 154 USPATFULL on STN

AN 2003:238734 USPATFULL

TI 58566, a human anion exchanger family member and uses therefor

IN Curtis, Rory A.J., Farmingham, MA, UNITED STATES

PA Millennium Pharmaceuticals, Inc. (U.S. corporation)

PI US 2003166892 A1 20030904

AI US 2002-128202 A1 20020423 (10)

PRAI US 2001-286029P 20010424 (60)

DT Utility

FS APPLICATION

LREP Jean M. Silveri, Millennium Pharmaceuticals, Inc., 75 Sidney Street, Cambridge, MA, 02139

CLMN Number of Claims: 22

ECL Exemplary Claim: 1

DRWN 1 Drawing Page(s)

LN.CNT 5263

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 58566 nucleic acid molecules, which encode novel anion exchanger family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 58566 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 58566 gene has been introduced or disrupted. The invention still further provides isolated 58566 proteins, fusion proteins, antigenic peptides and anti-58566 antibodies.
Diagnostic and therapeutic methods utilizing compositions of

the

invention are also provided.

L16 ANSWER 29 OF 154 USPATFULL on STN

AN 2003:238727 USPATFULL

TI 52948, a human ABC transporter family member and uses therefor

IN Curtis, Rory A.J., Framingham, MA, UNITED STATES

PA Millennium Pharmaceuticals, Inc. (U.S. corporation)

PI US 2003166885 A1 20030904

AI US 2002-79087 A1 20020220 (10)

PRAI US 2001-272958P 20010302 (60)

DT Utility

FS APPLICATION

LREP Jean M. Silveri, Millennium Pharmaceuticals, Inc., 75 Sidney Street,
Cambridge, MA, 02139

CLMN Number of Claims: 22

ECL Exemplary Claim: 1

DRWN 1 Drawing Page(s)

LN.CNT 4768

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 52948 nucleic acid molecules, which encode novel ABC transporter family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 52948 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 52948 gene has been introduced or disrupted. The invention still further provides isolated 52948 proteins, fusion proteins, antigenic peptides and anti-52948 antibodies.
Diagnostic and therapeutic methods utilizing compositions of

the

invention are also provided.

L16 ANSWER 30 OF 154 USPATFULL on STN

AN 2003:238087 USPATFULL

TI 57316 and 33338, human ubiquitin carboxyl terminal hydrolases and uses therefor

IN Kapeller-Libermann, Rosana, Chestnut Hill, MA, UNITED STATES

Bandaru, Rajasekhar, Watertown, MA, UNITED STATES

PA Millennium Pharmaceuticals, Inc. (U.S. corporation)

PI US 2003166244 A1 20030904

AI US 2002-98108 A1 20020313 (10)

PRAI US 2001-276395P 20010316 (60)

DT Utility

FS APPLICATION

LREP Jean M. Silveri, Millennium Pharmaceuticals, Inc., 75 Sidney Street,
Cambridge, MA, 02139

CLMN Number of Claims: 29
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 5521

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 57316 or 33338 nucleic acid molecules, which encode ubiquitin carboxyl terminal hydrolase proteins. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 57316 or 33338 nucleic acid molecules, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a 57316 or 33338 gene has been introduced or disrupted. The invention still further provides isolated 57316 or 33338 proteins, fusion proteins, antigenic peptides and anti-57316 or 33338 antibodies.
Diagnostic and therapeutic methods utilizing compositions of

the

invention are also provided.

L16 ANSWER 31 OF 154 USPATFULL on STN

AN 2003:238067 USPATFULL

TI 18232, a novel dual specificity phosphatase and uses therefor

IN Meyers, Rachel A., Newton, MA, UNITED STATES

Weich, Nadine, Brookline, MA, UNITED STATES

PA Millennium Pharmaceuticals, Inc., a Delaware corporation (U.S. corporation)

PI US 2003166224 A1 20030904

AI US 2002-165272 A1 20020607 (10)

RLI Continuation of Ser. No. US 2000-704139, filed on 1 Nov 2000, GRANTED, Pat. No. US 6420153

PRAI US 2000-185772P 20000229 (60)

DT Utility

FS APPLICATION

LREP FISH & RICHARDSON PC, 225 FRANKLIN ST, BOSTON, MA, 02110

CLMN Number of Claims: 26

ECL Exemplary Claim: 1

DRWN 8 Drawing Page(s)

LN.CNT 4569

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 18232 nucleic acid molecules, which encode novel dual specificity phosphatase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 18232 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 18232 gene has been introduced or disrupted. The invention still further provides isolated 18232 proteins, fusion proteins, antigenic peptides and anti-18232 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided. The invention also provides methods of modulating the differentiation and proliferation of hematopoietic cells (e.g., erythroid cells) utilizing the compositions of the invention. Accordingly, methods of treating, preventing and/or ***diagnosing*** erythroid-associated disorders such as anemias, leukemias, and erythrocytosis are disclosed.

L16 ANSWER 32 OF 154 USPATFULL on STN

AN 2003:238065 USPATFULL

TI 39267, human kinase family members and uses therefor

IN Meyers, Rachel E., Newton, MA, UNITED STATES
PA Millennium Pharmaceuticals, Inc. (non-U.S. corporation)
PI US 2003166222 A1 20030904
AI US 2003-335687 A1 20030102 (10)
PRAI US 2002-345773P 20020102 (60)
DT Utility
FS APPLICATION
LREP Jean M. Silveri, MILLENNIUM PHARMACEUTICALS, INC., 75 Sidney Street,
Cambridge, MA, 02139
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 7069

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 39267 nucleic acid molecules, which encode novel kinase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 39267 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 39267 gene has been introduced or disrupted. The invention still further provides isolated 39267 proteins, fusion proteins, antigenic peptides and anti-39267 antibodies.

Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.

L16 ANSWER 33 OF 154 USPATFULL on STN
AN 2003:237903 USPATFULL
TI 58297, an amino acid transporter and uses therefor
IN Curtis, Rory A.J., Southborough, MA, UNITED STATES
PA Millennium Pharmaceuticals, Inc. (U.S. corporation)
PI US 2003166060 A1 20030904
AI US 2002-44901 A1 20020110 (10)
PRAI US 2001-262515P 20010118 (60)
DT Utility
FS APPLICATION
LREP Jean M. Silveri, Millennium Pharmaceuticals, Inc., 75 Sidney Street,
Cambridge, MA, 02139
CLMN Number of Claims: 33
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 5115

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 58297 nucleic acid molecules, which encode amino acid transporter family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 58297 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 58297 gene has been introduced or disrupted. The invention still further provides isolated 58297 proteins, fusion proteins, antigenic peptides and anti-58297 antibodies.

Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.

L16 ANSWER 34 OF 154 USPATFULL on STN
AN 2003:237902 USPATFULL

TI 54498, an amino acid transporter and uses therefor
IN Curtis, Rory A.J., Southborough, MA, UNITED STATES
PA Millennium Pharmaceuticals, Inc. (U.S. corporation)
PI US 2003166059 A1 20030904
AI US 2002-44897 A1 20020110 (10)
PRAI US 2001-261408P 20010112 (60)
DT Utility
FS APPLICATION
LREP Jean M. Silveri, Millennium Pharmaceuticals, Inc., 75 Sidney Street,
Cambridge, MA, 02139
CLMN Number of Claims: 33
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 5028

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 54498 nucleic acid molecules, which encode amino acid transporter family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 54498 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 54498 gene has been introduced or disrupted. The invention still further provides isolated 54498 proteins, fusion proteins, antigenic peptides and anti-54498 antibodies.

Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.

L16 ANSWER 35 OF 154 USPATFULL on STN

AN 2003:237726 USPATFULL

TI 27091, a phospholipid transporting ATPase molecule and uses therefor
IN Curtis, Rory A.J., Framingham, MA, UNITED STATES
PA Millennium Pharmaceuticals, Inc. (U.S. corporation)
PI US 2003165883 A1 20030904
AI US 2002-122067 A1 20020412 (10)
PRAI US 2001-283434P 20010412 (60)

DT Utility
FS APPLICATION

LREP Millennium Pharmaceuticals, Inc., 75 Sidney Street, Cambridge, MA, 02139
CLMN Number of Claims: 22
ECL Exemplary Claim: 1
DRWN 6 Drawing Page(s)

LN.CNT 5217

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 27091 nucleic acid molecules, which encode novel ATPase/PLTR family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 27091 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 27091 gene has been introduced or disrupted. The invention still further provides isolated 27091 proteins, fusion proteins, antigenic peptides and anti-27091 antibodies.

Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.

L16 ANSWER 36 OF 154 USPATFULL on STN

AN 2003:231996 USPATFULL

TI Methods of using 69039, a novel human Na/Ca exchanger family member
IN Carroll, Joseph M., Cambridge, MA, UNITED STATES
PA Millennium Pharmaceuticals, Inc. (U.S. corporation)
PI US 2003162196 A1 20030828
AI US 2002-256537 A1 20020927 (10)
PRAI US 2001-325737P 20010928 (60)
DT Utility
FS APPLICATION
LREP Steven A. Bossone, Millennium Pharmaceuticals, Inc., 75 Sidney Street,
Cambridge, MA, 02139
CLMN Number of Claims: 9
ECL Exemplary Claim: 1
DRWN 7 Drawing Page(s)
LN.CNT 5615

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Isolated nucleic acids molecules, designated 69039 nucleic acid molecules, which encode novel Na.sup.+ /Ca.sup.2+ exchanger members, are disclosed. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 69039 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 69039 gene has been introduced or disrupted. Isolated 69039 proteins, fusion proteins, antigenic peptides and anti-69039 antibodies are also disclosed. The invention further provides methods of treating, preventing and ***diagnosing*** hematopoietic and neurological disorders.

L16 ANSWER 37 OF 154 USPATFULL on STN

AN 2003:213643 USPATFULL

TI 65499 and 58875, novel seven transmembrane receptors and uses thereof
IN Glucksmann, Maria A., Lexington, MA, UNITED STATES

PI US 2003148281 A1 20030807

AI US 2001-971269 A1 20011003 (9)

PRAI US 2000-237700P 20001005 (60)

DT Utility

FS APPLICATION

LREP Jean M. Silveri, Millennium Pharmaceuticals, Inc., 75 Sidney Street,
Cambridge, MA, 02139

CLMN Number of Claims: 23

ECL Exemplary Claim: 1

DRWN 10 Drawing Page(s)

LN.CNT 5168

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 65499 and 58875 nucleic acid molecules, which encode novel seven transmembrane domain (7TM) receptors, e.g., G-protein coupled receptor family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 65499 or 58875 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 65499 or 58875 gene has been introduced or disrupted. The invention still further provides isolated 65499 or 58875 proteins, fusion proteins, antigenic peptides and anti-65499 or 58875 antibodies.
Diagnostic methods utilizing compositions of the invention are also provided.

L16 ANSWER 38 OF 154 USPATFULL on STN

AN 2003:200949 USPATFULL

TI 80091, a novel human ubiquitin carboxy-terminal hydrolase family member
 and uses thereof
 IN Meyers, Rachel E., Newton, MA, UNITED STATES
 PI US 2003138934 A1 20030724
 AI US 2002-71275 A1 20020207 (10)
 PRAI US 2001-267054P 20010207 (60)
 DT Utility
 FS APPLICATION
 LREP LOUIS MYERS, Fish & Richardson P.C., 225 Franklin Street, Boston, MA,
 02110-2804
 CLMN Number of Claims: 20
 ECL Exemplary Claim: 1
 DRWN 2 Drawing Page(s)
 LN.CNT 5454

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated
 80091 nucleic acid molecules, which encode novel ubiquitin
 carboxy-terminal hydrolase members. The invention also provides
 antisense nucleic acid molecules, recombinant expression vectors
 containing 80091 nucleic acid molecules, host cells into which the
 expression vectors have been introduced, and nonhuman transgenic animals
 in which an 80091 gene has been introduced or disrupted. The invention
 still further provides isolated 80091 proteins, fusion proteins,
 antigenic peptides and anti-80091 antibodies. ***Diagnostic***
 methods utilizing compositions of the invention are also provided.

L16 ANSWER 39 OF 154 USPATFULL on STN

AN 2003:200905 USPATFULL

TI Novel G protein-coupled receptor family members, human thioredoxin
 family members, human leucine-rich repeat family members, and human
 ringfinger family member

IN Glucksmann, Maria Alexandra, Lexington, MA, UNITED STATES
 Silos-Santiago, Inmaculada, Jamaica Plain, MA, UNITED STATES
 Galvin, Katherine M., Jamaica Plain, MA, UNITED STATES
 Weich, Nadine, Brookline, MA, UNITED STATES
 Curtis, Rory A. J., Framingham, MA, UNITED STATES
 Bandaru, Rajasekhar, Watertown, MA, UNITED STATES
 Kapeller-Libermann, Rosana, Chestnut Hill, MA, UNITED STATES

PI US 2003138890 A1 20030724

AI US 2002-145586 A1 20020514 (10)

RLI Continuation-in-part of Ser. No. US 2001-796338, filed on 28 Feb 2001,
 PENDING Continuation-in-part of Ser. No. WO 2001-US6543, filed on 28 Feb
 2001, PENDING

PRAI WO 2001-US6057 20010223
 WO 2001-US23152 20010723
 WO 2001-US40476 20010409
 WO 2001-US7139 20010305
 WO 2001-US19544 20010615
 WO 2001-US29967 20010925
 WO 2001-US9470 20010323
 WO 2001-US10380 20010330
 WO 2001-US29968 20010925
 US 2000-186059P 20000229 (60)
 US 2000-220042P 20000721 (60)
 US 2000-187447P 20000307 (60)
 US 2000-211673P 20000615 (60)
 US 2000-235049P 20000925 (60)

US 2000-191863P 20000324 (60)
 US 2000-193919P 20000331 (60)
 US 2000-235032P 20000925 (60)
 DT Utility
 FS APPLICATION
 LREP JOHN W. FREEMAN, ESQ., Fish & Richardson P.C., 225 Franklin Street,
 Boston, MA, 02110-2804
 CLMN Number of Claims: 19
 ECL Exemplary Claim: 1
 DRWN 97 Drawing Page(s)
 LN.CNT 51652
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB The invention provides isolated nucleic acids molecules, designated
 20716, 65494, 44576, 1983, 52881, 2398, 45449, 50289, 52872, 22105,
 22109, 22108, 47916, 33395, 31939, and 84241 nucleic acid molecules,
 which encode novel G protein-coupled receptor family members, human
 thioredoxin family members, human leucine-rich repeat family members,
 and human ringfinger family member. The invention also provides
 antisense nucleic acid molecules, recombinant expression vectors
 containing 20716, 65494, 44576, 1983, 52881, 2398, 45449, 50289, 52872,
 22105, 22109, 22108, 47916, 33395, 31939, or 84241 nucleic acid
 molecules, host cells into which the expression vectors have been
 introduced, and nonhuman transgenic animals in which a 20716, 65494,
 44576, 1983, 52881, 2398, 45449, 50289, 52872, 22105, 22109, 22108,
 47916, 33395, 31939, or 84241 gene has been introduced or disrupted. The
 invention still further provides isolated 20716, 65494, 44576, 1983,
 52881, 2398, 45449, 50289, 52872, 22105, 22109, 22108, 47916, 33395,
 31939, or 84241 proteins, fusion proteins, antigenic peptides and
 anti-20716, 65494, 44576, 1983, 52881, 2398, 45449, 50289, 52872, 22105,
 22109, 22108, 47916, 33395, 31939, or 84241 antibodies.
 Diagnostic methods utilizing compositions of the invention are
 also provided.

L16 ANSWER 40 OF 154 USPATFULL on STN
 AN 2003:194506 USPATFULL
 TI 14815, a human kinase family member and uses therefor
 IN Meyers, Rachel E., Newton, MA, UNITED STATES
 PA Millennium Pharmaceuticals, Inc. (U.S. corporation)
 PI US 2003134317 A1 20030717
 US 6759222 B2 20040706
 AI US 2003-335711 A1 20030102 (10)
 PRAI US 2002-345853P 20020102 (60)
 DT Utility
 FS APPLICATION
 LREP Jean M. Silveri, Millennium Pharmaceuticals, Inc., 75 Sidney Street,
 Cambridge, MA, 02139
 CLMN Number of Claims: 20
 ECL Exemplary Claim: 1
 DRWN 1 Drawing Page(s)
 LN.CNT 5192
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB The invention provides isolated nucleic acids molecules, designated
 14815 nucleic acid molecules, which encode novel kinase family members.
 The invention also provides antisense nucleic acid molecules,
 recombinant expression vectors containing 14815 nucleic acid molecules,
 host cells into which the expression vectors have been introduced, and
 nonhuman transgenic animals in which a 14815 gene has been introduced or

disrupted. The invention still further provides isolated 14815 proteins, fusion proteins, antigenic peptides and anti-14815 antibodies.

Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.

L16 ANSWER 41 OF 154 USPATFULL on STN

AN 2003:188692 USPATFULL

TI Novel human genes and methods of use thereof

IN Meyers, Rachel E., Newton, MA, UNITED STATES

Curtis, Rory A. J., Framingham, MA, UNITED STATES

Glucksmann, Maria Alexandra, Lexington, MA, UNITED STATES

Bandaru, Rajasekhar, Watertown, MA, UNITED STATES

Kapeller-Libermann, Rosana, Chestnut Hill, MA, UNITED STATES

PI US 2003130485 A1 20030710

AI US 2002-176306 A1 20020620 (10)

RLI Continuation-in-part of Ser. No. US 2001-1137, filed on 14 Nov 2001,
PENDING Continuation-in-part of Ser. No. WO 2001-US45291, filed on 14
Nov 2001, PENDING

PRAI WO 2001-US49416 20011218

WO 2001-US46717 20011022

US 2000-248362P 20001114 (60)

US 2000-248331P 20001114 (60)

US 2000-248365P 20001114 (60)

US 2000-250077P 20001130 (60)

US 2000-250327P 20001130 (60)

US 2000-250176P 20001130 (60)

DT Utility

FS APPLICATION

LREP LOUIS MYERS, Fish & Richardson P.C., 225 Franklin Street, Boston, MA,
02110-2804

CLMN Number of Claims: 19

ECL Exemplary Claim: 1

DRWN 60 Drawing Page(s)

LN.CNT 26835

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 47476, 67210, 49875, 46842, 33201, 83378, 84233, 64708, 85041, 84234, 21617, 55562, 23566, 33489, and 57779 nucleic acid molecules, which encode novel human genes. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 47476, 67210, 49875, 46842, 33201, 83378, 84233, 64708, 85041, 84234, 21617, 55562, 23566, 33489, or 57779 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 47476, 67210, 49875, 46842, 33201, 83378, 84233, 64708, 85041, 84234, 21617, 55562, 23566, 33489, or 57779 gene has been introduced or disrupted. The invention still further provides isolated 47476, 67210, 49875, 46842, 33201, 83378, 84233, 64708, 85041, 84234, 21617, 55562, 23566, 33489, or 57779 proteins, fusion proteins, antigenic peptides and anti-47476, 67210, 49875, 46842, 33201, 83378, 84233, 64708, 85041, 84234, 21617, 55562, 23566, 33489, or 57779 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided.

L16 ANSWER 42 OF 154 USPATFULL on STN

AN 2003:187835 USPATFULL

TI Methods of using 5433, a human calcium channel family member

IN Silos-Santiago, Inmaculada, Jamaica Plain, MA, UNITED STATES
PA Millennium Pharmaceuticals, Inc. (U.S. corporation)
PI US 2003129625 A1 20030710
AI US 2002-245121 A1 20020917 (10)
PRAI US 2001-322983P 20010917 (60)
DT Utility
FS APPLICATION
LREP Steven A. Bossone, Millennium Pharmaceuticals, inc., 75 Sidney Street,
Cambridge, MA, 02139
CLMN Number of Claims: 9
ECL Exemplary Claim: 1
DRWN 7 Drawing Page(s)
LN.CNT 4991

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 5433 nucleic acid molecules, which encode calcium channel family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 5433 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 5433 gene has been introduced or disrupted. The invention still further provides isolated 5433 proteins, fusion proteins, antigenic peptides and anti-5433 antibodies.
Diagnostic methods utilizing compositions of the invention are also provided.

L16 ANSWER 43 OF 154 USPATFULL on STN

AN 2003:173317 USPATFULL
TI 32132, a novel fucosyltransferase family member and uses therefor
IN Meyers, Rachel A., Newton, MA, UNITED STATES
Williamson, Mark, Saugus, MA, UNITED STATES
PI US 2003119161 A1 20030626
AI US 2001-844948 A1 20010427 (9)
PRAI US 2000-200604P 20000428 (60)
DT Utility
FS APPLICATION
LREP FISH & RICHARDSON PC, 225 FRANKLIN ST, BOSTON, MA, 02110
CLMN Number of Claims: 29
ECL Exemplary Claim: 1
DRWN 3 Drawing Page(s)
LN.CNT 5346

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 32132 nucleic acid molecules, which encode novel fucosyltransferase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 32132 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 32132 gene has been introduced or disrupted. The invention still further provides isolated 32132 proteins, fusion proteins, antigenic peptides and anti-32132 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided.

L16 ANSWER 44 OF 154 USPATFULL on STN

AN 2003:172663 USPATFULL
TI Methods of using 46828, a human acyl-CoA synthetase
IN Hunter, John Joseph, Somerville, MA, UNITED STATES
PA Millennium Pharmaceuticals, Inc. (U.S. corporation)

PI US 2003118507 A1 20030626
AI US 2002-245537 A1 20020917 (10)
PRAI US 2001-322920P 20010917 (60)
DT Utility
FS APPLICATION
LREP Steven A. Bossone, Millennium Pharmaceuticals, Inc., 75 Sidney Street,
Cambridge, MA, 02139
CLMN Number of Claims: 7
ECL Exemplary Claim: 1
DRWN 5 Drawing Page(s)
LN.CNT 5071

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Isolated nucleic acids molecules, designated 46828 nucleic acid molecules, which encode AMP-binding enzymes, and in particular acyl-CoA synthases are disclosed. The invention provides methods of modulating the differentiation, proliferation, and/or inducing the cell killing of 46828-expressing hyperproliferative cells, e.g., 46828-expressing malignant cells from the lung, colon and ovaries. The invention further provides methods of treating, preventing and ***diagnosing*** solid tumors, soft tissue tumors, and/or metastatic lesions.

L16 ANSWER 45 OF 154 USPATFULL on STN

AN 2003:165985 USPATFULL
TI 8105, a novel human sugar transporter family member and uses thereof
IN Curtis, Rory A.J., Framingham, MA, UNITED STATES
Gu, Wei, Brookline, MA, UNITED STATES
PI US 2003113841 A1 20030619
AI US 2002-144624 A1 20020513 (10)
PRAI US 2001-290288P 20010511 (60)
DT Utility
FS APPLICATION
LREP LAURIE BUTLER LAWRENCE, FISH & RICHARDSON P.C., 225 Franklin Street,
Boston, MA, 02110-2804
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 3 Drawing Page(s)
LN.CNT 5398

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 8105 nucleic acid molecules, which encode novel sugar transporter members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 8105 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 8105 gene has been introduced or disrupted. The invention still further provides isolated 8105 proteins, fusion proteins, antigenic peptides and anti-8105 antibodies.
Diagnostic methods utilizing compositions of the invention are also provided.

L16 ANSWER 46 OF 154 USPATFULL on STN

AN 2003:159431 USPATFULL
TI Methods of using 279, a human G protein-coupled protein receptor
IN Logan, Thomas Joseph, Needham, MA, UNITED STATES
Galvin, Katherine M., Jamaica Plain, MA, UNITED STATES
PA Millennium Pharmaceuticals, Inc. (U.S. corporation)
PI US 2003109044 A1 20030612
AI US 2002-267811 A1 20021009 (10)

PRAI US 2001-329648P 20011016 (60)
DT Utility
FS APPLICATION
LREP MILLENNIUM PHARMACEUTICALS, INC., 75 Sidney Street, Cambridge, MA, 02139
CLMN Number of Claims: 6
ECL Exemplary Claim: 1
DRWN 7 Drawing Page(s)
LN.CNT 5366

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 279 nucleic acid molecules, which encode human G protein-coupled receptor (GPCR) family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 279 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 279 gene has been introduced or disrupted. The invention still further provides isolated 279 proteins, fusion proteins, antigenic peptides and anti-279 antibodies. Methods utilizing compositions of the invention to treat, prevent or ***diagnose*** angiogenic disorders, e.g., cardiovascular and cancerous disorders, are also provided.

L16 ANSWER 47 OF 154 USPATFULL on STN

AN 2003:146274 USPATFULL
TI 50352, a human ubiquitin-protein ligase family member and uses therefor
IN Meyers, Rachel E., Newton, MA, UNITED STATES
PA Millennium Pharmaceuticals, Inc. (U.S. corporation)
PI US 2003100020 A1 20030529
AI US 2002-268036 A1 20021009 (10)
PRAI US 2001-327820P 20011009 (60)
DT Utility
FS APPLICATION
LREP Jean M. Silveri, Millennium Pharmaceuticals, Inc., 75 Sidney Street, Cambridge, MA, 02139
CLMN Number of Claims: 29
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 4865

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 50352 nucleic acid molecules, which encode novel ubiquitin-protein ligase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 50352 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 50352 gene has been introduced or disrupted. The invention still further provides isolated 50352 proteins, fusion proteins, antigenic peptides and anti-50352 antibodies. ***Diagnostic*** and therapeutic methods utilizing compositions of the invention are also provided.

L16 ANSWER 48 OF 154 USPATFULL on STN

AN 2003:146256 USPATFULL
TI 46694, a human alpha/beta hydrolase family member and uses therefor
IN Kapeller-Libermann, Rosana, Chestnut Hill, MA, UNITED STATES
Spurling, Heidi Lynn, Malden, MA, UNITED STATES
PA Millennium Pharmaceuticals, Inc. (U.S. corporation)
PI US 2003100001 A1 20030529
AI US 2002-289148 A1 20021106 (10)

PRAI US 2001-334225P 20011129 (60)
DT Utility
FS APPLICATION
LREP Paul J. Paglierani, MILLENNIUM PHARMACEUTICALS, INC., 75 Sidney Street,
Cambridge, MA, 02139
CLMN Number of Claims: 29
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 4575

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 46694 nucleic acid molecules, which encode novel alpha/beta hydrolase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 46694 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 46694 gene has been introduced or disrupted. The invention still further provides isolated 46694 proteins, fusion proteins, antigenic peptides and anti-46694 antibodies. ***Diagnostic*** and therapeutic methods utilizing compositions of the invention are also provided.

L16 ANSWER 49 OF 154 USPATFULL on STN

AN 2003:146246 USPATFULL
TI Methods of using 33751, a human potassium channel family member
IN Silos-Santiago, Inmaculada, Jamaica Plain, MA, UNITED STATES
PA Millennium Pharmaceuticals, Inc. (U.S. corporation)
PI US 2003099991 A1 20030529
AI US 2002-255532 A1 20020926 (10)
PRAI US 2001-325854P 20010927 (60)
DT Utility
FS APPLICATION
LREP Steven A. Bossone, Millennium Pharmaceuticals, Inc., 75 Sidney Street,
Cambridge, MA, 02139
CLMN Number of Claims: 9
ECL Exemplary Claim: 1
DRWN 12 Drawing Page(s)
LN.CNT 5473

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Isolated nucleic acids molecules, designated 33751 nucleic acid molecules, which encode a human potassium channel family member, are disclosed. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 33751 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 33751 gene has been introduced or disrupted. Isolated 33751 proteins, fusion proteins, antigenic peptides and anti-33751 antibodies are also disclosed. The invention provides, inter alia, methods of modulating 33751 activity or expression, thereby modulating pain or nociceptive responses in a subject. The invention further provides methods of treating, preventing and ***diagnosing*** neural disorders.

L16 ANSWER 50 OF 154 USPATFULL on STN

AN 2003:142947 USPATFULL
TI 32140, a novel human aldehyde dehydrogenase and uses therefor
IN Meyers, Rachel, Newton, MA, United States
Cook, William J., Natick, MA, United States
PA Millennium Pharmaceuticals, Inc., Cambridge, MA, United States (U.S.)

corporation)
PI US 6569657 B1 20030527
AI US 2000-717926 20001121 (9)
PRAI US 2000-214707P 20000627 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Achutamurthy, Ponnathapu; Assistant Examiner: Pak,
Yong
LREP Alston & Bird LLP
CLMN Number of Claims: 31
ECL Exemplary Claim: 1
DRWN 12 Drawing Figure(s); 12 Drawing Page(s)
LN.CNT 4612

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 32140 nucleic acid molecules, which encode novel aldehyde dehydrogenase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 32140 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 32140 gene has been introduced or disrupted. The invention still further provides isolated 32140 proteins, fusion proteins, antigenic peptides and anti-32140 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided.

L16 ANSWER 51 OF 154 USPATFULL on STN

AN 2003:140551 USPATFULL
TI 21163, a novel human prolyl oligopeptidase and uses therefor
IN Hunter, John Joseph, Somerville, MA, UNITED STATES
Kapeller-Libermann, Rosana, Chestnut Hill, MA, UNITED STATES
PA Millennium Pharmaceuticals, Inc. (U.S. corporation)
PI US 2003096392 A1 20030522
AI US 2001-25950 A1 20011219 (10)
PRAI US 2000-257736P 20001222 (60)
DT Utility
FS APPLICATION
LREP ALSTON & BIRD LLP, BANK OF AMERICA PLAZA, 101 SOUTH TRYON STREET, SUITE
4000, CHARLOTTE, NC, 28280-4000
CLMN Number of Claims: 22
ECL Exemplary Claim: 1
DRWN 8 Drawing Page(s)
LN.CNT 4648

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 21163 nucleic acid molecules, which encode novel prolyl oligopeptidase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 21163 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 21163 gene has been introduced or disrupted. The invention still further provides isolated 21163 proteins, fusion proteins, antigenic peptides and anti-21163 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided.

L16 ANSWER 52 OF 154 USPATFULL on STN

AN 2003:140464 USPATFULL
TI Novel human membrane-associated protein and cell surface protein family

members

IN Meyers, Rachel E., Newton, MA, UNITED STATES
 Glucksmann, Maria Alexandra, Lexington, MA, UNITED STATES
 Curtis, Rory A. J., Framingham, MA, UNITED STATES
 Kapeller-Libermann, Rosana, Chestnut Hill, MA, UNITED STATES
 Bandaru, Rajasekhar, Watertown, MA, UNITED STATES
 Leiby, Kevin R., Natick, MA, UNITED STATES

PI US 2003096305 A1 20030522

AI US 2002-162435 A1 20020604 (10)

RLI Continuation-in-part of Ser. No. US 2001-836499, filed on 17 Apr 2001,
 PENDING

PRAI WO 2001-US12420 20010417
 WO 2001-US19963 20010625
 WO 2001-US16013 20010518
 WO 2001-US20055 20010621
 WO 2002-US275 20020108
 WO 2001-US41811 20010821
 US 2000-197507P 20000418 (60)
 US 2000-214220P 20000623 (60)
 US 2000-205674P 20000519 (60)
 US 2000-213963P 20000623 (60)
 US 2001-260286P 20010108 (60)
 US 2000-226612P 20000821 (60)

DT Utility

FS APPLICATION

LREP LOUIS MYERS, Fish & Richardson P.C., 225 Franklin Street, Boston, MA,
 02110-2804

CLMN Number of Claims: 19

ECL Exemplary Claim: 1

DRWN 22 Drawing Page(s)

LN.CNT 30445

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated
 16051a, 16051b, 58199, 57805, 56739, 39362, and 23228 nucleic acid
 molecules, which encode novel human membrane-associated protein family
 members, and human cell surface protein family members. The invention
 also provides antisense nucleic acid molecules, recombinant expression
 vectors containing 16051a, 16051b, 58199, 57805, 56739, 39362, or 23228
 nucleic acid molecules, host cells into which the expression vectors
 have been introduced, and nonhuman transgenic animals in which a 16051a,
 16051b, 58199, 57805, 56739, 39362, or 23228 gene has been introduced or
 disrupted. The invention still further provides isolated 16051a, 16051b,
 58199, 57805, 56739, 39362, or 23228 proteins, fusion proteins,
 antigenic peptides and anti-16051a, 16051b, 58199, 57805, 56739, 39362,
 or 23228 antibodies. ***Diagnostic*** methods utilizing compositions
 of the invention are also provided.

L16 ANSWER 53 OF 154 USPATFULL on STN

AN 2003:134569 USPATFULL

TI Novel human enzyme family members and uses thereof

IN Meyers, Rachel E., Newton, MA, UNITED STATES
 Glucksmann, Maria Alexandra, Lexington, MA, UNITED STATES
 Rudolph-Owen, Laura A., Jamaica Plain, MA, UNITED STATES

PI US 2003092658 A1 20030515

AI US 2002-175696 A1 20020620 (10)

RLI Continuation-in-part of Ser. No. US 2002-67668, filed on 4 Feb 2002,
 PENDING

PRAI US 2001-266140P 20010202 (60)
DT Utility
FS APPLICATION
LREP Intellectual Property Group, MILLENNIUM PHARMACEUTICALS, INC., 75 Sidney
Street, Cambridge, MA, 02139
CLMN Number of Claims: 19
ECL Exemplary Claim: 1
DRWN 27 Drawing Page(s)
LN.CNT 21384.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated
33312, 33303, 32579, 21509, 33770, 46638, and 50090 nucleic acid
molecules, which encode novel G protein-coupled receptor family members,
human thioredoxin family members, human leucine-rich repeat family
members, and human ringfinger family member. The invention also provides
antisense nucleic acid molecules, recombinant expression vectors
containing 33312, 33303, 32579, 21509, 33770, 46638, or 50090 nucleic
acid molecules, host cells into which the expression vectors have been
introduced, and nonhuman transgenic animals in which a 33312, 33303,
32579, 21509, 33770, 46638, or 50090 gene has been introduced or
disrupted. The invention still further provides isolated 33312, 33303,
32579, 21509, 33770, 46638, or 50090 proteins, fusion proteins,
antigenic peptides and anti-33312, 33303, 32579, 21509, 33770, 46638, or
50090 antibodies. ***Diagnostic*** methods utilizing compositions of
the invention are also provided.

L16 ANSWER 54 OF 154 USPATFULL on STN

AN 2003:133963 USPATFULL

TI 84604 and 84614, human anion transporter family members and uses
therefor

IN Curtis, Rory A.J., Framingham, MA, UNITED STATES
Ferreira, Holly M., Norton, MA, UNITED STATES

PA Millennium Pharmaceuticals, Inc. (U.S. corporation)

PI US 2003092048 A1 20030515

AI US 2002-252646 A1 20020923 (10)

PRAI US 2001-325106P 20010926 (60)

DT Utility

FS APPLICATION

LREP Jean M. Silveri, MILLENNIUM PHARMACEUTICALS, INC., 75 Sidney Street,
Cambridge, MA, 02139

CLMN Number of Claims: 20

ECL Exemplary Claim: 1

DRWN 2 Drawing Page(s)

LN.CNT 5870

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated
84604 or 84614 nucleic acid molecules, which encode novel anion
transporter family members. The invention also provides antisense
nucleic acid molecules, recombinant expression vectors containing 84604
or 84614 nucleic acid molecules, host cells into which the expression
vectors have been introduced, and nonhuman transgenic animals in which
an 84604 or 84614 gene has been introduced or disrupted. The invention
still further provides isolated 84604 or 84614 proteins, fusion
proteins, antigenic peptides and anti-84604 or 84614 antibodies.
Diagnostic and therapeutic methods utilizing compositions of

the

invention are also provided.

L16 ANSWER 55 OF 154 USPATFULL on STN

AN 2003:133421 USPATFULL

TI Methods of using 22417, a novel human aminoprotease family member

IN Hunter, John Joseph, Somerville, MA, UNITED STATES

PA Millennium Pharmaceuticals, Inc. (U.S. corporation)

PI US 2003091506 A1 20030515

AI US 2002-245538 A1 20020917 (10)

PRAI US 2001-322924P 20010917 (60)

DT Utility

FS APPLICATION

LREP Steven A. Bossone, Millennium Pharmaceuticals, Inc., 75 Sidney Street,
Cambridge, MA, 02139

CLMN Number of Claims: 7

ECL Exemplary Claim: 1

DRWN 3 Drawing Page(s)

LN.CNT 4744

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 22417 nucleic acid molecules, which encode novel aminoprotease members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 22417 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 22417 gene has been introduced or disrupted. The invention still further provides isolated 22417 proteins, fusion proteins, antigenic peptides and anti-22417 antibodies.
Diagnostic methods utilizing compositions of the invention are also provided.

L16 ANSWER 56 OF 154 USPATFULL on STN

AN 2003:127169 USPATFULL

TI 25501, a human transferase family member and uses therefor

IN Meyers, Rachel E., Newton, MA, UNITED STATES

PA Millennium Pharmaceuticals, Inc. (U.S. corporation)

PI US 2003087382 A1 20030508

AI US 2002-217168 A1 20020812 (10)

PRAI US 2001-312539P 20010815 (60)

DT Utility

FS APPLICATION

LREP Jean M. Silveri, Millennium Pharmaceuticals, Inc., 75 Sidney Street,
Cambridge, MA, 02139

CLMN Number of Claims: 22

ECL Exemplary Claim: 1

DRWN 1 Drawing Page(s)

LN.CNT 4851

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 25501 nucleic acid molecules, which encode novel transferase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 25501 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 25501 gene has been introduced or disrupted. The invention still further provides isolated 25501 proteins, fusion proteins, antigenic peptides and anti-25501 antibodies.
Diagnostic and therapeutic methods utilizing compositions of

the

invention are also provided.

L16 ANSWER 57 OF 154 USPATFULL on STN

AN 2003:127037 USPATFULL

TI 93870, a human G-protein coupled receptor and uses therefor

IN Glucksmann, Maria Alexandra, Lexington, MA, UNITED STATES

PA Millennium Pharmaceuticals, Inc. (U.S. corporation)

PI US 2003087249 A1 20030508

AI US 2002-85233 A1 20020228 (10)

PRAI US 2001-272677P 20010301 (60)

DT Utility

FS APPLICATION

LREP Jean M. Silveri, Millennium Pharmaceuticals, Inc., 75 Sidney Street,
Cambridge, MA, 02139

CLMN Number of Claims: 31

ECL Exemplary Claim: 1

DRWN 1 Drawing Page(s)

LN.CNT 4506

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 93870 nucleic acid molecules, which encode GPCRs. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 93870 nucleic acid molecules, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a 93870 gene has been introduced or disrupted. The invention still further provides isolated 93870 proteins, fusion proteins, antigenic peptides and anti-93870 antibodies.

Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.

L16 ANSWER 58 OF 154 USPATFULL on STN

AN 2003:120304 USPATFULL

TI 24554, a human ubiquitin carboxyl-terminal hydrolase family member and uses therefor

IN Libermann, Rosana K., Chestnut Hill, MA, UNITED STATES

Spurling, Heidi Lynn, Malden, MA, UNITED STATES

PA Millennium Pharmaceuticals, Inc. (U.S. corporation)

PI US 2003082785 A1 20030501

AI US 2002-269848 A1 20021011 (10)

PRAI US 2001-329218P 20011012 (60)

DT Utility

FS APPLICATION

LREP Paul J. Paglierani, Millennium Pharmaceuticals, Inc., 75 Sidney Street,
Cambridge, MA, 02139

CLMN Number of Claims: 29

ECL Exemplary Claim: 1

DRWN 1 Drawing Page(s)

LN.CNT 4493

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 24554 nucleic acid molecules, which encode novel ubiquitin carboxy-terminal hydrolase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 24554 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 24554 gene has been introduced or disrupted. The invention still further provides isolated 24554 proteins, fusion proteins,

antigenic peptides and anti-24554 antibodies. ***Diagnostic*** and therapeutic methods utilizing compositions of the invention are also provided.

L16 ANSWER 59 OF 154 USPTF on STN
AN 2003:120237 USPTF
TI 52908, a human potassium channel, and uses thereof
IN Curtis, Rory A.J., Framingham, MA, UNITED STATES
PA Millennium Pharmaceuticals, Inc. (U.S. corporation)
PI US 2003082718 A1 20030501
AI US 2002-192440 A1 20020710 (10)
PRAI US 2001-341953P 20011219 (60)
US 2001-304243P 20010710 (60)
DT Utility
FS APPLICATION
LREP Jean M. Silveri, MILLENNIUM PHARMACEUTICALS, INC., 75 Sidney Street,
Cambridge, MA, 02139
CLMN Number of Claims: 35
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 5676

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acid molecules, designated 52908 nucleic acid molecules, which encode novel 52908-related potassium channel molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 52908 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which an 52908 gene has been introduced or disrupted. The invention still further provides isolated 52908 proteins, fusion proteins, antigenic peptides and anti-52908 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided.

L16 ANSWER 60 OF 154 USPTF on STN
AN 2003:113015 USPTF
TI 96829, a human transporter family member and uses therefor
IN Curtis, Rory A.J., Framingham, MA, UNITED STATES
PA Millennium Pharmaceuticals, Inc. (U.S. corporation)
PI US 2003077748 A1 20030424
AI US 2002-264104 A1 20021003 (10)
PRAI US 2001-326906P 20011003 (60)
DT Utility
FS APPLICATION
LREP Jean M. Silveri, Millennium Pharmaceuticals, Inc., 75 Sidney Street,
Cambridge, MA, 02139
CLMN Number of Claims: 22
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 4769

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 96829 nucleic acid molecules, which encode novel transporter family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 96829 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 96829 gene has been introduced or disrupted. The invention still further provides isolated 96829 proteins,

fusion proteins, antigenic peptides and anti-96829 antibodies.
Diagnostic and therapeutic methods utilizing compositions of
the
invention are also provided.

L16 ANSWER 61 OF 154 USPATFULL on STN
AN 2003:106746 USPATFULL
TI 47619 and 47621, human ion channels, and uses thereof
IN Curtis, Rory A.J., Framingham, MA, UNITED STATES
PA Millennium Pharmaceuticals, Inc. (U.S. corporation)
PI US 2003073658 A1 20030417
AI US 2002-192116 A1 20020710 (10)
PRAI US 2001-304257P 20010710 (60)
DT Utility
FS APPLICATION
LREP Jean M. Silveri, Millennium Pharmaceuticals, Inc., 75 Sidney Street,
Cambridge, MA, 02139
CLMN Number of Claims: 35
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 5355

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acid molecules, designated 47619 and 47621 nucleic acid molecules, which encode novel 47619 and 47621-related ion channel molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 47619 and 47621 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which an 47619 and 47621 gene has been introduced or disrupted. The invention still further provides isolated 47619 and 47621 proteins, fusion proteins, antigenic peptides and anti-47619 and 47621 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided.

L16 ANSWER 62 OF 154 USPATFULL on STN
AN 2003:106187 USPATFULL
TI 65577, a human matrix metalloproteinase and uses therefor
IN Bandaru, Rajasekhar, Watertown, MA, UNITED STATES
PA Millennium Pharmaceuticals, Inc. (U.S. corporation)
PI US 2003073098 A1 20030417
AI US 2002-103377 A1 20020321 (10)
PRAI US 2001-278347P 20010323 (60)
DT Utility
FS APPLICATION
LREP Jean M. Silveri, Millennium Pharmaceuticals, Inc., 75 Sidney Street,
Cambridge, MA, 02139
CLMN Number of Claims: 33
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 4816

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 65577 nucleic acid molecules, which encode matrix metalloproteinases. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 65577 nucleic acid molecules, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a 65577 gene has been introduced

or disrupted. The invention still further provides isolated 65577 proteins, fusion proteins, antigenic peptides and anti-65577 antibodies.
Diagnostic and therapeutic methods utilizing compositions of

the
invention are also provided.

L16 ANSWER 63 OF 154 USPATFULL on STN

AN 2003:93080 USPATFULL

TI Novel nucleic acid sequences encoding melanoma associated antigen molecules, aminotransferase molecules, ATPase molecules, acyltransferase molecules, pyridoxal-phosphate dependant enzyme molecules and uses therefor

IN Bandaru, Rajasekhar, Watertown, MA, UNITED STATES
Glucksmann, Maria Alexandra, Lexington, MA, UNITED STATES
Meyers, Rachel E., Newton, MA, UNITED STATES
Rudolph-Owen, Laura A., Jamaica Plain, MA, UNITED STATES

PA Millennium Pharmaceuticals, Inc. (U.S. corporation)

PI US 2003064439 A1 20030403

AI US 2002-164966 A1 20020607 (10)

RLI Continuation-in-part of Ser. No. US 2001-34864, filed on 27 Dec 2001,
PENDING Continuation-in-part of Ser. No. US 2001-996194, filed on 28 Nov
2001, PENDING Continuation-in-part of Ser. No. US 2001-908928, filed on
19 Jul 2001, PENDING Continuation-in-part of Ser. No. US 2001-908180,
filed on 18 Jul 2001, PENDING Continuation-in-part of Ser. No. US
2001-887389, filed on 22 Jun 2001, PENDING Continuation-in-part of Ser.
No. US 2001-789300, filed on 20 Feb 2001, GRANTED, Pat. No. US 6458576

PRAI US 2000-258517P 20001228 (60)

US 2000-250348P 20001130 (60)

US 2000-250073P 20001130 (60)

US 2000-253878P 20001129 (60)

US 2000-250338P 20001130 (60)

US 2000-220465P 20000720 (60)

US 2000-219740P 20000720 (60)

US 2000-214138P 20000626 (60)

US 2000-183208P 20000217 (60)

DT Utility

FS APPLICATION

LREP Intellectual Property Group, MILLENNIUM PHARMACEUTICALS, INC., 75 Sidney
Street, Cambridge, MA, 02139

CLMN Number of Claims: 22

ECL Exemplary Claim: 1

DRWN 63 Drawing Page(s)

LN.CNT 27929

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules that encode novel ***polypeptides***. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing the nucleic acid molecules of the invention, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a sequence of the invention has been introduced or disrupted. The invention still further provides isolated proteins, fusion proteins, antigenic peptides and antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided.

L16 ANSWER 64 OF 154 USPATFULL on STN

AN 2003:78529 USPATFULL

TI 63744, a human sugar transporter family member and uses thereof

IN Curtis, Rory A.J., Southborough, MA, UNITED STATES
PA Millennium Pharmaceuticals, Inc. (U.S. corporation)
PI US 2003054449 A1 20030320
AI US 2002-62960 A1 20020131 (10)
PRAI US 2001-265757P 20010201 (60)
DT Utility
FS APPLICATION
LREP Jean M. Silveri, Millennium Pharmaceuticals, Inc., 75 Sidney Street,
Cambridge, MA, 02139
CLMN Number of Claims: 33
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 4421

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 63744 nucleic acid molecules, which encode novel sugar transporter family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 63744 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 63744 gene has been introduced or disrupted. The invention still further provides isolated 63744 proteins, fusion proteins, antigenic peptides and anti-63744 antibodies. ***Diagnostic*** and therapeutic methods utilizing compositions of the invention are also provided.

L16 ANSWER 65 OF 154 USPATFULL on STN

AN 2003:71415 USPATFULL
TI 22108 and 47916, novel human thioredoxin family members and uses thereof
IN Kapeller-Libermann, Rosana, Chestnut Hill, MA, UNITED STATES
Bandaru, Rajasekhar, Watertown, MA, UNITED STATES
PI US 2003049700 A1 20030313
AI US 2001-963339 A1 20010925 (9)
PRAI US 2000-235049P 20000925 (60)
DT Utility
FS APPLICATION
LREP LOUIS MYERS, Fish & Richardson P.C., 225 Franklin Street, Boston, MA,
02110-2804
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 4 Drawing Page(s)
LN.CNT 5569

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 22108 and 47916 nucleic acid molecules, which encode novel thioredoxin members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 22108 or 47916 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 22108 or 47916 gene has been introduced or disrupted. The invention still further provides isolated 22108 or 47916 proteins, fusion proteins, antigenic peptides and anti-22108 or 47916 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided.

L16 ANSWER 66 OF 154 USPATFULL on STN

AN 2003:71379 USPATFULL
TI 87144, human amino acid transporter family member and uses therefor
IN Curtis, Rory A.J., Framingham, MA, UNITED STATES

Silos-Santiago, Inmaculada, Jamaica Plain, MA, UNITED STATES
PA Millennium Pharmaceuticals, Inc. (U.S. corporation)
PI US 2003049664 A1 20030313
AI US 2002-191398 A1 20020709 (10)
PRAI US 2001-306108P 20010717 (60)
DT Utility
FS APPLICATION
LREP Jean M. Silveri, MILLENNIUM PHARMACEUTICALS, INC., 75 Sidney Street,
Cambridge, MA, 02139
CLMN Number of Claims: 35
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 4822

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 87144 nucleic acid molecules, which encode novel amino acid transporter family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 87144 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 87144 gene has been introduced or disrupted. The invention still further provides isolated 87144 proteins, fusion proteins, antigenic peptides and anti-87144 antibodies. ***Diagnostic*** and therapeutic methods utilizing compositions of the invention are also provided.

L16 ANSWER 67 OF 154 USPATFULL on STN

AN 2003:64812 USPATFULL
TI 96895, a human sodium-hydrogen exchanger family member and uses therefor
IN Curtis, Rory A.J., Framingham, MA, UNITED STATES
Ferriera, Holly M., Norton, MA, UNITED STATES
PA Millennium Pharmaceuticals, Inc. (U.S. corporation)
PI US 2003044933 A1 20030306
AI US 2002-217096 A1 20020812 (10)
PRAI US 2001-312554P 20010815 (60)
DT Utility
FS APPLICATION
LREP Jean M. Silveri, Millennium Pharmaceuticals, Inc., 75 Sidney Street,
Cambridge, MA, 02139
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 4897

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 96895 nucleic acid molecules, which encode novel sodium-hydrogen exchanger family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 96895 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 96895 gene has been introduced or disrupted. The invention still further provides isolated 96895 proteins, fusion proteins, antigenic peptides and anti-96895 antibodies. ***Diagnostic*** and therapeutic methods utilizing compositions of the invention are also provided.

L16 ANSWER 68 OF 154 USPATFULL on STN

AN 2003:57908 USPATFULL
TI 32229, a novel human acyl-CoA dehydrogenase family member and uses

thereof
IN Kapeller-Libermann, Rosana, Chestnut Hill, MA, UNITED STATES
Hunter, John J., Somerville, MA, UNITED STATES
Rudolph-Owen, Laura A., Jamaica Plain, MA, UNITED STATES
PI US 2003040474 A1 20030227
AI US 2001-999314 A1 20011022 (9)
PRAI US 2000-242211P 20001020 (60)
DT Utility
FS APPLICATION
LREP LOUIS MYERS, Fish & Richardson P.C., 225 Franklin Street, Boston, MA,
02110-2804
CLMN Number of Claims: 24
ECL Exemplary Claim: 1
DRWN 6 Drawing Page(s)
LN.CNT 5113

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated
32229 nucleic acid molecules, which encode novel acyl-CoA dehydrogenase
members. The invention also provides antisense nucleic acid molecules,
recombinant expression vectors containing 32229 nucleic acid molecules,
host cells into which the expression vectors have been introduced, and
nonhuman transgenic animals in which a 32229 gene has been introduced or
disrupted. The invention still further provides isolated 32229 proteins,
fusion proteins, antigenic peptides and anti-32229 antibodies.
Diagnostic methods utilizing compositions of the invention are
also provided.

L16 ANSWER 69 OF 154 USPATFULL on STN

AN 2003:57427 USPATFULL
TI 46798, a human matrix metalloproteinase and uses therefor
IN Curtis, Rory A.J., Southborough, MA, UNITED STATES
Lora, Jose M., Arlington, MA, UNITED STATES
PA Millennium Pharmaceuticals, Inc. (U.S. corporation)
PI US 2003039991 A1 20030227
AI US 2002-50216 A1 20020116 (10)
PRAI US 2001-262252P 20010116 (60)
DT Utility
FS APPLICATION
LREP Jean M. Silveri, Millennium Pharmaceuticals, Inc., 75 Sidney Street,
Cambridge, MA, 02139
CLMN Number of Claims: 33
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 5002

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated
46798 nucleic acid molecules, which encode matrix metalloproteinases.
The invention also provides antisense nucleic acid molecules,
recombinant expression vectors containing 46798 nucleic acid molecules,
host cells into which the expression vectors have been introduced, and
non-human transgenic animals in which a 46798 gene has been introduced
or disrupted. The invention still further provides isolated 46798
proteins, fusion proteins, antigenic peptides and anti-46798 antibodies.
Diagnostic and therapeutic methods utilizing compositions of

the
invention are also provided.

L16 ANSWER 70 OF 154 USPATFULL on STN

AN 2003:44781 USPATFULL

TI 48120, 23479 and 46689, novel human hydrolases and uses thereof

IN Meyers, Rachel E., Newton, MA, UNITED STATES

Bandaru, Rajasekhar, Watertown, MA, UNITED STATES

Curtis, Rory A.J., Southborough, MA, UNITED STATES

PI US 2003032091 A1 20030213

AI US 2001-971490 A1 20011005 (9)

PRAI US 2000-238170P 20001005 (60)

US 2000-237991P 20001005 (60)

DT Utility

FS APPLICATION

LREP LOUIS MEYERS, Fish & Richardson P.C., 225 Franklin Street, Boston, MA,
02110-2804

CLMN Number of Claims: 23

ECL Exemplary Claim: 1

DRWN 8 Drawing Page(s)

LN.CNT 7627

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 23479, 48120, and 46689 nucleic acid molecules, which encode novel hydrolases. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 23479, 48120, and 46689 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 23479, 48120, or 46689 gene has been introduced or disrupted. The invention still further provides isolated 23479, 48120, and 46689 proteins, fusion proteins, antigenic peptides and anti-23479, 48120, or 46689 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided.

L16 ANSWER 71 OF 154 USPATFULL on STN

AN 2003:38357 USPATFULL

TI 68730 and 69112, protein kinase molecules and uses therefor

IN Bandaru, Rajasekhar, Watertown, MA, UNITED STATES

PA Millennium Pharmaceuticals, Inc. (U.S. corporation)

PI US 2003028004 A1 20030206

AI US 2001-24036 A1 20011217 (10)

PRAI US 2000-258222P 20001222 (60)

DT Utility

FS APPLICATION

LREP Jean M. Silveri, Millennium Pharmaceuticals, Inc., 75 Sidney Street,
Cambridge, MA, 02139

CLMN Number of Claims: 22

ECL Exemplary Claim: 1

DRWN 8 Drawing Page(s)

LN.CNT 4460

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acid molecules, designated 68730 and 69112 nucleic acid molecules, which encode novel protein kinases. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 68730 and 69112 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 68730 and 69112 gene has been introduced or disrupted. The invention still further provides isolated 68730 and 69112 proteins, fusion proteins, antigenic peptides and anti-68730 and anti-69112 antibodies. ***Diagnostic***

and therapeutic methods utilizing compositions of the invention are also provided.

L16 ANSWER 72 OF 154 USPATFULL on STN

AN 2003:37671 USPATFULL

TI 16051a and 16051b, novel human PDZ family members and uses thereof

IN Meyers, Rachel E., Newton, MA, UNITED STATES

PI US 2003027316 A1 20030206

AI US 2001-836499 A1 20010417 (9)

PRAI US 2000-197507P 20000418 (60)

DT Utility

FS APPLICATION

LREP LOUIS MYERS, FISH & RICHARDSON P.C., 225 Franklin Street, Boston, MA,
02110-2804

CLMN Number of Claims: 31

ECL Exemplary Claim: 1

DRWN 4 Drawing Page(s)

LN.CNT 5268

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 16051a and 16051b nucleic acid molecules, which encode novel PDZ family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 16051a or 16051b nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 16051a or 16051b gene has been introduced or disrupted. The invention still further provides isolated 16051a or 16051b proteins, fusion proteins, antigenic peptides and anti-16051a or 16051b antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided.

L16 ANSWER 73 OF 154 USPATFULL on STN

AN 2003:30272 USPATFULL

TI 85080, a human metal ion transporter family member and uses thereof

IN Curtis, Rory A.J., Framingham, MA, UNITED STATES

PA Millennium Pharmaceuticals, Inc. (U.S. corporation)

PI US 2003022219 A1 20030130

AI US 2002-186511 A1 20020701 (10)

PRAI US 2001-305260P 20010713 (60)

DT Utility

FS APPLICATION

LREP Jean M. Silveri, Millennium Pharmaceuticals, Inc., 75 Sidney Street,
Cambridge, MA, 02139

CLMN Number of Claims: 22

ECL Exemplary Claim: 1

DRWN 1 Drawing Page(s)

LN.CNT 4965

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 85080 nucleic acid molecules, which encode novel metal transporter members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 85080 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which an 85080 gene has been introduced or disrupted. The invention still further provides isolated 85080 proteins, fusion proteins, antigenic peptides and anti-85080 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided.

L16 ANSWER 74 OF 154 USPATFULL on STN

AN 2003:30265 USPATFULL

TI 65649, a human metalloprotease family member and uses therefor

IN Curtis, Rory A.J., Framingham, MA, UNITED STATES

PA Millennium Pharmaceuticals, Inc. (U.S. corporation)

PI US 2003022212 A1 20030130

AI US 2002-167555 A1 20020612 (10)

PRAI US 2001-297938P 20010613 (60)

DT Utility

FS APPLICATION

LREP Jean M. Silveri, Millennium Pharmaceuticals, Inc., 75 Sidney Street,
Cambridge, MA, 02139

CLMN Number of Claims: 33

ECL Exemplary Claim: 1

DRWN 2 Drawing Page(s)

LN.CNT 4216

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 65649 nucleic acid molecules, which encode novel metalloprotease family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 65649 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 65649 gene has been introduced or disrupted. The invention still further provides isolated 65649 proteins, fusion proteins, antigenic peptides and anti-65649 antibodies.

Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.

L16 ANSWER 75 OF 154 USPATFULL on STN

AN 2003:30258 USPATFULL

TI 98359, a sodium channel beta 4 subunit, and uses therefor

IN Curtis, Rory A.J., Framingham, MA, UNITED STATES

PA Millennium Pharmaceuticals, Inc. (U.S. corporation)

PI US 2003022205 A1 20030130

AI US 2002-142201 A1 20020509 (10)

PRAI US 2001-289893P 20010509 (60)

DT Utility

FS APPLICATION

LREP Jean M. Silveri, Millennium Pharmaceuticals, Inc., 75 Sidney Street,
Cambridge, MA, 02139

CLMN Number of Claims: 23

ECL Exemplary Claim: 1

DRWN 1 Drawing Page(s)

LN.CNT 4856

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides an isolated nucleic acid molecule encoding a novel human sodium channel protein .beta. subunit. This nucleic acid molecule encodes a transmembrane protein that bears substantially sequence similarity to mammalian sodium channel protein .beta. subunits. The invention also provides antisense nucleic acid molecules, expression vectors containing the nucleic acid molecules of the invention, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a nucleic acid molecule of the invention has been introduced or disrupted. The invention still further provides isolated ***polypeptides***, fusion ***polypeptides***,

antigenic peptides and antibodies. ***Diagnostic***, screening and therapeutic methods utilizing compositions of the invention are also provided. The nucleic acids and ***polypeptides*** of the present invention are useful as modulating agents in regulating a variety of cellular processes.

L16 ANSWER 76 OF 154 USPATFULL on STN

AN 2003:30254 USPATFULL

TI 68999, a human ubiquitin carboxyl-terminal hydrolase family member and uses therefor

IN Kapeller-Libermann, Rosana, Chestnut Hill, MA, UNITED STATES

PA Millennium Pharmaceuticals, Inc. (U.S. corporation)

PI US 2003022201 A1 20030130

AI US 2002-107695 A1 20020327 (10)

PRAI US 2001-279184P 20010327 (60)

DT Utility

FS APPLICATION

LREP Millennium Pharmaceuticals, Inc., 75 Sidney Street, Cambridge, MA, 02139

CLMN Number of Claims: 29

ECL Exemplary Claim: 1

DRWN 1 Drawing Page(s)

LN.CNT 4533

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 68999 nucleic acid molecules, which encode ubiquitin carboxyl-terminal hydrolase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 68999 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 68999 gene has been introduced or disrupted. The invention still further provides isolated 68999 proteins, fusion proteins, antigenic peptides and anti-68999 antibodies. ***Diagnostic*** and therapeutic methods utilizing compositions of the invention are also provided.

L16 ANSWER 77 OF 154 USPATFULL on STN

AN 2003:30248 USPATFULL

TI 59914 and 59921, choline transporters and uses therefor

IN Curtis, Rory A.J., Framingham, MA, UNITED STATES

PA Millennium Pharmaceuticals, Inc. (U.S. corporation)

PI US 2003022195 A1 20030130

AI US 2002-62937 A1 20020131 (10)

PRAI US 2001-267076P 20010201 (60)

DT Utility

FS APPLICATION

LREP Jean M. Silveri, Millennium Pharmaceuticals, Inc., 75 Sidney Street, Cambridge, MA, 02139

CLMN Number of Claims: 36

ECL Exemplary Claim: 1

DRWN 4 Drawing Page(s)

LN.CNT 5980

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 59914 and 59921 nucleic acid molecules, which encode choline transporter family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 59914 and 59921 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which 59914 and

59921 genes have been introduced or disrupted. The invention still further provides isolated 59914 and 59921 proteins, fusion proteins, antigenic peptides and anti-59914 and 59921 antibodies.

Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.

L16 ANSWER 78 OF 154 USPATFULL on STN

AN 2003:23732 USPATFULL

TI 56294 and 56629, novel human metalloproteases and uses thereof

IN Bandaru, Rajasekhar, Watertown, MA, UNITED STATES

PI US 2003017572 A1 20030123

AI US 2001-961656 A1 20010924 (9)

PRAI US 2000-235035P 20000925 (60)

DT Utility

FS APPLICATION

LREP LOUIS MYERS, Fish & Richardson P.C., 225 Franklin Street, Boston, MA, 02110-2804

CLMN Number of Claims: 20

ECL Exemplary Claim: 1

DRWN 6 Drawing Page(s)

LN.CNT 5895

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 56294 and 56629 nucleic acid molecules, which encode novel metalloprotease family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 56294 or 56629 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 56294 or 56629 gene has been introduced or disrupted. The invention still further provides isolated 56294 or 56629 proteins, fusion proteins, antigenic peptides and anti-56294, anti-56629 antibodies.

Diagnostic methods utilizing compositions of the invention are also provided.

L16 ANSWER 79 OF 154 USPATFULL on STN

AN 2003:23729 USPATFULL

TI 2150, human protein kinase family member and uses therefor

IN Meyers, Rachel E., Newton, MA, UNITED STATES

Lora, Jose M., Arlington, MA, UNITED STATES

PA Millennium Pharmaceuticals, Inc. (U.S. corporation)

PI US 2003017569 A1 20030123

AI US 2002-184563 A1 20020627 (10)

PRAI US 2001-301702P 20010628 (60)

DT Utility

FS APPLICATION

LREP Jean M. Silveri, Millennium Pharmaceuticals, Inc., 75 Sidney Street, Cambridge, MA, 02139

CLMN Number of Claims: 35

ECL Exemplary Claim: 1

DRWN 1 Drawing Page(s)

LN.CNT 4485

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 2150 nucleic acid molecules, which encode novel protein kinase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 2150 nucleic acid molecules,

host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 2150 gene has been introduced or disrupted. The invention still further provides isolated 2150 proteins, fusion proteins, antigenic peptides and anti-2150 antibodies.

Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.

L16 ANSWER 80 OF 154 USPATFULL on STN

AN 2003:11319 USPATFULL

TI 46584, a human transporter family member and uses therefor

IN Curtis, Rory A.J., Framingham, MA, UNITED STATES

PA Millennium Pharmaceuticals, Inc. (U.S. corporation)

PI US 2003009024 A1 20030109

AI US 2002-170528 A1 20020613 (10)

PRAI US 2001-298012P 20010613 (60)

DT Utility

FS APPLICATION

LREP Jean M. Silveri, Millennium Pharmaceuticals, Inc., 75 Sidney Street, Cambridge, MA, 02139

CLMN Number of Claims: 22

ECL Exemplary Claim: 1

DRWN 1 Drawing Page(s)

LN.CNT 4994

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 46584 nucleic acid molecules, which encode transporter family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 46584 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 46584 gene has been introduced or disrupted. The invention still further provides isolated 46584 proteins, fusion proteins, antigenic peptides and anti-46584 antibodies.

Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.

L16 ANSWER 81 OF 154 USPATFULL on STN

AN 2003:11312 USPATFULL

TI 38650, 28472, 5495, 65507, 81588 and 14354 methods and compositions of human proteins and uses thereof

IN Leiby, Kevin R., Natick, MA, UNITED STATES

Kapeller-Libermann, Rosana, Chestnut Hill, MA, UNITED STATES

Glucksmann, Maria A., Lexington, MA, UNITED STATES

PI US 2003009017 A1 20030109

AI US 2001-12140 A1 20011108 (10)

PRAI US 2000-246768P 20001108 (60)

US 2000-246772P 20001108 (60)

US 2000-249185P 20001115 (60)

DT Utility

FS APPLICATION

LREP MORRISON & FOERSTER LLP, 3811 VALLEY CENTRE DRIVE, SUITE 500, SAN DIEGO, CA, 92130-2332

CLMN Number of Claims: 24

ECL Exemplary Claim: 1

DRWN 27 Drawing Page(s)

LN.CNT 6763

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 38650, 28472, 5495, 65507, 81588 or 14354 nucleic acid molecules, which encode novel adenosine deaminase, glycoprotease, or seven transmembrane receptor family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 38650, 28472, 5495, 65507, 81588 or 14354 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 38650, 28472, 5495, 65507, 81588 or 14354 gene has been introduced or disrupted. The invention still further provides isolated 38650, 28472, 5495, 65507, 81588 or 14354 proteins, fusion proteins, antigenic peptides and anti-38650, 28472, 5495, 65507, 81588 or 14354 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided.

L16 ANSWER 82 OF 154 USPATFULL on STN

AN 2003:3504 USPATFULL

TI 67108, a human phospholipid transporter family member and uses therefor

IN Curtis, Rory A.J., Framingham, MA, UNITED STATES

PA Millennium Pharmaceuticals, Inc. (U.S. corporation)

PI US 2003003539 A1 20030102

AI US 2002-170102 A1 20020612 (10)

PRAI US 2001-297840P 20010613 (60)

DT Utility

FS APPLICATION

LREP Jean M. Silveri, Millennium Pharmaceuticals, Inc., 75 Sidney Street, Cambridge, MA, 02139

CLMN Number of Claims: 22

ECL Exemplary Claim: 1

DRWN 1 Drawing Page(s)

LN.CNT 5762

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 67108 nucleic acid molecules, which encode novel phospholipid transporter members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 67108 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 67108 gene has been introduced or disrupted. The invention still further provides isolated 67108 proteins, fusion proteins, antigenic peptides and anti-67108 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided.

L16 ANSWER 83 OF 154 USPATFULL on STN

AN 2002:343977 USPATFULL

TI 65552, a human matrix metalloproteinase and uses therefor

IN Kapeller-Libermann, Rosana, Chestnut Hill, MA, UNITED STATES

PA Millennium Pharmaceuticals, Inc. (U.S. corporation)

PI US 2002197703 A1 20021226

AI US 2002-163316 A1 20020605 (10)

PRAI US 2001-297863P 20010613 (60)

DT Utility

FS APPLICATION

LREP Jean M. Silveri, Millennium Pharmaceuticals, Inc., 75 Sidney Street, Cambridge, MA, 02139

CLMN Number of Claims: 33

ECL Exemplary Claim: 1

DRWN 1 Drawing Page(s)

LN.CNT 4981

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 65552 nucleic acid molecules, which encode matrix metalloproteinases. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 65552 nucleic acid molecules, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a 65552 gene has been introduced or disrupted. The invention still further provides isolated 65552 proteins, fusion proteins, antigenic peptides and anti-65552 antibodies. ***Diagnostic*** and therapeutic methods utilizing compositions of the invention are also provided.

L16 ANSWER 84 OF 154 USPATFULL on STN

AN 2002:343969 USPATFULL

TI 80090, 52874, 52880, 63497, and 33425 methods and compositions of human proteins and uses thereof

IN Glucksmann, Maria A., Lexington, MA, UNITED STATES

Meyers, Rachel, Newton, MA, UNITED STATES

PI US 2002197695 A1 20021226

AI US 2001-80960 A1 20011019 (10)

PRAI US 2000-242040P 20001020 (60)

US 2000-242038P 20001020 (60)

US 2000-241992P 20001020 (60)

US 2000-242637P 20001023 (60)

DT Utility

FS APPLICATION

LREP Carolyn A. Favorito, Morrison & Foerster LLP, Suite 500, 3811 Valley Centre Drive, San Diego, CA, 92130-2332

CLMN Number of Claims: 24

ECL Exemplary Claim: 1

DRWN 24 Drawing Page(s)

LN.CNT 6340

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 80090, 52874, 52880, 63497, or 33425 nucleic acid molecules, which encode novel fucosyltransferase, seven transmembrane receptor, or RhoGAP family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 80090, 52874, 52880, 63497, or 33425 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which an 80090, 52874, 52880, 63497, or 33425 gene has been introduced or disrupted. The invention still further provides isolated 80090, 52874, 52880, 63497, or 33425 proteins, fusion proteins, antigenic peptides and anti-80090, 52874, 52880, 63497, or 33425 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided.

L16 ANSWER 85 OF 154 USPATFULL on STN

AN 2002:338212 USPATFULL

TI 69624, a novel human transporter family member and uses therefor

IN Curtis, Rory A.J., Framingham, MA, UNITED STATES

PA Millennium Pharmaceuticals, Inc. (U.S. corporation)

PI US 2002193582 A1 20021219

AI US 2002-173519 A1 20020617 (10)

PRAI US 2001-298970P 20010618 (60)
DT Utility
FS APPLICATION
LREP Jean M. Silveri, Millennium Pharmaceuticals, Inc., 75 Sidney Street,
Cambridge, MA, 02139
CLMN Number of Claims: 22
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 5142

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 69624 nucleic acid molecules, which encode novel transporter members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 69624 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 69624 gene has been introduced or disrupted. The invention still further provides isolated 69624 proteins, fusion proteins, antigenic peptides and anti-69624 antibodies.
Diagnostic methods utilizing compositions of the invention are also provided.

L16 ANSWER 86 OF 154 USPATFULL on STN

AN 2002:337938 USPATFULL
TI 58860, a human cholesteryl ester hydrolase and uses therefor
IN Kapeller-Libermann, Rosana, Chestnut Hill, MA, UNITED STATES
PA Millennium Pharmaceuticals, Inc.
PI US 2002193303 A1 20021219
AI US 2002-56744 A1 20020125 (10)
PRAI US 2001-264167P 20010125 (60)
DT Utility
FS APPLICATION
LREP Jean M. Silveri, Millennium Pharmaceuticals, Inc., 75 Sidney Street,
Cambridge, MA, 02139
CLMN Number of Claims: 33
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 4459

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 58860 nucleic acid molecules, which encode cholesteryl ester hydrolases. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 58860 nucleic acid molecules, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a 58860 gene has been introduced or disrupted. The invention still further provides isolated 58860 proteins, fusion proteins, antigenic peptides and anti-58860 antibodies.
Diagnostic and therapeutic methods utilizing compositions of

the
invention are also provided.

L16 ANSWER 87 OF 154 USPATFULL on STN

AN 2002:336850 USPATFULL
TI 15985, a novel human serine/threonine protein kinase family member and uses thereof
IN Kapeller-Libermann, Rosana, Chestnut Hill, MA, UNITED STATES
PI US 2002192204 A1 20021219
AI US 2001-934406 A1 20010821 (9)

PRAI US 2000-226740P 20000821 (60)
DT Utility
FS APPLICATION
LREP LOUIS MYERS, FISH & RICHARDSON P.C., 225 Franklin Street, Boston, MA,
02110-2804
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 6 Drawing Page(s)
LN.CNT 5347

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 15985 nucleic acid molecules, which encode novel serine/threonine protein kinase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 15985 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 15985 gene has been introduced or disrupted. The invention still further provides isolated 15985 proteins, fusion proteins, antigenic peptides and anti-15985 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided.

L16 ANSWER 88 OF 154 USPATFULL on STN

AN 2002:329459 USPATFULL

TI 15368, a novel human GTP-releasing factor family member and uses therefor

IN Meyers, Rachel, Newton, MA, UNITED STATES

PI US 2002187138 A1 20021212

AI US 2001-922199 A1 20010802 (9)

PRAI US 2000-222622P 20000802 (60)

DT Utility

FS APPLICATION

LREP MORRISON & FOERSTER LLP, 3811 VALLEY CENTRE DRIVE, SUITE 500, SAN DIEGO, CA, 92130-2332

CLMN Number of Claims: 24

ECL Exemplary Claim: 1

DRWN 15 Drawing Page(s)

LN.CNT 4492

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 15368 nucleic acid molecules, which encode novel GTP-releasing factor family member family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 15368 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 15368 gene has been introduced or disrupted. The invention still further provides isolated 15368 proteins, fusion proteins, antigenic peptides and anti-15368 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided.

L16 ANSWER 89 OF 154 USPATFULL on STN

AN 2002:322472 USPATFULL

TI 53010, a novel human carboxylesterase family member and uses thereof

IN Curtis, Rory A. J., Southborough, MA, UNITED STATES

Silos-Santiago, Inmaculada, Jamaica Plain, MA, UNITED STATES

PI US 2002182636 A1 20021205

US 6664091 B2 20031216

AI US 2001-23515 A1 20011218 (10)

PRAI US 2000-256369P 20001218 (60)
US 2001-279508P 20010328 (60)
DT Utility
FS APPLICATION
LREP LOUIS MYERS, Fish & Richardson P.C., 225 Franklin Street, Boston, MA,
02110-2804
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 3 Drawing Page(s)
LN.CNT 4777

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 53010 nucleic acid molecules, which encode novel carboxylesterase members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 53010 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 53010 gene has been introduced or disrupted. The invention still further provides isolated 53010 proteins, fusion proteins, antigenic peptides and anti-53010 antibodies.
Diagnostic methods utilizing compositions of the invention are also provided.

L16 ANSWER 90 OF 154 USPATFULL on STN
AN 2002:301198 USPATFULL
TI 59079 and 12599, protein kinase family members and uses therefor
IN Kapeller-Libermann, Rosana, Chestnut Hill, MA, UNITED STATES
Acton, Susan L., Lexington, MA, UNITED STATES
PA Millennium Pharmaceuticals, Inc. (U.S. corporation)
PI US 2002168742 A1 20021114
AI US 2002-77130 A1 20020215 (10)
PRAI US 2001-269201P 20010215 (60)
DT Utility
FS APPLICATION
LREP Jean M. Silveri, Millennium Pharmaceuticals, Inc., 75 Sidney Street,
Cambridge, MA, 02139
CLMN Number of Claims: 22
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 8442

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 59079 and 12599 nucleic acid molecules, which encode novel protein kinase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 59079 or 12599 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 59079 or 12599 gene has been introduced or disrupted. The invention still further provides isolated 59079 and 12599 proteins, fusion proteins, antigenic peptides and anti-59079 and anti-12599 antibodies.
Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.

L16 ANSWER 91 OF 154 USPATFULL on STN
AN 2002:301169 USPATFULL
TI 46980, a novel human neuroligin family member and uses thereof
IN Curtis, Rory A.J., Southborough, MA, UNITED STATES

PI US 2002168713 A1 20021114
AI US 2001-875353 A1 20010606 (9)
PRAI US 2000-209949P 20000606 (60)
DT Utility
FS APPLICATION
LREP LOUIS MYERS, Fish & Richardson P.C., 225 Franklin Street, Boston, MA,
02110-2804
CLMN Number of Claims: 32
ECL Exemplary Claim: 1
DRWN 5 Drawing Page(s)
LN.CNT 5549

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 46980 nucleic acid molecules, which encode novel neuroligin members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 46980 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 46980 gene has been introduced or disrupted. The invention still further provides isolated 46980 proteins, fusion proteins, antigenic peptides and anti-46980 antibodies.
Diagnostic methods utilizing compositions of the invention are also provided.

L16 ANSWER 92 OF 154 USPATFULL on STN

AN 2002:301125 USPATFULL
TI 14691, a human glutamate receptor family member and uses therefor
IN Curtis, Rory A.J., Southborough, MA, UNITED STATES
PA Millennium Pharmaceuticals, Inc. (U.S. corporation)
PI US 2002168668 A1 20021114
AI US 2002-106534 A1 20020326 (10)
PRAI US 2001-279086P 20010327 (60)
DT Utility
FS APPLICATION
LREP Jean M. Silveri, Millennium Pharmaceuticals, Inc., 75 Sidney Street,
Cambridge, MA, 02139
CLMN Number of Claims: 22
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 5213

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 14691 nucleic acid molecules, which encode novel glutamate receptor family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 14691 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 14691 gene has been introduced or disrupted. The invention still further provides isolated 14691 proteins, fusion proteins, antigenic peptides and anti-14691 antibodies. ***Diagnostic*** and therapeutic methods utilizing compositions of the invention are also provided.

L16 ANSWER 93 OF 154 USPATFULL on STN

AN 2002:295307 USPATFULL
TI 38554, 57301 and 58324, human organic ion transporters and uses therefor
IN Curtis, Rory A.J., Southborough, MA, UNITED STATES
Silos-Santiago, Inmaculada, Jamaica Plain, MA, UNITED STATES
PA Millennium Pharmaceuticals, Inc. (U.S. corporation)

PI US 2002165357 A1 20021107
AI US 2002-95139 A1 20020311 (10)
PRAI US 2001-275172P 20010312 (60)
DT Utility
FS APPLICATION
LREP Millennium Pharmaceuticals, Inc., 75 Sidney Street, Cambridge, MA, 02139
CLMN Number of Claims: 24
ECL Exemplary Claim: 1
DRWN 4 Drawing Page(s)
LN.CNT 7172

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 38554, 57301 or 58324 nucleic acid molecules, which encode novel SLC21 or SLC22 family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 38554, 57301 or 58324 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 38554, 57301 or 58324 gene has been introduced or disrupted. The invention still further provides isolated 38554, 57301 or 58324 proteins, fusion proteins, antigenic peptides and anti-38554, 57301 or 58324 antibodies. ***Diagnostic*** and therapeutic methods utilizing compositions of the invention are also provided.

L16 ANSWER 94 OF 154 USPATFULL on STN

AN 2002:294726 USPATFULL

TI 32144, a novel human fatty acid amide hydrolase family member and uses thereof

IN Curtis, Rory A.J., Southborough, MA, UNITED STATES

MacBeth, Kyle J., Boston, MA, UNITED STATES

Rudolph-Owen, Laura A., Jamaica Plain, MA, UNITED STATES

PI US 2002164769 A1 20021107

AI US 2001-966614 A1 20010927 (9)

PRAI US 2000-238054P 20001005 (60)

DT Utility

FS APPLICATION

LREP LOUIS MYERS, FISH & RICHARDSON P.C., 225 Franklin Street, Boston, MA, 02110-2804

CLMN Number of Claims: 25

ECL Exemplary Claim: 1

DRWN 4 Drawing Page(s)

LN.CNT 5256

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 32144 nucleic acid molecules, which encode novel fatty acid amide hydrolase members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 32144 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 32144 gene has been introduced or disrupted. The invention still further provides isolated 32144 proteins, fusion proteins, antigenic peptides and anti-32144 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided.

L16 ANSWER 95 OF 154 USPATFULL on STN

AN 2002:294723 USPATFULL

TI 57406, a novel human metalloprotease family member and uses thereof

IN Bandaru, Rajasekhar, Watertown, MA, UNITED STATES

PI US 2002164766 A1 20021107
AI US 2001-7271 A1 20011022 (10)
PRAI US 2000-242303P 20001020 (60)
DT Utility
FS APPLICATION
LREP LOUIS MYERS, Fish & Richardson P.C., 225 Franklin Street, Boston, MA,
02110-2804
CLMN Number of Claims: 24
ECL Exemplary Claim: 1
DRWN 3 Drawing Page(s)
LN.CNT 4931

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 57406 nucleic acid molecules, which encode novel metalloprotease members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 57406 nucleic acid molecules, host cells into that the expression vectors have been introduced, and nonhuman transgenic animals in that a 57406 gene has been introduced or disrupted. The invention still further provides isolated 57406 proteins, fusion proteins, antigenic peptides and anti-57406 antibodies.
Diagnostic methods utilizing compositions of the invention are also provided.

L16 ANSWER 96 OF 154 USPATFULL on STN

AN 2002:294703 USPATFULL

TI 47174, a novel human glycosyltransferase and uses thereof

IN Kapeller-Libermann, Rosana, Chestnut Hill, MA, UNITED STATES

PI US 2002164746 A1 20021107

US 6703230 B2 20040309

AI US 2001-973457 A1 20011009 (9)

PRAI US 2000-238849P 20001006 (60)

DT Utility

FS APPLICATION

LREP LOUIS MEYERS, FISH & RICHARDSON P.C., 225 Franklin Street, Boston, MA,
02110-2804

CLMN Number of Claims: 20

ECL Exemplary Claim: 1

DRWN 4 Drawing Page(s)

LN.CNT 4577

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 47174 nucleic acid molecules, which encode novel glycosyltransferase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 47174 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 47174 gene has been introduced or disrupted. The invention still further provides isolated 47174 proteins, fusion proteins, antigenic peptides and anti-47174 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided. The invention also provides methods of modulating pain or pain related disorders utilizing the compositions of the invention. Accordingly, methods of treating, preventing and/or ***diagnosing*** neurological disorders are disclosed.

L16 ANSWER 97 OF 154 USPATFULL on STN

AN 2002:294702 USPATFULL

TI 53320, a novel human acyltransferase and uses therefor
 IN Meyers, Rachel A., Newton, MA, UNITED STATES
 Tsai, Fong-Ying, Newton, MA, UNITED STATES
 PI US 2002164745 A1 20021107
 AI US 2001-882872 A1 20010615 (9)
 PRAI US 2000-212077P 20000615 (60)
 DT Utility
 FS APPLICATION
 LREP LOUIS MYERS, Fish & Richardson P.C., 225 Franklin Street, Boston, MA,
 02110-2804
 CLMN Number of Claims: 30
 ECL Exemplary Claim: 1
 DRWN 5 Drawing Page(s)
 LN.CNT 5295
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB The invention provides isolated nucleic acids molecules, designated
 53320 nucleic acid molecules, which encode novel acyltransferase
 members. The invention also provides antisense nucleic acid molecules,
 recombinant expression vectors containing 53320 nucleic acid molecules,
 host cells into which the expression vectors have been introduced, and
 nonhuman transgenic animals in which a 53320 gene has been introduced or
 disrupted. The invention still further provides isolated 53320 proteins,
 fusion proteins, antigenic peptides and anti-53320 antibodies.
 Diagnostic methods utilizing compositions of the invention are
 also provided. The 53320 nucleic acids are expressed in endothelial
 cells.

L16 ANSWER 98 OF 154 USPATFULL on STN
 AN 2002:294282 USPATFULL
 TI 56939, a novel human acyl-CoA thioesterase family member and uses
 thereof
 IN Meyers, Rachel A., Newton, MA, UNITED STATES
 PI US 2002164320 A1 20021107
 AI US 2001-911317 A1 20010723 (9)
 PRAI US 2000-220040P 20000721 (60)
 DT Utility
 FS APPLICATION
 LREP LOUIS MYERS, FISH & RICHARDSON P.C., 225 Franklin Street, Boston, MA,
 02110-2804
 CLMN Number of Claims: 19
 ECL Exemplary Claim: 1
 DRWN 2 Drawing Page(s)
 LN.CNT 5096
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB The invention provides isolated nucleic acids molecules, designated
 56939 nucleic acid molecules, which encode novel acyl-CoA thioesterase
 family members. The invention also provides antisense nucleic acid
 molecules, recombinant expression vectors containing 56939 nucleic acid
 molecules, host cells into which the expression vectors have been
 introduced, and nonhuman transgenic animals in which a 56939 gene has
 been introduced or disrupted. The invention still further provides
 isolated 56939 proteins, fusion proteins, antigenic peptides and
 anti-56939 antibodies. ***Diagnostic*** methods utilizing
 compositions of the invention are also provided.

L16 ANSWER 99 OF 154 USPATFULL on STN
 AN 2002:287589 USPATFULL

TI 25206, a novel human short-chain dehydrogenase/reductase family member
and uses thereof
IN Meyers, Rachel E., Newton, MA, UNITED STATES
MacBeth, Kyle J., Boston, MA, UNITED STATES
PI US 2002160452 A1 20021031
AI US 2001-997816 A1 20011129 (9)
PRAI US 2000-250186P 20001130 (60)
DT Utility
FS APPLICATION
LREP P. LOUIS MYERS, Fish & Richardson P.C., 225 Franklin Street, Boston, MA,
02110-2804
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 4862

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated
25206 nucleic acid molecules, which encode novel short-chain
dehydrogenase/reductase members. The invention also provides antisense
nucleic acid molecules, recombinant expression vectors containing 25206
nucleic acid molecules, host cells into which the expression vectors
have been introduced, and nonhuman transgenic animals in which a 25206
gene has been introduced or disrupted. The invention still further
provides isolated 25206 proteins, fusion proteins, antigenic peptides
and anti-25206 antibodies. ***Diagnostic*** methods utilizing
compositions of the invention are also provided.

L16 ANSWER 100 OF 154 USPATFULL on STN

AN 2002:287508 USPATFULL
TI 56739, a novel CUB domain containing protein and uses thereof
IN Kapeller-Libermann, Rosana, Chestnut Hill, MA, UNITED STATES
PI US 2002160371 A1 20021031
AI US 2001-886429 A1 20010621 (9)
PRAI US 2000-213963P 20000623 (60)
DT Utility
FS APPLICATION
LREP LOUIS MAYERS, Fish & Richardson P.C., 225 Franklin Street, Boston, MA,
02110-2804
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 4691

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated
56739 nucleic acid molecules, which encode novel CUB family members. The
invention also provides antisense nucleic acid molecules, recombinant
expression vectors containing 56739 nucleic acid molecules, host cells
into which the expression vectors have been introduced, and nonhuman
transgenic animals in which a 56739 gene has been introduced or
disrupted. The invention still further provides isolated 56739 proteins,
fusion proteins, antigenic peptides and anti-56739 antibodies.
Diagnostic methods utilizing compositions of the invention are
also provided.

L16 ANSWER 101 OF 154 USPATFULL on STN

AN 2002:280557 USPATFULL
TI 32620, a novel human sodium-sugar symporter family member and uses

thereof
IN Curtis, Rory A.J., Southborough, MA, UNITED STATES
Silos-Santiago, Inmaculada, Cambridge, MA, UNITED STATES
PI US 2002156002 A1 20021024
AI US 2001-928530 A1 20010813 (9)
PRAI US 2000-227068P 20000822 (60)
DT Utility
FS APPLICATION
LREP LOUIS MYERS, Fish & Richardson P.C., 225 Franklin Street, Boston, MA,
02110-2804
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 5 Drawing Page(s)
LN.CNT 4837

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 32620 nucleic acid molecules, which encode novel sodium-sugar symporter members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 32620 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 32620 gene has been introduced or disrupted. The invention still further provides isolated 32620 proteins, fusion proteins, antigenic peptides and anti-32620 antibodies.
Diagnostic methods utilizing compositions of the invention are also provided.

L16 ANSWER 102 OF 154 USPATFULL on STN

AN 2002:273565 USPATFULL

TI 84242,8035, 55304, 52999, and 21999, novel human proteins and methods of use thereof

IN Bandaru, Rajaschkar, Watertown, MA, UNITED STATES

PA Millennium Pharmaceuticals, Inc. (U.S. corporation)

PI US 2002151696 A1 20021017

AI US 2001-996194 A1 20011128 (9)

PRAI US 2000-250348P 20001130 (60)

US 2000-250073P 20001130 (60)

US 2000-253878P 20001129 (60)

US 2000-250338P 20001130 (60)

DT Utility

FS APPLICATION

LREP ALSTON & BIRD LLP, BANK OF AMERICA PLAZA, 101 SOUTH TRYON STREET, SUITE 4000, CHARLOTTE, NC, 28280-4000

CLMN Number of Claims: 22

ECL Exemplary Claim: 1

DRWN 19 Drawing Page(s)

LN.CNT 8034

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 8035, 84242, 55304, 52999, or 21999 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 8035, 84242, 55304, 52999, or 21999 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which an 8035, 84242, 55304, 52999, or 21999 gene has been introduced or disrupted. The invention still further provides isolated 8035, 84242, 55304, 52999, or 21999 proteins, fusion proteins, antigenic peptides and anti-8035, anti-84242, anti-55304, anti-52999, or anti-21999 antibodies.

Diagnostic methods utilizing compositions of the invention are also provided.

L16 ANSWER 103 OF 154 USPATFULL on STN
AN 2002:272795 USPATFULL
TI 43716, a novel human G-protein and uses thereof
IN Meyers, Rachel, Newton, MA, UNITED STATES
PI US 2002150916 A1 20021017
AI US 2001-972529 A1 20011005 (9)
PRAI US 2000-237716P 20001005 (60)
DT Utility
FS APPLICATION
LREP MORRISON & FOERSTER LLP, 3811 VALLEY CENTRE DRIVE, SUITE 500, SAN DIEGO, CA, 92130-2332
CLMN Number of Claims: 24
ECL Exemplary Claim: 1
DRWN 4 Drawing Page(s)
LN.CNT 4405

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 47316 nucleic acid molecules, which encode novel G-protein family members, preferably Ras family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 47316 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 47316 gene has been introduced or disrupted. The invention still further provides isolated 47316 proteins, fusion proteins, antigenic peptides and anti-47316 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided.

L16 ANSWER 104 OF 154 USPATFULL on STN
AN 2002:272789 USPATFULL
TI 33410, a novel human carboxylesterase family member and uses thereof
IN Curtis, Rory A.J., Southborough, MA, UNITED STATES
PI US 2002150910 A1 20021017
AI US 2001-934323 A1 20010821 (9)
PRAI US 2000-226774P 20000821 (60)
DT Utility
FS APPLICATION
LREP LOUIS MYERS, FISH & RICHARDSON P.C., 225 Franklin Street, Boston, MA, 02110-2804
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 4 Drawing Page(s)
LN.CNT 5103

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 33410 nucleic acid molecules, which encode novel carboxylesterase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 33410 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 33410 gene has been introduced or disrupted. The invention still further provides isolated 33410 proteins, fusion proteins, antigenic peptides and anti-33410 antibodies.

Diagnostic methods utilizing compositions of the invention are also provided.

L16 ANSWER 105 OF 154 USPATFULL on STN
AN 2002:265924 USPATFULL
TI 48921, a novel human GTP releasing factor and uses therefor
IN Curtis, Rory A.J., Southborough, MA, UNITED STATES
PI US 2002146800 A1 20021010
AI US 2001-940836 A1 20010827 (9)
PRAI US 2000-228760P 20000830 (60)
DT Utility
FS APPLICATION
LREP MORRISON & FOERSTER LLP, 3811 VALLEY CENTRE DRIVE, SUITE 500, SAN DIEGO,
CA, 92130-2332
CLMN Number of Claims: 24
ECL Exemplary Claim: 1
DRWN 6 Drawing Page(s)
LN.CNT 4196

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 48921 nucleic acid molecules, which encode novel GTP releasing factor family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 48921 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 48921 gene has been introduced or disrupted. The invention still further provides isolated 48921 proteins, fusion proteins, antigenic peptides and anti-48921 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided.

L16 ANSWER 106 OF 154 USPATFULL on STN
AN 2002:251234 USPATFULL
TI 14087, a novel serine protease molecule and uses therefor
IN Meyers, Rachel, Newton, MA, UNITED STATES
PI US 2002137181 A1 20020926
AI US 2001-910151 A1 20010718 (9)
PRAI US 2000-219022P 20000718 (60)
DT Utility
FS APPLICATION
LREP Carolyn A. Favorito, Morrison & Foerster LLP, Suite 500, 3811 Valley
Centre Drive, San Diego, CA, 92130-2332
CLMN Number of Claims: 23
ECL Exemplary Claim: 1
DRWN 4 Drawing Page(s)
LN.CNT 4064

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 14087 nucleic acid molecules, which encode novel serine protease family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 14087 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 14087 gene has been introduced or disrupted. The invention still further provides isolated 14087 proteins, fusion proteins, antigenic peptides and anti-14087 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided.

L16 ANSWER 107 OF 154 USPATFULL on STN
AN 2002:251157 USPATFULL
TI 46638, a novel human lipoxxygenase family member and uses thereof

IN Meyers, Rachel A., Newton, MA, UNITED STATES

PI US 2002137101 A1 20020926

AI US 2001-862658 A1 20010521 (9)

PRAI US 2000-205675P 20000519 (60)

DT Utility

FS APPLICATION

LREP DIANA M. COLLAZO, FISH & RICHARDSON P.C., 225 Franklin Street, Boston, MA, 02110-2804

CLMN Number of Claims: 22

ECL Exemplary Claim: 1

DRWN 3 Drawing Page(s)

LN.CNT 5374

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 46638 nucleic acid molecules, which encode novel lipoxxygenase members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 46638 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 46638 gene has been introduced or disrupted. The invention still further provides isolated 46638 proteins, fusion proteins, antigenic peptides and anti-46638 antibodies.
Diagnostic methods utilizing compositions of the invention are also provided.

L16 ANSWER 108 OF 154 USPATFULL on STN

AN 2002:251119 USPATFULL

TI 57242, a novel human G protein-coupled receptor family member and uses therefor

IN Glucksmann, Maria Alexandra, Lexington, MA, UNITED STATES

Gimeno, Ruth, Wellesley, MA, UNITED STATES

White, David, Braintree, MA, UNITED STATES

PA Millennium Pharmaceuticals, Inc. (U.S. corporation)

PI US 2002137063 A1 20020926

AI US 2001-942374 A1 20010829 (9)

PRAI US 2000-228409P 20000829 (60)

DT Utility

FS APPLICATION

LREP Kerri Pollard Schray, Millennium Pharmaceuticals, 75 Sidney Street, Cambridge, MA, 02139

CLMN Number of Claims: 104

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 4723

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to methods and compositions for the ***diagnosis*** and treatment of metabolic disorders, including, but not limited to, obesity, diabetes, hyperlipidemia, overweight anorexia, or cachexia. The invention provides isolated nucleic acids molecules, designated 57242 nucleic acid molecules, which encode novel G protein-coupled receptor family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 57242 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 57242 gene has been introduced or disrupted. The invention still further provides isolated 57242 proteins, fusion proteins, antigenic peptides and anti-57242 antibodies. Methods of use of the provided 57242 compositions for screening, ***diagnostic*** and

therapeutic methods in connection with metabolic disorders are also disclosed.

L16 ANSWER 109 OF 154 USPATFULL on STN
AN 2002:243117 USPATFULL
TI 69318, a human sodium/calcium exchanger (transporter) family member and uses therefor
IN Curtis, Rory A.J., Southborough, MA, UNITED STATES
PA Millennium Pharmaceuticals, Inc. (U.S. corporation)
PI US 2002132303 A1 20020919
AI US 2002-94214 A1 20020308 (10)
PRAI US 2001-275078P 20010312 (60)
DT Utility
FS APPLICATION
LREP Jean M. Silveri, Millennium Pharmaceuticals, Inc., 75 Sidney Street, Cambridge, MA, 02139
CLMN Number of Claims: 22
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 4738

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 69318 nucleic acid molecules, which encode novel sodium/calcium exchanger family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 69318 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 69318 gene has been introduced or disrupted. The invention still further provides isolated 69318 proteins, fusion proteins, antigenic peptides and anti-69318 antibodies. ***Diagnostic*** and therapeutic methods utilizing compositions of the invention are also provided.

L16 ANSWER 110 OF 154 USPATFULL on STN
AN 2002:243115 USPATFULL
TI 25466, a human transporter family member and uses therefor
IN Curtis, Rory A.J., Southborough, MA, UNITED STATES
PI US 2002132301 A1 20020919
AI US 2002-74547 A1 20020212 (10)
PRAI US 2001-269072P 20010215 (60)
DT Utility
FS APPLICATION
LREP Millennium Pharmaceuticals, Inc., 75 Sidney Street, Cambridge, MA, 02139
CLMN Number of Claims: 22
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 4778

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 25466 nucleic acid molecules, which encode novel transporter molecules. The 25466 transporter molecules are homologous to monocarboxylate (MCT) transporters, and in particular to SLC16 family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 25466 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 25466 gene has been introduced or disrupted. The invention still further provides isolated 25466 proteins, fusion proteins, antigenic peptides and anti-25466 antibodies.

the ***Diagnostic*** and therapeutic methods utilizing compositions of the invention are also provided.

L16 ANSWER 111 OF 154 USPATFULL on STN
AN 2002:235461 USPATFULL
TI 32468, a human sugar transporter family member and uses therefor
IN Curtis, Rory A.J., Southborough, MA, UNITED STATES
PA Millennium Pharmaceuticals, Inc. (U.S. corporation)
PI US 2002127650 A1 20020912
AI US 2002-94059 A1 20020308 (10)
PRAI US 2001-275053P 20010312 (60)
DT Utility
FS APPLICATION
LREP Millennium Pharmaceuticals, Inc., 75 Sidney Street, Cambridge, MA, 02139
CLMN Number of Claims: 22
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 4893
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 32468 nucleic acid molecules, which encode novel sugar transporter family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 32468 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 32468 gene has been introduced or disrupted. The invention still further provides isolated 32468 proteins, fusion proteins, antigenic peptides and anti-32468 antibodies. ***Diagnostic*** and therapeutic methods utilizing compositions of the invention are also provided.

L16 ANSWER 112 OF 154 USPATFULL on STN
AN 2002:235379 USPATFULL
TI 47324, a novel human G-protein and uses therefor
IN Meyers, Rachel, Newton, MA, UNITED STATES
PI US 2002127568 A1 20020912
AI US 2001-945173 A1 20010831 (9)
PRAI US 2000-229293P 20000901 (60)
DT Utility
FS APPLICATION
LREP Carolyn A. Favorito, Morrison & Foerster LLP, Suite 500, 3811 Valley Centre Drive, San Diego, CA, 92130-2332
CLMN Number of Claims: 24
ECL Exemplary Claim: 1
DRWN 6 Drawing Page(s)
LN.CNT 4527
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 47324 nucleic acid molecules, which encode novel G-protein family members, preferably Ras family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 47324 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 47324 gene has been introduced or disrupted. The invention still further provides isolated 47324 proteins, fusion proteins, antigenic peptides and anti-47324 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided.

L16 ANSWER 113 OF 154 USPATFULL on STN

AN 2002:235378 USPATFULL

TI 52991, a novel human transporter and uses therefor

IN Glucksmann, Maria A., Lexington, MA, UNITED STATES

PI US 2002127567 A1 20020912

AI US 2001-942447 A1 20010829 (9)

PRAI US 2000-229036P 20000831 (60)

DT Utility

FS APPLICATION

LREP Carolyn A. Favorito, Morrison & Foerster LLP, Suite 500, 3811 Valley
Centre Drive, San Diego, CA, 92130-2332

CLMN Number of Claims: 24

ECL Exemplary Claim: 1

DRWN 6 Drawing Page(s)

LN.CNT 4581

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 52991 nucleic acid molecules, which encode novel transporter family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 52991 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 52991 gene has been introduced or disrupted. The invention still further provides isolated 52991 proteins, fusion proteins, antigenic peptides and anti-52991 antibodies.

Diagnostic methods utilizing compositions of the invention are also provided.

L16 ANSWER 114 OF 154 USPATFULL on STN

AN 2002:228315 USPATFULL

TI 32626, a novel human UDP-glycosyltransferase and uses thereof

IN Leiby, Kevin R., Natick, MA, UNITED STATES

Spaltmann, Frank, Cambridge, MA, UNITED STATES

Cook, William James, Natick, MA, UNITED STATES

PI US 2002123475 A1 20020905

AI US 2001-895728 A1 20010629 (9)

PRAI US 2000-215749P 20000630 (60)

DT Utility

FS APPLICATION

LREP Carolyn A. Favorito, Morrison & Foerster LLP, Suite 500, 3811 Valley
Centre Drive, San Diego, CA, 92130-2332

CLMN Number of Claims: 23

ECL Exemplary Claim: 1

DRWN 5 Drawing Page(s)

LN.CNT 4203

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 32626 nucleic acid molecules, which encode novel UDP-glycosyltransferase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 32626 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 32626 gene has been introduced or disrupted. The invention still further provides isolated 32626 proteins, fusion proteins, antigenic peptides and anti-32626 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided.

L16 ANSWER 115 OF 154 USPATFULL on STN
AN 2002:221771 USPATFULL
TI 61833, a novel human pyridoxyl-dependent decarboxylase family member and
uses thereof
IN Glucksmann, Maria Alexandra, Lexington, MA, UNITED STATES
PI US 2002119913 A1 20020829
AI US 2001-841880 A1 20010424 (9)
PRAI US 2000-199559P 20000425 (60)
DT Utility
FS APPLICATION
LREP LOUIS MYERS, FISH & RICHARDSON P.C., 225 Franklin Street, Boston, MA,
02110-2804
CLMN Number of Claims: 27
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 4953

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated
61833 nucleic acid molecules, which encode novel pyridoxyl-dependent
decarboxylase members. The invention also provides antisense nucleic
acid molecules, recombinant expression vectors containing 61833 nucleic
acid molecules, host cells into which the expression vectors have been
introduced, and nonhuman transgenic animals in which a 61833 gene has
been introduced or disrupted. The invention still further provides
isolated 61833 proteins, fusion proteins, antigenic peptides and
anti-61833 antibodies. ***Diagnostic*** methods utilizing
compositions of the invention are also provided.

L16 ANSWER 116 OF 154 USPATFULL on STN
AN 2002:221414 USPATFULL
TI 53014, a human metalloprotease family member and uses therefor
IN Bandaru, Rajasehkar, Watertown, MA, UNITED STATES
Curtis, Rory A.J., Southborough, MA, UNITED STATES
Spurling, Heidi Lynn, Malden, MA, UNITED STATES
PI US 2002119555 A1 20020829
AI US 2001-14070 A1 20011113 (10)
PRAI US 2000-258373P 20001222 (60)
DT Utility
FS APPLICATION
LREP Jean M. Silveri, Millennium Pharmaceuticals, Inc., 75 Sidney Street,
Cambridge, MA, 02139
CLMN Number of Claims: 22
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 6025

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated
53014 nucleic acid molecules, which encode novel metalloprotease family
members. The invention also provides antisense nucleic acid molecules,
recombinant expression vectors containing 53014 nucleic acid molecules,
host cells into which the expression vectors have been introduced, and
nonhuman transgenic animals in which a 53014 gene has been introduced or
disrupted. The invention still further provides isolated 53014 proteins,
fusion proteins, antigenic peptides and anti-53014 antibodies.

Diagnostic and therapeutic methods utilizing compositions of
the
invention are also provided.

L16 ANSWER 117 OF 154 USPATFULL on STN

AN 2002:221383 USPATFULL

TI 67073, a human phospholipid transporter family member and uses therefor

IN Curtis, Rory A.J., Southborough, MA, UNITED STATES

PA Millennium Pharmaceuticals, Inc. (U.S. corporation)

PI US 2002119523 A1 20020829

AI US 2002-41395 A1 20020108 (10)

PRAI US 2001-262216P 20010117 (60)

US 2001-289358P 20010508 (60)

DT Utility

FS APPLICATION

LREP Jean M. Silveri, Millennium Pharmaceuticals, Inc., 75 Sidney Street,
Cambridge, MA, 02139

CLMN Number of Claims: 22

ECL Exemplary Claim: 1

DRWN 1 Drawing Page(s)

LN.CNT 5599

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 67073 nucleic acid molecules, which encode novel phospholipid transporter family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 67073 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 67073 gene has been introduced or disrupted. The invention still further provides isolated 67073 proteins, fusion proteins, antigenic peptides and anti-67073 antibodies. ***Diagnostic*** and therapeutic methods utilizing compositions of the invention are also provided.

L16 ANSWER 118 OF 154 USPATFULL on STN

AN 2002:213801 USPATFULL

TI 16816 and 16839, novel human phospholipase C molecules and uses therefor

IN Meyers, Rachel, Newton, MA, UNITED STATES

Rudolph-Owen, Laura S., Jamaica Plains, MA, UNITED STATES

Tsai, Fong Ying, Newton, MA, UNITED STATES

PI US 2002115178 A1 20020822

AI US 2001-908664 A1 20010717 (9)

PRAI US 2000-218675P 20000717 (60)

DT Utility

FS APPLICATION

LREP Carolyn A. Favorito, Morrison & Foerster LLP, Suite 500, 3811 Valley
Centre Drive, San Diego, CA, 92130-2332

CLMN Number of Claims: 24

ECL Exemplary Claim: 1

DRWN 12 Drawing Page(s)

LN.CNT 4734

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 16816 or 16839 nucleic acid molecules, which encode novel phospholipase C family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 16816 or 16839 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 16816 or 16839 gene has been introduced or disrupted. The invention still further provides isolated 16816 or 16839 proteins, fusion proteins, antigenic peptides and anti-16816 or 16839 antibodies.

Diagnostic methods utilizing compositions of the invention are also provided.

L16 ANSWER 119 OF 154 USPATFULL on STN

AN 2002:213761 USPATFULL

TI 22406, a novel human pyridoxal-phosphate dependent enzyme family member and uses therefor

IN Meyers, Rachel A., Newton, MA, UNITED STATES

Rudolph-Owen, Laura A., Jamaica Plain, MA, UNITED STATES

PA Millennium Pharmaceuticals, Inc. (U.S. corporation)

PI US 2002115137 A1 20020822

US 6458576 B2 20021001

AI US 2001-789300 A1 20010220 (9)

PRAI US 2000-183208P 20000217 (60)

DT Utility

FS APPLICATION

LREP ALSTON & BIRD LLP, BANK OF AMERICA PLAZA, 101 SOUTH TRYON STREET, SUITE 4000, CHARLOTTE, NC, 28280-4000

CLMN Number of Claims: 22

ECL Exemplary Claim: 1

DRWN 12 Drawing Page(s)

LN.CNT 4017

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 22406 nucleic acid molecules, which encode a novel pyridoxal-phosphate dependent enzyme family member. In particular, the invention relates to 22406 serine racemase ***polypeptide*** and encoding nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 22406 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 22406 gene has been introduced or disrupted. The invention still further provides isolated 22406 proteins, fusion proteins, antigenic peptides and anti-22406 antibodies.

Diagnostic methods utilizing compositions of the invention are also provided.

L16 ANSWER 120 OF 154 USPATFULL on STN

AN 2002:206613 USPATFULL

TI 25219, a novel human aminotransferase and uses therefor

IN Meyers, Rachel, Newton, MA, UNITED STATES

PI US 2002111310 A1 20020815

AI US 2001-972528 A1 20011005 (9)

PRAI US 2000-238131P 20001006 (60)

DT Utility

FS APPLICATION

LREP Carolyn A. Favorito, Morrison & Foerster LLP, Suite 500, 3811 Valley Centre Drive, San Diego, CA, 92130-2332

CLMN Number of Claims: 23

ECL Exemplary Claim: 1

DRWN 4 Drawing Page(s)

LN.CNT 4419

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated aminotransferase nucleic acids molecules, designated 25219 nucleic acid molecules, which encode novel 25219 family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 25219 nucleic acid molecules, host cells into which the expression vectors have been

introduced, and nonhuman transgenic animals in which a 25219 gene has been introduced or disrupted. The invention still further provides isolated 25219 proteins, fusion proteins, antigenic peptides and anti-25219 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided.

L16 ANSWER 121 OF 154 USPATFULL on STN
AN 2002:206610 USPATFULL
TI 46508, a novel human peptidyl-tRNA hydrolase family member and uses thereof
IN Glucksmann, Maria Alexandra, Lexington, MA, UNITED STATES
Rudolph-Owen, Laura A., Jamaica Plain, MA, UNITED STATES
PI US 2002111307 A1 20020815
AI US 2001-888911 A1 20010625 (9)
PRAI US 2000-213688P 20000623 (60)
DT Utility
FS APPLICATION
LREP LOUIS MYERS, Fish & Richardson P.C., 225 Franklin Street, Boston, MA, 02110-2804
CLMN Number of Claims: 28
ECL Exemplary Claim: 1
DRWN 5 Drawing Page(s)
LN.CNT 5043

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 46508 nucleic acid molecules, which encode novel peptidyl-tRNA hydrolase members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 46508 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 46508 gene has been introduced or disrupted. The invention still further provides isolated 46508 proteins, fusion proteins, antigenic peptides and anti-46508 antibodies.
Diagnostic methods utilizing compositions of the invention are also provided.

L16 ANSWER 122 OF 154 USPATFULL on STN
AN 2002:199265 USPATFULL
TI 26199, 33530, 33949, 47148, 50226, and 58764, novel human transferase family members and uses therefor
IN Meyers, Rachel, Newton, MA, UNITED STATES
MacBeth, Kyle, Boston, MA, UNITED STATES
PI US 2002107376 A1 20020808
AI US 2001-924358 A1 20010806 (9)
PRAI US 2000-229300P 20000901 (60)
DT Utility
FS APPLICATION
LREP Intellectual Property Group, MILLENNIUM PHARMACEUTICALS, INC, 75 Sidney Street, Cambridge, MA, 02139
CLMN Number of Claims: 24
ECL Exemplary Claim: 1
DRWN 28 Drawing Page(s)
LN.CNT 6380

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 26199, 33530, 33949, 47148, 50226, or 58764 nucleic acid molecules, which encode novel transferase family members. The invention also provides antisense nucleic acid molecules, recombinant expression

vectors containing 26199, 33530, 33949, 47148, 50226, or 58764 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 26199, 33530, 33949, 47148, 50226, or 58764 gene has been introduced or disrupted. The invention still further provides isolated 26199, 33530, 33949, 47148, 50226, or 58764 proteins, fusion proteins, antigenic peptides and anti-26199, -33530, -33949, -47148, -50226, or -58764 antibodies.
Diagnostic methods utilizing compositions of the invention are also provided.

L16 ANSWER 123 OF 154 USPATFULL on STN

AN 2002:198674 USPATFULL

TI 32544, a novel human phospholipase C and uses thereof

IN Meyers, Rachel, Newton, MA, UNITED STATES

Silos-Santiago, Inmaculada, Cambridge, MA, UNITED STATES

PI US 2002106774 A1 20020808

AI US 2001-927112 A1 20010810 (9)

PRAI US 2000-246808P 20001108 (60)

DT Utility

FS APPLICATION

LREP Carolyn A. Favorito, Morrison & Foerster LLP, Suite 500, 3811 Valley Centre Drive, San Diego, CA, 92130-2332

CLMN Number of Claims: 23

ECL Exemplary Claim: 1

DRWN 8 Drawing Page(s)

LN.CNT 4611

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 32544 nucleic acid molecules, which encode novel phospholipase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 32544 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 32544 gene has been introduced or disrupted. The invention still further provides isolated 32544 proteins, fusion proteins, antigenic peptides and anti-32544 antibodies.
Diagnostic methods utilizing compositions of the invention are also provided.

L16 ANSWER 124 OF 154 USPATFULL on STN

AN 2002:198670 USPATFULL

TI 25233, a novel human aminotransferase and uses therefor

IN Meyers, Rachel A., Newton, MA, UNITED STATES

PA Millennium Pharmaceuticals, Inc. (U.S. corporation)

PI US 2002106770 A1 20020808

AI US 2001-908928 A1 20010719 (9)

PRAI US 2000-220465P 20000720 (60)

DT Utility

FS APPLICATION

LREP ALSTON & BIRD LLP, BANK OF AMERICA PLAZA, 101 SOUTH TRYON STREET, SUITE 4000, CHARLOTTE, NC, 28280-4000

CLMN Number of Claims: 22

ECL Exemplary Claim: 1

DRWN 13 Drawing Page(s)

LN.CNT 4268

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 25233 nucleic acid molecules, which encode novel aminotransferase family

members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 25233 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 25233 gene has been introduced or disrupted. The invention still further provides isolated 25233 proteins, fusion proteins, antigenic peptides and anti-25233 antibodies.

Diagnostic methods utilizing compositions of the invention are also provided.

L16 ANSWER 125 OF 154 USPATFULL on STN

AN 2002:174981 USPATFULL

TI 18232, a novel dual specificity phosphatase and uses therefor

IN Meyers, Rachel A., Newton, MA, United States

Weich, Nadine, Brookline, MA, United States

PA Millennium Pharmaceuticals, Inc., Cambridge, MA, United States (U.S. corporation)

PI US 6420153 B1 20020716

AI US 2000-704139 20001101 (9)

PRAI US 2000-185772P 20000229 (60)

DT Utility

FS GRANTED

EXNAM Primary Examiner: Achutamurthy, Ponnathapu; Assistant Examiner: Pak, Yong

LREP Fish & Richardson P.C.

CLMN Number of Claims: 15

ECL Exemplary Claim: 1

DRWN 9 Drawing Figure(s); 8 Drawing Page(s)

LN.CNT 4450

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 18232 nucleic acid molecules, which encode novel dual specificity phosphatase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 18232 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 18232 gene has been introduced or disrupted. The invention still further provides isolated 18232 proteins, fusion proteins, antigenic peptides and anti-18232 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided. The invention also provides methods of modulating the differentiation and proliferation of hematopoietic cells (e.g., erythroid cells) utilizing the compositions of the invention. Accordingly, methods of treating, preventing and/or ***diagnosing*** erythroid-associated disorders such as anemias, leukemias, and erythrocytosis are disclosed.

L16 ANSWER 126 OF 154 USPATFULL on STN

AN 2002:172478 USPATFULL

TI 54370, a novel human sulfate transporter and uses therefor

IN Curtis, Rory A.J., Southborough, MA, UNITED STATES

PI US 2002091238 A1 20020711

AI US 2001-938970 A1 20010824 (9)

PRAI US 2000-228762P 20000830 (60)

DT Utility

FS APPLICATION

LREP Carolyn A. Favorito, Morrison & Foerster LLP, Suite 500, 3811 Valley Centre Drive, San Diego, CA, 92130-2332

CLMN Number of Claims: 23

ECL Exemplary Claim: 1

DRWN 6 Drawing Page(s)

LN.CNT 4569

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 54370 nucleic acid molecules, which encode novel transporter family members, preferably sulfate transporters. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 54370 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 54370 gene has been introduced or disrupted. The invention still further provides isolated 54370 proteins, fusion proteins, antigenic peptides and anti-54370 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided.

L16 ANSWER 127 OF 154 USPATFULL on STN

AN 2002:171961 USPATFULL

TI 57800, a novel human cadherin and uses thereof

IN Curtis, Rory A.J., Southborough, MA, UNITED STATES

PI US 2002090710 A1 20020711

AI US 2001-972086 A1 20011004 (9)

PRAI US 2000-237698P 20001005 (60)

DT Utility

FS APPLICATION

LREP Carolyn A. Favorito, Morrison & Foerster LLP, Suite 500, 3811 Valley Centre Drive, San Diego, CA, 92130-2332

CLMN Number of Claims: 23

ECL Exemplary Claim: 1

DRWN 9 Drawing Page(s)

LN.CNT 4465

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 57800 nucleic acid molecules, which encode novel cadherin family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 57800 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 57800 gene has been introduced or disrupted. The invention still further provides isolated 57800 proteins, fusion proteins, antigenic peptides and anti-57800 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided.

L16 ANSWER 128 OF 154 USPATFULL on STN

AN 2002:171950 USPATFULL

TI 27439, novel human hydroxylase and uses therefor

IN Glucksmann, Maria A., Lexington, MA, UNITED STATES

Tsai, Fong-Ying, Newton, MA, UNITED STATES

PI US 2002090699 A1 20020711

AI US 2001-945301 A1 20010831 (9)

PRAI US 2000-229301P 20000901 (60)

DT Utility

FS APPLICATION

LREP Carolyn A. Favorito, Morrison & Foerster LLP, Suite 500, 3811 Valley Centre Drive, San Diego, CA, 92130-2332

CLMN Number of Claims: 24

ECL Exemplary Claim: 1

DRWN 8 Drawing Page(s)

LN.CNT 4656

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 27439 nucleic acid molecules, which encode novel hydroxylases, preferably Cytochrome P450 family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 27439 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 27439 gene has been introduced or disrupted. The invention still further provides isolated 27439 proteins, fusion proteins, antigenic peptides and anti-27439 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided.

L16 ANSWER 129 OF 154 USPATFULL on STN

AN 2002:171878 USPATFULL

TI 27419, a novel human arginine-N-methyl transferase and uses thereof

IN Meyers, Rachel, Newton, MA, UNITED STATES

PI US 2002090627 A1 20020711

AI US 2001-970638 A1 20011003 (9)

PRAI US 2000-237717P 20001005 (60)

DT Utility

FS APPLICATION

LREP Carolyn A. Favorito, Morrison & Foerster LLP, Suite 500, 3811 Valley Centre Drive, San Diego, CA, 92130-2332

CLMN Number of Claims: 23

ECL Exemplary Claim: 1

DRWN 5 Drawing Page(s)

LN.CNT 4572

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 27419 nucleic acid molecules, which encode novel methyltransferase family members, preferably arginine methyltransferase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 27419 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 27419 gene has been introduced or disrupted. The invention still further provides isolated 27419 proteins, fusion proteins, antigenic peptides and anti-27419 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided.

L16 ANSWER 130 OF 154 USPATFULL on STN

AN 2002:164787 USPATFULL

TI 56638, a novel human neprilysin protease and uses thereof

IN Silos-Santiago, Inmaculada, Cambridge, MA, UNITED STATES
Bandaru, Rajasekhar, Watertown, MA, UNITED STATES

PI US 2002086405 A1 20020704

AI US 2001-928531 A1 20010813 (9)

PRAI US 2000-235035P 20000925 (60)

DT Utility

FS APPLICATION

LREP LOUIS MYERS, Fish & Richardson P.C., 225 Franklin Street, Boston, MA, 02110-2804

CLMN Number of Claims: 24

ECL Exemplary Claim: 1

DRWN 7 Drawing Page(s)

LN.CNT 5123

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 56638 nucleic acid molecules, which encode novel neprilysin family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 56638 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 56638 gene has been introduced or disrupted. The invention still further provides isolated 56638 proteins, fusion proteins, antigenic peptides and anti-56638 antibodies.
Diagnostic methods utilizing compositions of the invention are also provided. The invention also provides methods of modulating pain or pain related disorders utilizing the compositions of the invention. Accordingly, methods of treating, preventing and/or ***diagnosing*** pain or pain related disorders are disclosed.

L16 ANSWER 131 OF 154 USPATFULL on STN

AN 2002:157608 USPATFULL

TI 7716, a novel human ATPase and uses therefor

IN Meyers, Rachel A., Newton, MA, UNITED STATES

PA Millennium Pharmaceuticals, Inc. (U.S. corporation)

PI US 2002082212 A1 20020627

AI US 2001-908180 A1 20010718 (9)

PRAI US 2000-219740P 20000720 (60)

DT Utility

FS APPLICATION

LREP ALSTON & BIRD LLP, BANK OF AMERICA PLAZA, 101 SOUTH TRYON STREET, SUITE 4000, CHARLOTTE, NC, 28280-4000

CLMN Number of Claims: 22

ECL Exemplary Claim: 1

DRWN 10 Drawing Page(s)

LN.CNT 4113

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 7716 nucleic acid molecules, which encode novel ATPase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 7716 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 7716 gene has been introduced or disrupted. The invention still further provides isolated 7716 proteins, fusion proteins, antigenic peptides and anti-7716 antibodies.
Diagnostic methods utilizing compositions of the invention are also provided.

L16 ANSWER 132 OF 154 USPATFULL on STN

AN 2002:157606 USPATFULL

TI 56201, a novel human sodium ion channel family member and uses thereof

IN Curtis, Rory A.J., Southborough, MA, UNITED STATES

PI US 2002082210 A1 20020627

AI US 2001-875363 A1 20010605 (9)

PRAI US 2000-209238P 20000605 (60)

DT Utility

FS APPLICATION

LREP LOUIS MYERS, Fish & Richardson P.C., 225 Franklin Street, Boston, MA, 02110-2804

CLMN Number of Claims: 28

ECL Exemplary Claim: 1

DRWN 5 Drawing Page(s)

LN.CNT 5052

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 56201 nucleic acid molecules, which encode novel ion channel members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 56201 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 56201 gene has been introduced or disrupted. The invention still further provides isolated 56201 proteins, fusion proteins, antigenic peptides and anti-56201 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided.

L16 ANSWER 133 OF 154 USPATFULL on STN

AN 2002:157080 USPATFULL

TI NARC8 programmed cell-death-associated molecules and uses thereof

IN Chiang, Lillian Wei-Ming, Cambridge, MA, UNITED STATES

PA Millennium Pharmaceuticals, Inc. (U.S. corporation)

PI US 2002081679 A1 20020627

AI US 2001-775009 A1 20010201 (9)

RLI Continuation-in-part of Ser. No. US 2000-692785, filed on 20 Oct 2000, PENDING

PRAI US 1999-161188P 19991022 (60)

DT Utility

FS APPLICATION

LREP ALSTON & BIRD LLP, BANK OF AMERICA PLAZA, 101 SOUTH TRYON STREET, SUITE 4000, CHARLOTTE, NC, 28280-4000

CLMN Number of Claims: 22

ECL Exemplary Claim: 1

DRWN 4 Drawing Page(s)

LN.CNT 4095

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated NARC8 nucleic acid molecules, which encode novel programmed cell death-associated proteins. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing NARC8 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a NARC8 gene has been introduced or disrupted. The invention still further provides isolated NARC8 proteins, fusion proteins, antigenic peptides and anti-NARC8 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided.

L16 ANSWER 134 OF 154 USPATFULL on STN

AN 2002:157058 USPATFULL

TI 21784, a novel human calcium channel family member and uses thereof

IN Curtis, Rory A.J., Southborough, MA, UNITED STATES

PI US 2002081657 A1 20020627

AI US 2001-875423 A1 20010605 (9)

PRAI US 2000-209257P 20000605 (60)

DT Utility

FS APPLICATION

LREP LOUIS MYERS, FISH & RICHARDSON P.C., 225 Franklin Street, Boston, MA, 02110-2804

CLMN Number of Claims: 31

ECL Exemplary Claim: 1

DRWN 4 Drawing Page(s)

LN.CNT 5663

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 21784 nucleic acid molecules, which encode novel calcium channel members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 21784 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 21784 gene has been introduced or disrupted. The invention still further provides isolated 21784 proteins, fusion proteins, antigenic peptides and anti-21784 antibodies.
Diagnostic methods utilizing compositions of the invention are also provided.

L16 ANSWER 135 OF 154 USPATFULL on STN

AN 2002:149154 USPATFULL

TI 32225, a novel human alpha/beta hydrolase family member and uses thereof

IN Meyers, Rachel A., Newton, MA, UNITED STATES

PI US 2002077310 A1 20020620

AI US 2001-896578 A1 20010629 (9)

PRAI US 2000-214948P 20000629 (60)

DT Utility

FS APPLICATION

LREP LOUIS MYERS, Fish & Richardson P.C., 225 Franklin Street, Boston, MA, 02110-2804

CLMN Number of Claims: 31

ECL Exemplary Claim: 1

DRWN 4 Drawing Page(s)

LN.CNT 5094

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 32225 nucleic acid molecules, which encode novel .alpha./.beta. hydrolase members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 32225 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 32225 gene has been introduced or disrupted. The invention still further provides isolated 32225 proteins, fusion proteins, antigenic peptides and anti-32225 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided.

L16 ANSWER 136 OF 154 USPATFULL on STN

AN 2002:148635 USPATFULL

TI 33428, a novel human metalloprotease family member and uses thereof

IN Kapeller-Libermann, Rosana, Chestnut Hill, MA, UNITED STATES

Cook, William James, Natick, MA, UNITED STATES

Silos-Santiago, Inmaculada, Cambridge, MA, UNITED STATES

PI US 2002076778 A1 20020620

AI US 2001-858068 A1 20010515 (9)

PRAI US 2000-204159P 20000515 (60)

DT Utility

FS APPLICATION

LREP LOUIS MYERS, Fish & Richardson P.C., 225 Franklin Street, Boston, MA, 02110-2804

CLMN Number of Claims: 30

ECL Exemplary Claim: 1

DRWN 3 Drawing Page(s)

LN.CNT 5308

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 33428 nucleic acid molecules, which encode novel metalloprotease family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 33428 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 33428 gene has been introduced or disrupted. The invention still further provides isolated 33428 proteins, fusion proteins, antigenic peptides and anti-33428 antibodies.
Diagnostic methods utilizing compositions of the invention are also provided.

L16 ANSWER 137 OF 154 USPATFULL on STN

AN 2002:148611 USPATFULL

TI 31939, a novel human leucine-rich repeat family member and uses thereof

IN Glucksmann, Maria Alexandra, Lexington, MA, UNITED STATES

PI US 2002076753 A1 20020620

AI US 2001-822687 A1 20010330 (9)

PRAI US 2000-193919P 20000331 (60)

DT Utility

FS APPLICATION

LREP LOUIS M. MYERS, Fish & Richardson P.C., 225 Franklin Street, Boston, MA, 02110-2804

CLMN Number of Claims: 21

ECL Exemplary Claim: 1

DRWN 7 Drawing Page(s)

LN.CNT 5039

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 31939 nucleic acid molecules, which encode novel leucine-rich repeat (LRR) members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 31939 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 31939 gene has been introduced or disrupted. The invention still further provides isolated 31939 proteins, fusion proteins, antigenic peptides and anti-31939 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided.

L16 ANSWER 138 OF 154 USPATFULL on STN

AN 2002:148610 USPATFULL

TI 33395, a novel human leucine-rich repeat family member and uses thereof

IN Glucksmann, Maria Alexandra, Lexington, MA, UNITED STATES

PI US 2002076752 A1 20020620

AI US 2001-815626 A1 20010323 (9)

PRAI US 2000-191863P 20000324 (60)

DT Utility

FS APPLICATION

LREP LOUIS MYERS, FISH & RICHARDSON P.C., 225 Franklin Street, Boston, MA, 02110-2804

CLMN Number of Claims: 24

ECL Exemplary Claim: 1

DRWN 11 Drawing Page(s)

LN.CNT 5407

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 33395 nucleic acid molecules, which encode novel leucine rich repeat

(LRR) family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 33395 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 33395 gene has been introduced or disrupted. The invention still further provides isolated 33395 proteins, fusion proteins, antigenic peptides and anti-33395 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided.

L16 ANSWER 139 OF 154 USPATFULL on STN

AN 2002:141504 USPATFULL

TI 33428, a novel human metalloprotease family member and uses thereof

IN Kapeller-Libermann, Rosana, Chestnut Hill, MA, UNITED STATES

Cook, William James, Natick, MA, UNITED STATES

Silos-Santiago, Inmaculada, Cambridge, MA, UNITED STATES

PI US 2002072490 A1 20020613

AI US 2001-858081 A1 20010515 (9)

PRAI US 2000-204159P 20000515 (60)

DT Utility

FS APPLICATION

LREP LOUIS MYERS, FISH & RICHARDSON P.C., 225 Franklin Street, Boston, MA, 02110-2804

CLMN Number of Claims: 30

ECL Exemplary Claim: 1

DRWN 11 Drawing Page(s)

LN.CNT 5531

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 33428 nucleic acid molecules, which encode novel metalloprotease family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 33428 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 33428 gene has been introduced or disrupted. The invention still further provides isolated 33428 proteins, fusion proteins, antigenic peptides and anti-33428 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided.

L16 ANSWER 140 OF 154 USPATFULL on STN

AN 2002:133840 USPATFULL

TI 13237, 18480, 2245 or 16228 novel human protein kinase molecules and uses therefor

IN Meyers, Rachel, Newton, MA, UNITED STATES

Rudolph-Owen, Laura A., Jamaica Plains, MA, UNITED STATES

Kapeller-Libermann, Rosana, Chestnut Hill, MA, UNITED STATES

Tsai, Fong Ying, Newton, MA, UNITED STATES

PI US 2002068698 A1 20020606

AI US 2001-910150 A1 20010718 (9)

PRAI US 2000-219028P 20000718 (60)

DT Utility

FS APPLICATION

LREP Carolyn A. Favorito, Morrison & Foerster LLP, Suite 500, 3811 Valley Centre Drive, San Diego, CA, 92130-2332

CLMN Number of Claims: 23

ECL Exemplary Claim: 1

DRWN 23 Drawing Page(s)

LN.CNT 5427

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 13237, 18480, 2245 or 16228 nucleic acid molecules, which encode novel protein kinase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 13237, 18480, 2245 or 16228 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 13237, 18480, 2245 or 16228 gene has been introduced or disrupted. The invention still further provides isolated 13237, 18480, 2245 or 16228 proteins, fusion proteins, antigenic peptides and anti-13237, -18480, -2245 or -16228 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided.

L16 ANSWER 141 OF 154 USPATFULL on STN

AN 2002:133440 USPATFULL

TI 32252, a novel human AMP-binding family member and uses thereof

IN Meyers, Rachel A., Newton, MA, UNITED STATES

Hunter, John J., Somerville, MA, UNITED STATES

PI US 2002068291 A1 20020606

AI US 2001-882836 A1 20010615 (9)

PRAI US 2000-211730P 20000615 (60)

DT Utility

FS APPLICATION

LREP LOUIS MYERS, FISH & RICHARDSON P.C., 225 Franklin Street, Boston, MA, 02110-2804

CLMN Number of Claims: 28

ECL Exemplary Claim: 1

DRWN 9 Drawing Page(s)

LN.CNT 5439

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 32252 nucleic acid molecules, which encode novel AMP-binding enzyme members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 32252 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 32252 gene has been introduced or disrupted. The invention still further provides isolated 32252 proteins, fusion proteins, antigenic peptides and anti-32252 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided.

L16 ANSWER 142 OF 154 USPATFULL on STN

AN 2002:120026 USPATFULL

TI 54372, a novel human anion transporter and uses therefor

IN Curtis, Rory A.J., Southborough, MA, UNITED STATES

PI US 2002062015 A1 20020523

AI US 2001-942446 A1 20010829 (9)

PRAI US 2000-229121P 20000831 (60)

DT Utility

FS APPLICATION

LREP Carolyn A. Favorito, Morrison & Foerster LLP, Suite 500, 3811 Valley Centre Drive, San Diego, CA, 92130-2332

CLMN Number of Claims: 23

ECL Exemplary Claim: 1

DRWN 10 Drawing Page(s)

LN.CNT 4614

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 54372 nucleic acid molecules, which encode novel transporter family members, preferably anion transporters. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 54372 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 54372 gene has been introduced or disrupted. The invention still further provides isolated 54372 proteins, fusion proteins, antigenic peptides and anti-54372 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided.

L16 ANSWER 143 OF 154 USPATFULL on STN

AN 2002:119592 USPATFULL

TI 27803, a novel human adenylate kinase family member and uses therefor

IN Meyers, Rachel, Newton, MA, UNITED STATES

PI US 2002061575 A1 20020523

AI US 2001-925108 A1 20010808 (9)

PRAI US 2000-224035P 20000809 (60)

DT Utility

FS APPLICATION

LREP Intellectual Property Group, MILLENNIUM PHARMACEUTICALS, INC., 75 Sidney Street, Cambridge, MA, 02139

CLMN Number of Claims: 22

ECL Exemplary Claim: 1

DRWN 4 Drawing Page(s)

LN.CNT 3940

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 27803 nucleic acid molecules, which encode novel adenylate kinase family member family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 27803 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 27803 gene has been introduced or disrupted. The invention still further provides isolated 27803 proteins, fusion proteins, antigenic peptides and anti-27803 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided.

L16 ANSWER 144 OF 154 USPATFULL on STN

AN 2002:119591 USPATFULL

TI 16658, 14223, and 16002, novel human kinases and uses therefor

IN Meyers, Rachel, Newton, MA, UNITED STATES

Silos-Santiago, Inmaculada, Cambridge, MA, UNITED STATES

PI US 2002061574 A1 20020523

AI US 2001-922138 A1 20010803 (9)

PRAI US 2000-229299P 20000901 (60)

DT Utility

FS APPLICATION

LREP Carolyn A. Favorito, Morrison & Foerster LLP, Suite 500, 3811 Valley Centre Drive, San Diego, CA, 92130-2332

CLMN Number of Claims: 24

ECL Exemplary Claim: 1

DRWN 20 Drawing Page(s)

LN.CNT 4922

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 16658, 14223, and 16002 nucleic acid molecules, which encode novel

kinase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 16658, 14223, and 16002 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 16658, 14223, and 16002 gene has been introduced or disrupted. The invention still further provides isolated 16658, 14223, and 16002 proteins, fusion proteins, antigenic peptides and anti-16658, -14223, and -16002 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided.

L16 ANSWER 145 OF 154 USPATFULL on STN
 AN 2002:119590 USPATFULL
 TI 18431 and 32374, novel human protein kinase family members and uses therefor
 IN Meyers, Rachel, Newton, MA, UNITED STATES
 Kapeller-Libermann, Rosana, Chestnut Hill, MA, UNITED STATES
 Silos-Santiago, Inmaculada, Cambridge, MA, UNITED STATES
 PI US 2002061573 A1 20020523
 AI US 2001-916790 A1 20010727 (9)
 PRAI US 2000-221543P 20000728 (60)
 DT Utility
 FS APPLICATION
 LREP Carolyn A. Favorito, Morrison & Foerster LLP, Suite 500, 3811 Valley Centre Drive, San Diego, CA, 92130-2332
 CLMN Number of Claims: 24
 ECL Exemplary Claim: 1
 DRWN 16 Drawing Page(s)
 LN.CNT 4936
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB The invention provides isolated nucleic acids molecules, designated 32374 or 18431 nucleic acid molecules, which encode novel protein kinase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 32374 or 18431 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 32374 or 18431 gene has been introduced or disrupted. The invention still further provides isolated 32374 or 18431 proteins, fusion proteins, antigenic peptides and anti-32374 or -18431 antibodies.
 Diagnostic methods utilizing compositions of the invention are also provided.

L16 ANSWER 146 OF 154 USPATFULL on STN
 AN 2002:105955 USPATFULL
 TI 57658, a novel human uridine kinase and uses thereof
 IN Glucksmann, Maria A., Lexington, MA, UNITED STATES
 PI US 2002055161 A1 20020509
 AI US 2001-896522 A1 20010628 (9)
 PRAI US 2000-216503P 20000630 (60)
 DT Utility
 FS APPLICATION
 LREP Carolyn A. Favorito, Morrison & Foerster LLP, Suite 500, 3811 Valley Centre Drive, San Diego, CA, 92130-2332
 CLMN Number of Claims: 22
 ECL Exemplary Claim: 1
 DRWN 5 Drawing Page(s)
 LN.CNT 3955
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 57658 nucleic acid molecules, which encode novel uridine kinase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 57658 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 57658 gene has been introduced or disrupted. The invention still further provides isolated 57658 proteins, fusion proteins, antigenic peptides and anti-57658 antibodies.
Diagnostic methods utilizing compositions of the invention are also provided.

L16 ANSWER 147 OF 154 USPATFULL on STN

AN 2002:105954 USPATFULL

TI 23680, a novel human aminotransferase and uses therefor

IN Meyers, Rachel A., Newton, MA, UNITED STATES

PI US 2002055159 A1 20020509

AI US 2001-883060 A1 20010615 (9)

PRAI US 2000-212079P 20000615 (60)

DT Utility

FS APPLICATION

LREP LOUIS MYERS, FISH & RICHARDSON P.C., 225 Franklin Street, Boston, MA, 02110-2804

CLMN Number of Claims: 36

ECL Exemplary Claim: 1

DRWN 2 Drawing Page(s)

LN.CNT 5098

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 23680 nucleic acid molecules, which encode a novel human aminotransferase. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 23680 nucleic acid molecules, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a 23680 gene has been introduced or disrupted. The invention still further provides isolated 23680 proteins, fusion proteins, antigenic peptides and anti-23680 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided.

L16 ANSWER 148 OF 154 USPATFULL on STN

AN 2002:72636 USPATFULL

TI 47885, a novel human ubiquitin-activating enzyme and uses therefor

IN Kapeller-Libermann, Rosana, Chestnut Hill, MA, UNITED STATES

PI US 2002039773 A1 20020404

AI US 2001-905211 A1 20010712 (9)

PRAI US 2000-218041P 20000713 (60)

DT Utility

FS APPLICATION

LREP Carolyn A. Favorito, Morrison & Foerster LLP, Suite 500, 3811 Valley Centre Drive, San Diego, CA, 92130

CLMN Number of Claims: 22

ECL Exemplary Claim: 1

DRWN 11 Drawing Page(s)

LN.CNT 4166

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 47885 nucleic acid molecules, which encode novel ubiquitin-activating enzyme family members. The invention also provides antisense nucleic

acid molecules, recombinant expression vectors containing 47885 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 47885 gene has been introduced or disrupted. The invention still further provides isolated 47885 proteins, fusion proteins, antigenic peptides and anti-47885 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided.

L16 ANSWER 149 OF 154 USPATFULL on STN

AN 2002:54654 USPATFULL

TI 46619, a novel human beta-ketoacyl synthase and uses thereof

IN Meyers, Rachel A., Newton, MA, UNITED STATES

Williamson, Mark, Saugus, MA, UNITED STATES

PA Millennium Pharmaceuticals, Inc. (U.S. corporation)

PI US 2002031815 A1 20020314

AI US 2001-892870 A1 20010626 (9)

PRAI US 2000-214174P 20000626 (60)

DT Utility

FS APPLICATION

LREP ALSTON & BIRD LLP, BANK OF AMERICA PLAZA, 101 SOUTH TRYON STREET, SUITE 4000, CHARLOTTE, NC, 28280-4000

CLMN Number of Claims: 22

ECL Exemplary Claim: 1

DRWN 8 Drawing Page(s)

LN.CNT 4474

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated and novel nucleic acids molecules, designated beta-ketoacyl synthase nucleic acid molecules, which encode novel beta-ketoacyl synthase ***polypeptides***. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing beta-ketoacyl synthase nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a beta-ketoacyl synthase gene has been introduced or disrupted. The invention still further provides isolated beta-ketoacyl synthase proteins, fusion proteins, antigenic peptides and anti-beta-ketoacyl synthase antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided.

L16 ANSWER 150 OF 154 USPATFULL on STN

AN 2002:43191 USPATFULL

TI 32447, a novel human acyltransferase and uses thereof

IN Glucksmann, Maria Alexandra, Lexington, MA, UNITED STATES

PI US 2002025557 A1 20020228

AI US 2001-887389 A1 20010622 (9)

PRAI US 2000-214138P 20000626 (60)

DT Utility

FS APPLICATION

LREP ALSTON & BIRD LLP, BANK OF AMERICA PLAZA, 101 SOUTH TRYON STREET, SUITE 4000, CHARLOTTE, NC, 28280-4000

CLMN Number of Claims: 22

ECL Exemplary Claim: 1

DRWN 4 Drawing Page(s)

LN.CNT 4178

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 32447 nucleic acid molecules, which encode novel acyltransferase family members. The invention also provides antisense nucleic acid molecules,

recombinant expression vectors containing 32447 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 32447 gene has been introduced or disrupted. The invention still further provides isolated 32447 proteins, fusion proteins, antigenic peptides and anti-32447 antibodies.
Diagnostic methods utilizing compositions of the invention are also provided.

L16 ANSWER 151 OF 154 USPATFULL on STN

AN 2002:27601 USPATFULL

TI 46743 and 27417, novel human acyltransferase family members and uses therefor

IN Meyers, Rachel A., Newton, MA, UNITED STATES

Macbeth, Kyle J., Boston, MA, UNITED STATES

Williamson, Mark, Saugus, MA, UNITED STATES

Rudolph-Owen, Laura A., Jamaica Plain, MA, UNITED STATES

Tsai, Fong-Ying, Newton, MA, UNITED STATES

PI US 2002016449 A1 20020207

AI US 2001-817910 A1 20010326 (9)

PRAI US 2000-192092P 20000324 (60)

DT Utility

FS APPLICATION

LREP LOUIS MYERS, FISH & RICHARDSON P.C., 225 Franklin Street, Boston, MA, 02110-2804

CLMN Number of Claims: 31

ECL Exemplary Claim: 1

DRWN 19 Drawing Page(s)

LN.CNT 5587

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 46743 or 27417 nucleic acid molecules, which encode novel acyltransferase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 46743 or 27417 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 46743 or 27417 gene has been introduced or disrupted. The invention still further provides isolated 46743 or 27417 proteins, fusion proteins, antigenic peptides and anti-46743 or anti-27417 antibodies.
Diagnostic methods utilizing compositions of the invention are also provided.

L16 ANSWER 152 OF 154 USPATFULL on STN

AN 2002:16897 USPATFULL

TI 25552, a novel human methyltransferase family member and uses thereof

IN Meyers, Rachel A., Newton, MA, UNITED STATES

Williamson, Mark, Saugus, MA, UNITED STATES

PI US 2002009777 A1 20020124

AI US 2001-816714 A1 20010323 (9)

PRAI US 2000-191865P 20000324 (60)

DT Utility

FS APPLICATION

LREP LOUIS MYERS, FISH & RICHARDSON P.C., 225 Franklin Street, Boston, MA, 02110-2804

CLMN Number of Claims: 31

ECL Exemplary Claim: 1

DRWN 17 Drawing Page(s)

LN.CNT 5107

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 25552 nucleic acid molecules, which encode novel ubiE methyltransferase members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 25552 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 25552 gene has been introduced or disrupted. The invention still further provides isolated 25552 proteins, fusion proteins, antigenic peptides and anti-25552 antibodies.
Diagnostic methods utilizing compositions of the invention are also provided.

L16 ANSWER 153 OF 154 USPATFULL on STN

AN 2002:8237 USPATFULL

TI 27960, a novel ubiquitin conjugating enzyme family member and uses therefor

IN Meyers, Rachel A., Newton, MA, UNITED STATES

Tsai, Fong-Ying, Newton, MA, UNITED STATES

PI US 2002004236 A1 20020110

AI US 2001-842528 A1 20010425 (9)

PRAI US 2000-199500P 20000425 (60)

DT Utility

FS APPLICATION

LREP LOUIS MYERS, FISH & RICHARDSON P.C., 225 Franklin Street, Boston, MA, 02110-2804

CLMN Number of Claims: 40

ECL Exemplary Claim: 1

DRWN 2 Drawing Page(s)

LN.CNT 4951

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 27960 nucleic acid molecules, which encode novel ubiquitin-conjugating enzyme family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 27960 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 27960 gene has been introduced or disrupted. The invention still further provides isolated 27960 proteins, fusion proteins, antigenic peptides and anti-27960 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided.

L16 ANSWER 154 OF 154 USPATFULL on STN

AN 2002:3832 USPATFULL

TI 21509 and 33770, novel human dehydrogenase family members and uses thereof

IN Meyers, Rachel A., Newton, MA, UNITED STATES

Rudolph-Owen, Laura A., Jamaica Plain, MA, UNITED STATES

PI US 2002001807 A1 20020103

AI US 2001-823901 A1 20010330 (9)

PRAI US 2000-193920P 20000331 (60)

DT Utility

FS APPLICATION

LREP LOUIS MYERS, FISH & RICHARDSON P.C., 225 Franklin Street, Boston, MA, 02110-2804

CLMN Number of Claims: 32

ECL Exemplary Claim: 1

DRWN 11 Drawing Page(s)

LN.CNT 5930

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 21509 or 33770 nucleic acid molecules, which encode novel dehydrogenase members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 21509 or 33770 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 21509 or 33770 gene has been introduced or disrupted. The invention still further provides isolated 21509 or 33770 proteins, fusion proteins, antigenic peptides and anti-21509 or 33770 antibodies. ***Diagnostic*** methods utilizing compositions of the invention are also provided.

=> logoff y

STN INTERNATIONAL LOGOFF AT 13:50:59 ON 27 APR 2005

Connection closed by remote host